{"PMC7332737": [["Our point of view is the long felt need to transform a school model that, having been built in the nineteenth century, spanned the twentieth century and arrived, showing signs of fragility, in the twenty-first century.", [["fragility", "PROBLEM", 179, 188], ["fragility", "OBSERVATION", 179, 188]]], ["The pandemic just made inevitable what was already needed.Rethinking the school modelMany of us have written, in recent years, about the end of the school model (N\u00f3voa 2006) and the need to rethink the institutional bases of the school.", [["pandemic", "OBSERVATION", 4, 12]]], ["The reinforcement of education as a public and common good is the beacon that guides the transformations we support.Rethinking the school modelLet us point out, in rough lines, three dimensions of the school model that need to be rethought today:Rethinking the school modelFirst: The acceptance of a social contract that assigns the primary responsibility for the education of children to specialized education systems.Rethinking the school modelSecond: The consolidation of an organizational structure, built around a delimited school space whose central reference is the classroom, in which activities are developed with precise schedules.Rethinking the school modelThird: The consecration of the lesson as the basis of a pedagogy that can be explained through the \u201cblackboard metaphor\u201d, in which a teacher lectures a relatively homogeneous class of students.Rethinking the school modelAlthough simplistic, almost to the point of caricature, this description allows us to mark three essential aspects of the process of change or metamorphosis of the school (N\u00f3voa 2019).", [["children", "ORGANISM", 377, 385], ["children", "SPECIES", 377, 385], ["an organizational structure", "PROBLEM", 475, 502], ["rough lines", "OBSERVATION", 164, 175], ["consolidation", "OBSERVATION", 458, 471], ["organizational structure", "OBSERVATION", 478, 502], ["central", "OBSERVATION_MODIFIER", 548, 555]]], ["It is true that the twentieth century was fertile for debates and pedagogical innovations, but the school model has hardly changed.", [["pedagogical innovations", "TREATMENT", 66, 89]]], ["At least, until the pandemic crisis.Rethinking the school modelIn early 2020, the world was surprised by COVID-19.", [["the pandemic crisis", "PROBLEM", 16, 35]]], ["Need prevailed over inertia, albeit with fragile and precarious solutions.The \u201cdeath of the school\u201dVarious groups and authors have been announcing, at least since the beginning of the twenty-first century, the \u201cdeath of the school\u201d.", [["death", "DISEASE", 79, 84], ["death", "DISEASE", 211, 216], ["fragile and precarious solutions", "TREATMENT", 41, 73]]], ["Perhaps their common denominator is the definition of education as a \u201cprivate good\u201d, placing the focus not so much on education as on learning (and this language change is not innocent), and assuming that the most important thing is to respond to the individual needs of each student.The \u201cdeath of the school\u201dIn one way or another, these trends emphasize a consumerist approach to education.", [["death", "DISEASE", 289, 294]]], ["In this way, education is called into question as a public and common good.The \u201cdeath of the school\u201dTwo of these trends, perhaps the most influential, will be highlighted shortly.", [["death", "DISEASE", 80, 85]]], ["Alexandre (2019), for example, believes that the future will bring an increased \u201cindividualization of teaching thanks to a growing use of digital technologies boosted with AI\u201d, even stating that \u201cschool will become transhumanist and will find it normal to modify the brains of the students using all the panoply of NBIC technologies\u201d (p.", [["digital technologies", "TREATMENT", 138, 158], ["NBIC technologies", "TREATMENT", 315, 332]]], ["203).The \u201cdeath of the school\u201dThese authors were prepared to respond to the emergency situation created by the pandemic, through the mobilization of online platforms and teaching materials.", [["death", "DISEASE", 10, 15], ["teaching materials", "TREATMENT", 170, 188]]], ["However, it would be tragic\u2014for the public dimension of education, for the autonomy of schools, and for teachers\u2019 professionalism\u2014if the answers to the urgency of the crisis served as the pretext for establishing a new educational norm based on these proposals.The \u201cdeath of the school\u201dOn the other hand, we find many scholars who, in the last decades, gathered around the so-called \u201clearning sciences\u201d.", [["death", "DISEASE", 266, 271], ["the crisis", "PROBLEM", 163, 173]]], ["Brain studies and learning are a powerful symbolic universe, reinforcing the idea that it is possible to find personalized responses for each child and that these responses can be given in a domestic setting.", [["Brain", "ANATOMY", 0, 5], ["Brain studies", "TEST", 0, 13]]], ["The basic idea is to build an evidence-based education along the same lines as evidence-based medicine.", [["the same lines", "TREATMENT", 61, 75]]], ["Educational neuroscience seeks to calculate the educational and pedagogical universe by explaining learning through scientific research of the brain.The \u201cdeath of the school\u201dThese scholars were also prepared to respond to the pandemic crisis, with many families retiring to protected and confined spaces and looking for individualized answers for their children.", [["brain", "ANATOMY", 143, 148], ["death", "DISEASE", 154, 159], ["brain", "ORGAN", 143, 148], ["children", "ORGANISM", 353, 361], ["children", "SPECIES", 353, 361], ["the pandemic crisis", "PROBLEM", 222, 241], ["brain", "ANATOMY", 143, 148]]], ["Most of the digital materials made available during the pandemic followed this matrix.", [["matrix", "CELLULAR_COMPONENT", 79, 85]]], ["However, it would be tragic for educators to perpetuate these practices over time, as education requires human relationships and interaction and cannot be fully accomplished in isolation and with \u201csocial distancing\u201d.The \u201cdeath of the school\u201dThe call for a \u201cpersonalization\u201d of learning in \u201cdomestic\u201d spaces, through the use of a panoply of digital means leads to the disintegration of the school.", [["death", "DISEASE", 221, 226], ["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110]]], ["But we must subordinate these approaches to a transformation of the school model that does not diminish but, rather, reinforces education as a public and common good.Lessons learned in responding to the pandemicLet us return to the three dimensions of the school model mentioned at the beginning of this article, in order to assess, briefly, the educational responses given during the pandemic.Lessons learned in responding to the pandemicFirst: In general, the response of national education systems was fragile and inconsistent.", [["fragile", "PROBLEM", 505, 512]]], ["More than ever, it has become clear that teachers are essential to the present and future of education.Lessons learned in responding to the pandemicIn recent weeks, numerous publications describing the responses of different countries to the pandemic confirm this assessment (Reimers and Schleicher 2020; UNESCO 2020).", [["this assessment", "TEST", 259, 274]]], ["We must invest in teacher education and curriculum policies that ensure and acknowledge teaching autonomy.", [["curriculum policies", "TREATMENT", 40, 59]]], ["Uniform and rigid structures have no future.", [["Uniform and rigid structures", "PROBLEM", 0, 28], ["rigid", "OBSERVATION", 12, 17], ["no", "UNCERTAINTY", 34, 36]]], ["And, he added, referring to the Earth system: \u201cDisintegration is probable.", [["probable", "UNCERTAINTY", 65, 73]]], ["Metamorphosis is improbable, but possible\u201d (Morin 2010).Lessons learned in responding to the pandemicWhat is true for the Earth\u2019s natural system is also true for the education system.", [["pandemicWhat", "DISEASE", 93, 105]]], ["Metamorphosis is the renewal, not the \u201cdeath\u201d of school.", [["death", "DISEASE", 39, 44]]], ["Most of the responses to the COVID-19 crisis reinforce this trend.", [["the COVID", "TREATMENT", 25, 34]]], ["But metamorphosis is also still possible, as can be seen in many initiatives taken by teachers and schools, which were able to reinvent pedagogy and learning environments, to increase the porosity of educational life in its connection with public spaces\u2014with the polis, the city.The post-pandemic school, after the school modelIt is difficult to write the history of the future, but necessary.", [["the porosity of educational life", "TREATMENT", 184, 216], ["metamorphosis", "OBSERVATION", 4, 17]]], ["We do not want the disintegration of the school but, rather, its profound transformation in the context of new relations with society and knowledge, always valuing teachers and a humanist vision of education.", [["profound", "OBSERVATION_MODIFIER", 65, 73], ["transformation", "OBSERVATION", 74, 88]]], ["Like Greene (1982), we cannot imagine a coherent sense of purpose in education if something common does not arise in a public space.The post-pandemic school, after the school modelThus, summarizing the three dimensions of the school model presented at the beginning of this viewpoint\u2014the social contract celebrated in the nineteenth century, the spatial-temporal structure of the school, and the pedagogy of the lesson\u2014we would like the transformation of the school to be inspired by countless initiatives and experiences that already exist throughout the world.", [["temporal", "ANATOMY_MODIFIER", 354, 362]]], ["Fifty years ago, the Permanent Education movement already had this idea in mind when it enshrined the principle that people learn in various places and in various ways, supporting the need for the recognition of prior learning achieved through life, experience, and work.", [["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123]]], ["The construction of this new social contract centred around education, which implies the existence of participation and democratic deliberation, is essential to rethink the school model.The post-pandemic school, after the school modelSecond: It is necessary to transform the organizational structure of the school.", [["new", "OBSERVATION_MODIFIER", 25, 28]]], ["Today, the opposite movement is required: diversification of spaces and times, curricula and forms of assessment, the work of teachers and students\u2026What does this mean?", [["assessment", "TEST", 102, 112]]], ["The creation of new educational environments, very different from the traditional classroom space, which allow individual study and group work, monitoring by teachers, and research projects, face-to-face, and digital work.", [["individual study", "TEST", 111, 127], ["new", "OBSERVATION_MODIFIER", 16, 19]]], ["Metaphorically, we can imagine these new environments as a large library: some students study alone, connected to the internet or not; others work in groups; others discuss with one or more teachers; others develop a research project; others present their work; others are in contact with people outside, perhaps even abroad\u2026The post-pandemic school, after the school modelThird: The idea of a standard pedagogy around the lesson has to give way to pedagogies that value a diversity of methods and modalities of study and work.", [["people", "ORGANISM", 289, 295], ["people", "SPECIES", 289, 295], ["modalities of study", "TEST", 498, 517]]], ["A profound change in the day-to-day school life of students and teachers.", [["A profound change", "PROBLEM", 0, 17], ["profound", "OBSERVATION_MODIFIER", 2, 10], ["change", "OBSERVATION_MODIFIER", 11, 17]]], ["The best responses to the pandemic were the result of collaboration between groups of teachers, from the same school and from different schools, who were able to present innovative ideas and projects, maintaining links with students and managing to keep them mobilized from the point of view of knowledge, learning, and education.ConclusionsNone of this is new.", [["new", "OBSERVATION_MODIFIER", 357, 360]]], ["Many educators and families were already aware of the need to change the school model, but the pandemic revealed the urgency and the possibility of this transformation.", [["the pandemic", "PROBLEM", 91, 103], ["the urgency", "PROBLEM", 113, 124], ["this transformation", "PROBLEM", 148, 167], ["urgency", "OBSERVATION", 117, 124]]], ["That would be a highly undesirable transformation.", [["a highly undesirable transformation", "PROBLEM", 14, 49], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["undesirable", "OBSERVATION_MODIFIER", 23, 34], ["transformation", "OBSERVATION", 35, 49]]], ["Contrary to what is heard every day, neither a new world nor a new school will arise as a result of the pandemic.", [["the pandemic", "PROBLEM", 100, 112]]], ["After the pandemic, perhaps the most likely outcome is an acceleration of the disintegration of the school.", [["most likely", "UNCERTAINTY", 32, 43], ["acceleration", "OBSERVATION_MODIFIER", 58, 70]]], ["But metamorphosis is still possible.ConclusionsEducation is always defined over a very long time, never a short one.", [["metamorphosis", "OBSERVATION", 4, 17], ["still possible", "UNCERTAINTY", 21, 35]]], ["There are no inevitabilities, nor are histories already decided.", [["inevitabilities", "PROBLEM", 13, 28], ["no", "UNCERTAINTY", 10, 12], ["inevitabilities", "OBSERVATION", 13, 28]]]], "PMC4883030": [], "PMC7444494": [["IntroductionCOVID-19 is an infectious disease caused by a newly discovered positive-sense single-stranded RNA virus called the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).", [["infectious disease", "DISEASE", 27, 45], ["acute respiratory syndrome coronavirus", "DISEASE", 146, 184], ["SARS-CoV-2", "ORGANISM", 127, 137], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 127, 184], ["IntroductionCOVID", "TEST", 0, 17], ["an infectious disease", "PROBLEM", 24, 45], ["a newly discovered positive-sense single-stranded RNA virus", "PROBLEM", 56, 115], ["the SARS", "TEST", 123, 131], ["CoV", "TEST", 132, 135], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 139, 184], ["infectious", "OBSERVATION", 27, 37], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["respiratory syndrome", "OBSERVATION", 152, 172]]], ["The disease has emerged as a pandemic and causes respiratory complications in a majority of the cases and has caused lakhs of deaths worldwide owing to the lack of any treatment option.", [["respiratory", "ANATOMY", 49, 60], ["respiratory complications", "DISEASE", 49, 74], ["deaths", "DISEASE", 126, 132], ["The disease", "PROBLEM", 0, 11], ["a pandemic", "PROBLEM", 27, 37], ["respiratory complications", "PROBLEM", 49, 74], ["deaths", "PROBLEM", 126, 132], ["any treatment option", "TREATMENT", 164, 184], ["disease", "OBSERVATION", 4, 11], ["respiratory complications", "OBSERVATION", 49, 74]]], ["The family Coronaviridae under the order Nidovirales contains the members of Coronavirus (CoV) that are a potential health concern to human beings and possibly to other animals [1,2], having been responsible diseases such as severe acute respiratory syndrome (China) and Middle-East respiratory syndrome (MERS) [3].", [["acute respiratory syndrome", "DISEASE", 232, 258], ["Middle-East respiratory syndrome", "DISEASE", 271, 303], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 77, 88], ["CoV", "ORGANISM", 90, 93], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["CoV", "SPECIES", 90, 93], ["human", "SPECIES", 134, 139], ["Middle-East respiratory syndrome (MERS)", "SPECIES", 271, 310], ["Coronavirus", "PROBLEM", 77, 88], ["responsible diseases", "PROBLEM", 196, 216], ["severe acute respiratory syndrome", "PROBLEM", 225, 258], ["Middle-East respiratory syndrome", "PROBLEM", 271, 303], ["diseases", "OBSERVATION", 208, 216], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["respiratory syndrome", "OBSERVATION", 238, 258], ["Middle", "ANATOMY_MODIFIER", 271, 277], ["respiratory syndrome", "OBSERVATION", 283, 303]]], ["Bats and other animals are natural reservoirs for CoVs, and SARS-CoV-2 [4].", [["Bats", "CELL", 0, 4], ["CoVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["SARS-CoV-2", "ORGANISM", 60, 70], ["SARS-CoV", "SPECIES", 60, 68], ["natural reservoirs", "TREATMENT", 27, 45], ["CoVs", "PROBLEM", 50, 54]]], ["However, the reported route of transmission till date is human to human that occurs by sneezing, coughing and spread of respiratory aerosols.IntroductionThe symptoms manifested by infection of SARS-CoV-2 include the alteration in lung functioning, localized lesions, pneumonia, bronchiolitis and these are presented in a majority of the patients.", [["lung", "ANATOMY", 230, 234], ["lesions", "ANATOMY", 258, 265], ["sneezing", "DISEASE", 87, 95], ["coughing", "DISEASE", 97, 105], ["infection", "DISEASE", 180, 189], ["SARS", "DISEASE", 193, 197], ["pneumonia", "DISEASE", 267, 276], ["bronchiolitis", "DISEASE", 278, 291], ["human", "ORGANISM", 57, 62], ["human", "ORGANISM", 66, 71], ["lung", "ORGAN", 230, 234], ["lesions", "PATHOLOGICAL_FORMATION", 258, 265], ["patients", "ORGANISM", 337, 345], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 66, 71], ["patients", "SPECIES", 337, 345], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 66, 71], ["SARS-CoV", "SPECIES", 193, 201], ["sneezing", "PROBLEM", 87, 95], ["coughing", "PROBLEM", 97, 105], ["respiratory aerosols", "TREATMENT", 120, 140], ["The symptoms", "PROBLEM", 153, 165], ["infection of SARS", "PROBLEM", 180, 197], ["the alteration in lung functioning", "PROBLEM", 212, 246], ["localized lesions", "PROBLEM", 248, 265], ["pneumonia", "PROBLEM", 267, 276], ["bronchiolitis", "PROBLEM", 278, 291], ["respiratory aerosols", "OBSERVATION", 120, 140], ["infection", "OBSERVATION", 180, 189], ["lung", "ANATOMY", 230, 234], ["localized", "OBSERVATION_MODIFIER", 248, 257], ["lesions", "OBSERVATION", 258, 265], ["pneumonia", "OBSERVATION", 267, 276], ["bronchiolitis", "OBSERVATION", 278, 291]]], ["The virus infects the lung endothelial cells and induces a pathological state like the lymphocytic endothelialitis and inflammatory cell invasion [5].", [["lung endothelial cells", "ANATOMY", 22, 44], ["lymphocytic endothelialitis", "ANATOMY", 87, 114], ["inflammatory cell", "ANATOMY", 119, 136], ["endothelialitis", "DISEASE", 99, 114], ["lung endothelial cells", "CELL", 22, 44], ["inflammatory cell", "CELL", 119, 136], ["lung endothelial cells", "CELL_TYPE", 22, 44], ["The virus infects the lung endothelial cells", "PROBLEM", 0, 44], ["a pathological state", "PROBLEM", 57, 77], ["the lymphocytic endothelialitis", "PROBLEM", 83, 114], ["inflammatory cell invasion", "PROBLEM", 119, 145], ["virus infects", "OBSERVATION", 4, 17], ["lung", "ANATOMY", 22, 26], ["endothelial cells", "OBSERVATION", 27, 44], ["lymphocytic endothelialitis", "OBSERVATION", 87, 114], ["inflammatory cell invasion", "OBSERVATION", 119, 145]]], ["The SARS-CoV-2 infects multiple organs and recruits enormous numbers of immune cells and complexes in these organs [4].", [["organs", "ANATOMY", 32, 38], ["immune cells", "ANATOMY", 72, 84], ["organs", "ANATOMY", 108, 114], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["organs", "ORGAN", 32, 38], ["immune cells", "CELL", 72, 84], ["organs", "ORGAN", 108, 114], ["immune cells", "CELL_TYPE", 72, 84], ["SARS-CoV-2", "SPECIES", 4, 14], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["immune cells", "PROBLEM", 72, 84], ["organs", "ANATOMY", 32, 38], ["enormous", "OBSERVATION_MODIFIER", 52, 60], ["immune cells", "OBSERVATION", 72, 84], ["organs", "ANATOMY", 108, 114]]], ["It may also show central nervous system invasion can be presented in advanced stages of the CoV infection [6].", [["central nervous system", "ANATOMY", 17, 39], ["CoV infection", "DISEASE", 92, 105], ["nervous system", "ANATOMICAL_SYSTEM", 25, 39], ["CoV", "ORGANISM", 92, 95], ["central nervous system invasion", "PROBLEM", 17, 48], ["the CoV infection", "PROBLEM", 88, 105], ["may also show", "UNCERTAINTY", 3, 16], ["central", "ANATOMY_MODIFIER", 17, 24], ["nervous system", "ANATOMY", 25, 39], ["invasion", "OBSERVATION", 40, 48], ["CoV", "OBSERVATION_MODIFIER", 92, 95], ["infection", "OBSERVATION", 96, 105]]], ["Other mild manifestations of the COVID-19 include fever, dry cough, dyspnoea, myalgia and fatigue.", [["fever", "DISEASE", 50, 55], ["dry cough", "DISEASE", 57, 66], ["dyspnoea", "DISEASE", 68, 76], ["myalgia", "DISEASE", 78, 85], ["fatigue", "DISEASE", 90, 97], ["Other mild manifestations", "PROBLEM", 0, 25], ["the COVID", "TEST", 29, 38], ["fever", "PROBLEM", 50, 55], ["dry cough", "PROBLEM", 57, 66], ["dyspnoea", "PROBLEM", 68, 76], ["myalgia", "PROBLEM", 78, 85], ["fatigue", "PROBLEM", 90, 97], ["mild", "OBSERVATION_MODIFIER", 6, 10], ["cough", "OBSERVATION", 61, 66], ["myalgia", "OBSERVATION", 78, 85]]], ["The hematological and serological examination reveals the augmentation in the levels of lactate dehydrogenase, serum amyloid A (SAA), and thrombocytopenia [7,8].IntroductionSARS-CoV-2 comprising of about 30,000 RNA, encodes for about 66% non-structural region.", [["serum", "ANATOMY", 111, 116], ["lactate", "CHEMICAL", 88, 95], ["thrombocytopenia", "DISEASE", 138, 154], ["lactate", "CHEMICAL", 88, 95], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 88, 109], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["amyloid A", "GENE_OR_GENE_PRODUCT", 117, 126], ["SAA", "GENE_OR_GENE_PRODUCT", 128, 131], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 183], ["lactate dehydrogenase", "PROTEIN", 88, 109], ["serum amyloid A", "PROTEIN", 111, 126], ["SAA", "PROTEIN", 128, 131], ["30,000 RNA", "RNA", 204, 214], ["serological examination", "TEST", 22, 45], ["lactate dehydrogenase", "TEST", 88, 109], ["serum amyloid A (SAA)", "PROBLEM", 111, 132], ["thrombocytopenia", "PROBLEM", 138, 154], ["IntroductionSARS", "TEST", 161, 177], ["CoV", "TEST", 178, 181], ["lactate dehydrogenase", "OBSERVATION", 88, 109], ["thrombocytopenia", "OBSERVATION", 138, 154]]], ["The nsP5 is chymotrypsin-like (CL) and possesses cysteine protease activity [9].", [["cysteine", "CHEMICAL", 49, 57], ["nsP5", "GENE_OR_GENE_PRODUCT", 4, 8], ["chymotrypsin-like (CL)", "GENE_OR_GENE_PRODUCT", 12, 34], ["cysteine", "AMINO_ACID", 49, 57], ["nsP5", "PROTEIN", 4, 8], ["chymotrypsin", "PROTEIN", 12, 24], ["cysteine protease", "PROTEIN", 49, 66], ["chymotrypsin", "PROBLEM", 12, 24], ["possesses cysteine protease activity", "TREATMENT", 39, 75]]], ["It is called the main protease or 3CLPro.", [["3CLPro", "GENE_OR_GENE_PRODUCT", 34, 40], ["protease", "PROTEIN", 22, 30], ["3CLPro", "PROTEIN", 34, 40], ["3CLPro", "TREATMENT", 34, 40]]], ["This protease is essential for the processing of polyproteins PP1A and PP1B, translated from the RNA of the virus.", [["PP1A", "GENE_OR_GENE_PRODUCT", 62, 66], ["PP1B", "GENE_OR_GENE_PRODUCT", 71, 75], ["protease", "PROTEIN", 5, 13], ["polyproteins", "PROTEIN", 49, 61], ["PP1A", "PROTEIN", 62, 66], ["PP1B", "PROTEIN", 71, 75], ["This protease", "TREATMENT", 0, 13], ["polyproteins PP1A", "TREATMENT", 49, 66], ["PP1B", "TREATMENT", 71, 75], ["the virus", "PROBLEM", 104, 113]]], ["The 3CLPro is very important for virus to replicate and propagate and its inhibitors may therefore be able to halt the replication of the virus.", [["3CLPro", "GENE_OR_GENE_PRODUCT", 4, 10], ["The 3CLPro", "TREATMENT", 0, 10], ["virus", "PROBLEM", 33, 38], ["its inhibitors", "TREATMENT", 70, 84], ["the virus", "PROBLEM", 134, 143]]], ["It recognizes and cleaves the virus non-structural polyprotein at 12 sites.", [["virus non-structural polyprotein", "DNA", 30, 62], ["the virus non-structural polyprotein", "PROBLEM", 26, 62]]], ["It generally acts on the sequence Leu-Gln denotes the cleavage site).", [["Leu-Gln", "CHEMICAL", 34, 41], ["Leu", "CHEMICAL", 34, 37], ["Gln", "CHEMICAL", 38, 41], ["the cleavage site", "PROBLEM", 50, 67]]], ["Due to its role in initiation events of viral replication, it is an attractive drug target.", [["viral replication", "TREATMENT", 40, 57], ["viral replication", "OBSERVATION", 40, 57]]], ["Besides 3CLPro, nucleocapsid protein (N), envelope protein (E), spike glycoprotein (S), membrane protein (M), and two isoforms of replicase polyprotein, namely 1a and 1ab are considered as potential drug/vaccine targets [10].", [["3CLPro", "GENE_OR_GENE_PRODUCT", 8, 14], ["nucleocapsid protein (N), envelope protein", "GENE_OR_GENE_PRODUCT", 16, 58], ["E", "GENE_OR_GENE_PRODUCT", 60, 61], ["spike glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 64, 86], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["3CLPro", "PROTEIN", 8, 14], ["nucleocapsid protein", "PROTEIN", 16, 36], ["N", "PROTEIN", 38, 39], ["envelope protein", "PROTEIN", 42, 58], ["E", "PROTEIN", 60, 61], ["spike glycoprotein", "PROTEIN", 64, 82], ["S", "PROTEIN", 84, 85], ["membrane protein", "PROTEIN", 88, 104], ["M", "PROTEIN", 106, 107], ["replicase polyprotein", "PROTEIN", 130, 151], ["nucleocapsid protein", "TEST", 16, 36], ["envelope protein", "TEST", 42, 58], ["membrane protein", "TEST", 88, 104], ["replicase polyprotein", "PROBLEM", 130, 151], ["drug/vaccine targets", "TREATMENT", 199, 219], ["replicase polyprotein", "OBSERVATION", 130, 151]]], ["Its indispensable role in the initiation events of the replication cycle makes it an attractive drug target [11].", [["the replication cycle", "TREATMENT", 51, 72]]], ["3CLPro is an attractive and relatively safer drug target because its recognition sequence is dissimilar to any of the proteases in the human body.IntroductionA number of clinically approved drugs are being tested for their potential to ameliorate the effects of the SARS-CoV-2 infection.", [["body", "ANATOMY", 141, 145], ["3CLPro", "CHEMICAL", 0, 6], ["infection", "DISEASE", 277, 286], ["3CLPro", "SIMPLE_CHEMICAL", 0, 6], ["human", "ORGANISM", 135, 140], ["body", "ORGANISM_SUBDIVISION", 141, 145], ["SARS-CoV-2", "ORGANISM", 266, 276], ["proteases", "PROTEIN", 118, 127], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["SARS-CoV", "SPECIES", 266, 274], ["the proteases in the human body", "PROBLEM", 114, 145], ["drugs", "TREATMENT", 190, 195], ["the SARS", "PROBLEM", 262, 270], ["CoV-2 infection", "PROBLEM", 271, 286], ["human", "ANATOMY", 135, 140], ["body", "ANATOMY_MODIFIER", 141, 145], ["infection", "OBSERVATION", 277, 286]]], ["We tested the different classes of drugs - nucleoside analogues, antiretroviral agents, HIV protease inhibitors and neuraminidase inhibitors - for their potential antiviral effect.", [["nucleoside", "CHEMICAL", 43, 53], ["nucleoside", "CHEMICAL", 43, 53], ["drugs - nucleoside analogues", "SIMPLE_CHEMICAL", 35, 63], ["HIV", "ORGANISM", 88, 91], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 116, 140], ["HIV", "SPECIES", 88, 91], ["drugs", "TREATMENT", 35, 40], ["nucleoside analogues", "TREATMENT", 43, 63], ["antiretroviral agents", "TREATMENT", 65, 86], ["HIV protease inhibitors", "TREATMENT", 88, 111], ["neuraminidase inhibitors", "TREATMENT", 116, 140], ["antiviral effect", "OBSERVATION", 163, 179]]], ["Teicoplanin is an effective glycopeptide antibiotic used in the prevention and treatment of various serious infections caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis.", [["Teicoplanin", "CHEMICAL", 0, 11], ["infections", "DISEASE", 108, 118], ["methicillin", "CHEMICAL", 163, 174], ["Staphylococcus aureus", "DISEASE", 185, 206], ["Teicoplanin", "CHEMICAL", 0, 11], ["methicillin", "CHEMICAL", 163, 174], ["Teicoplanin", "SIMPLE_CHEMICAL", 0, 11], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 163, 206], ["MRSA", "CANCER", 208, 212], ["Enterococcus faecalis", "ORGANISM", 218, 239], ["Staphylococcus aureus", "SPECIES", 185, 206], ["MRSA", "SPECIES", 208, 212], ["Enterococcus faecalis", "SPECIES", 218, 239], ["Staphylococcus aureus", "SPECIES", 185, 206], ["MRSA", "SPECIES", 208, 212], ["Enterococcus faecalis", "SPECIES", 218, 239], ["Teicoplanin", "TREATMENT", 0, 11], ["an effective glycopeptide antibiotic", "TREATMENT", 15, 51], ["various serious infections", "PROBLEM", 92, 118], ["gram-positive bacteria", "PROBLEM", 129, 151], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 163, 206], ["MRSA", "PROBLEM", 208, 212], ["Enterococcus faecalis", "PROBLEM", 218, 239], ["serious", "OBSERVATION_MODIFIER", 100, 107], ["infections", "OBSERVATION", 108, 118], ["positive bacteria", "OBSERVATION_MODIFIER", 134, 151], ["Staphylococcus aureus", "OBSERVATION", 185, 206], ["Enterococcus faecalis", "OBSERVATION", 218, 239]]], ["Some of the drugs under clinical trials for COVID-19 like hydroxychloroquine, chloroquine, nitazoxanide, oseltamivir, amoxicillin, famciclovir, aciclovir, lopinavir, atazanavir, and azithromycin [12] have been screened in this study.", [["COVID-19", "CHEMICAL", 44, 52], ["hydroxychloroquine", "CHEMICAL", 58, 76], ["chloroquine", "CHEMICAL", 78, 89], ["nitazoxanide", "CHEMICAL", 91, 103], ["oseltamivir", "CHEMICAL", 105, 116], ["amoxicillin", "CHEMICAL", 118, 129], ["famciclovir", "CHEMICAL", 131, 142], ["aciclovir", "CHEMICAL", 144, 153], ["lopinavir", "CHEMICAL", 155, 164], ["atazanavir", "CHEMICAL", 166, 176], ["azithromycin", "CHEMICAL", 182, 194], ["COVID-19", "CHEMICAL", 44, 52], ["hydroxychloroquine", "CHEMICAL", 58, 76], ["chloroquine", "CHEMICAL", 78, 89], ["nitazoxanide", "CHEMICAL", 91, 103], ["oseltamivir", "CHEMICAL", 105, 116], ["amoxicillin", "CHEMICAL", 118, 129], ["famciclovir", "CHEMICAL", 131, 142], ["aciclovir", "CHEMICAL", 144, 153], ["lopinavir", "CHEMICAL", 155, 164], ["atazanavir", "CHEMICAL", 166, 176], ["azithromycin", "CHEMICAL", 182, 194], ["COVID-19", "SIMPLE_CHEMICAL", 44, 52], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 58, 76], ["chloroquine", "SIMPLE_CHEMICAL", 78, 89], ["nitazoxanide", "SIMPLE_CHEMICAL", 91, 103], ["oseltamivir", "SIMPLE_CHEMICAL", 105, 116], ["amoxicillin", "SIMPLE_CHEMICAL", 118, 129], ["famciclovir", "SIMPLE_CHEMICAL", 131, 142], ["aciclovir", "SIMPLE_CHEMICAL", 144, 153], ["lopinavir", "SIMPLE_CHEMICAL", 155, 164], ["atazanavir", "SIMPLE_CHEMICAL", 166, 176], ["azithromycin", "SIMPLE_CHEMICAL", 182, 194], ["the drugs", "TREATMENT", 8, 17], ["COVID", "TEST", 44, 49], ["hydroxychloroquine", "TREATMENT", 58, 76], ["chloroquine", "TREATMENT", 78, 89], ["nitazoxanide", "TREATMENT", 91, 103], ["oseltamivir", "TREATMENT", 105, 116], ["amoxicillin", "TREATMENT", 118, 129], ["famciclovir", "TREATMENT", 131, 142], ["aciclovir", "TREATMENT", 144, 153], ["lopinavir", "TREATMENT", 155, 164], ["atazanavir", "TREATMENT", 166, 176], ["azithromycin", "TREATMENT", 182, 194], ["this study", "TEST", 222, 232]]], ["Here, we present Teicoplanin as a potent inhibitor of main protease and speculate its role as to halt the replication of the virus.Cloning and purification of 3CLPro ::: Materials and methodsSARS-CoV-2 3CLPro gene was cloned between BamHI and XhoI sites in pET28a vector having N terminal 6\u00d7-His tag, FLAG tag and PreScission protease tag.", [["Teicoplanin", "CHEMICAL", 17, 28], ["Teicoplanin", "CHEMICAL", 17, 28], ["N", "CHEMICAL", 278, 279], ["Teicoplanin", "GENE_OR_GENE_PRODUCT", 17, 28], ["methodsSARS-CoV-2 3CLPro", "GENE_OR_GENE_PRODUCT", 184, 208], ["BamHI", "GENE_OR_GENE_PRODUCT", 233, 238], ["XhoI", "GENE_OR_GENE_PRODUCT", 243, 247], ["pET28a", "GENE_OR_GENE_PRODUCT", 257, 263], ["FLAG", "GENE_OR_GENE_PRODUCT", 301, 305], ["protease", "PROTEIN", 59, 67], ["3CLPro", "PROTEIN", 159, 165], ["methodsSARS-CoV-2 3CLPro gene", "DNA", 184, 213], ["BamHI and XhoI sites", "DNA", 233, 253], ["pET28a vector", "DNA", 257, 270], ["N terminal 6\u00d7-His tag", "DNA", 278, 299], ["FLAG tag", "DNA", 301, 309], ["PreScission protease tag", "PROTEIN", 314, 338], ["Teicoplanin", "TREATMENT", 17, 28], ["a potent inhibitor", "TREATMENT", 32, 50], ["main protease", "TREATMENT", 54, 67], ["the virus", "PROBLEM", 121, 130], ["Materials", "TEST", 170, 179], ["methodsSARS", "TEST", 184, 195], ["CoV-2 3CLPro gene", "TREATMENT", 196, 213], ["BamHI and XhoI sites", "TREATMENT", 233, 253], ["His tag", "TREATMENT", 292, 299], ["FLAG tag", "TREATMENT", 301, 309], ["PreScission protease tag", "TREATMENT", 314, 338]]], ["Protein was transformed in BL-21DE3 Rosetta RIL cells and autoinduction method was used for expression and purification.", [["BL-21DE3 Rosetta RIL cells", "ANATOMY", 27, 53], ["BL-21DE3 Rosetta RIL cells", "CELL", 27, 53], ["BL-21DE3 Rosetta RIL cells", "CELL_LINE", 27, 53], ["BL-21DE3", "SPECIES", 27, 35], ["Protein", "TEST", 0, 7], ["BL", "TEST", 27, 29], ["Rosetta RIL cells", "TREATMENT", 36, 53], ["autoinduction method", "TREATMENT", 58, 78], ["purification", "TEST", 107, 119]]], ["The culture was grown at 37 \u00b0C for 2\u20133 h and 18 \u00b0C for overnight.", [["The culture", "TEST", 0, 11]]], ["The cell pellet after centrifugation at 10,000 \u00d7g for 30 min, was resuspended in 50 mM Tris pH 7.5, 500 mM NaCl, 10% glycerol, 10 mM Imidazole, 1 mM DTT, 0.5 mM PMSF, 10 \u03bcg DNaseI and lysozyme (1 mg/mL).", [["cell pellet", "ANATOMY", 4, 15], ["NaCl", "CHEMICAL", 107, 111], ["glycerol", "CHEMICAL", 117, 125], ["Imidazole", "CHEMICAL", 133, 142], ["NaCl", "CHEMICAL", 107, 111], ["glycerol", "CHEMICAL", 117, 125], ["Imidazole", "CHEMICAL", 133, 142], ["DTT", "CHEMICAL", 149, 152], ["PMSF", "CHEMICAL", 161, 165], ["cell", "CELL", 4, 8], ["glycerol", "SIMPLE_CHEMICAL", 117, 125], ["Imidazole", "SIMPLE_CHEMICAL", 133, 142], ["DTT", "SIMPLE_CHEMICAL", 149, 152], ["PMSF", "SIMPLE_CHEMICAL", 161, 165], ["DNaseI", "SIMPLE_CHEMICAL", 173, 179], ["lysozyme", "PROTEIN", 184, 192], ["Tris pH", "TEST", 87, 94], ["500 mM NaCl", "TREATMENT", 100, 111], ["glycerol", "TREATMENT", 117, 125], ["10 mM Imidazole", "TREATMENT", 127, 142], ["1 mM DTT", "TREATMENT", 144, 152], ["0.5 mM PMSF", "TREATMENT", 154, 165], ["10 \u03bcg DNaseI", "TREATMENT", 167, 179], ["lysozyme", "TREATMENT", 184, 192], ["cell pellet", "OBSERVATION", 4, 15]]], ["The supernatant was applied on Ni-NTA columns in FPLC system (\u00c4KTA\u2122 start, GE Healthcare).", [["supernatant", "ANATOMY", 4, 15], ["Ni-NTA", "CHEMICAL", 31, 37], ["Ni-NTA", "CHEMICAL", 31, 37], ["Ni-NTA", "SIMPLE_CHEMICAL", 31, 37], ["The supernatant", "TREATMENT", 0, 15], ["Ni-NTA columns", "TREATMENT", 31, 45]]], ["The bound proteins were eluted with 300 mM imidazole gradient.", [["imidazole", "CHEMICAL", 43, 52], ["imidazole", "CHEMICAL", 43, 52], ["imidazole", "SIMPLE_CHEMICAL", 43, 52], ["The bound proteins", "TEST", 0, 18], ["300 mM imidazole gradient", "TREATMENT", 36, 61]]], ["The protein fractions were applied on Q-FF ion-exchange chromatography, eluted with 500 mM NaCl gradient.", [["NaCl", "CHEMICAL", 91, 95], ["NaCl", "CHEMICAL", 91, 95], ["The protein fractions", "TEST", 0, 21], ["ion-exchange chromatography", "TEST", 43, 70], ["500 mM NaCl gradient", "TREATMENT", 84, 104], ["protein fractions", "OBSERVATION", 4, 21]]], ["The His tag was cleaved with PreScission protease and subjected to size exclusion chromatography (SEC) (Superdex\u2122 75 10/300 GL, GE Healthcare).", [["His", "CHEMICAL", 4, 7], ["His tag", "PROTEIN", 4, 11], ["PreScission protease", "PROTEIN", 29, 49], ["PreScission protease", "TREATMENT", 29, 49]]], ["Homogeneous fractions were pooled, dialyzed and kept at \u221280 \u00b0C for all biochemical and biophysical studies.Protease activity using specific substrate ::: Activity inhibition assay ::: Materials and methodsA well-established method for assessment of protease activity by 3CLPro of SARS-CoV has been described previously [15].", [["SARS", "DISEASE", 280, 284], ["Protease", "GENE_OR_GENE_PRODUCT", 107, 115], ["3CLPro", "SIMPLE_CHEMICAL", 270, 276], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 280, 288], ["protease", "PROTEIN", 249, 257], ["SARS-CoV", "SPECIES", 280, 288], ["all biochemical and biophysical studies", "TEST", 67, 106], ["methodsA", "TREATMENT", 198, 206], ["assessment", "TEST", 235, 245], ["protease activity", "TREATMENT", 249, 266], ["SARS", "PROBLEM", 280, 284]]], ["Thus, a custom synthesized fluorogenic peptide substrate was procured for the 3CLPro protease, DABCYL-MYTPHTVLQAVGACVLCN-EDANS {FRET pair as EDANS (Flourophore) and DABCYL (Quencher)} (Henan Tianfu Chemical Co., Ltd., China).", [["3CLPro protease", "PROTEIN", 78, 93], ["DABCYL", "PROTEIN", 95, 101], ["MYTPHTVLQAVGACVLCN", "PROTEIN", 102, 120], ["EDANS", "PROTEIN", 121, 126], ["a custom synthesized fluorogenic peptide substrate", "TREATMENT", 6, 56], ["the 3CLPro protease", "TREATMENT", 74, 93], ["DABCYL", "TEST", 95, 101], ["MYTPHTVLQAVGACVLCN", "TEST", 102, 120]]], ["This peptide substrate qualifies as a generic substrate for the main protease of various coronaviruses including the SARS-CoV, by the virtue of it possessing the nsp12/nsp13 cleavage sequence, MYTPHTVLQ\u2193AVGACVLCN.", [["SARS", "DISEASE", 117, 121], ["coronaviruses", "ORGANISM", 89, 102], ["SARS-CoV", "ORGANISM", 117, 125], ["nsp12", "GENE_OR_GENE_PRODUCT", 162, 167], ["nsp13", "GENE_OR_GENE_PRODUCT", 168, 173], ["protease", "PROTEIN", 69, 77], ["nsp12", "PROTEIN", 162, 167], ["nsp13", "PROTEIN", 168, 173], ["MYTPHTVLQ", "PROTEIN", 193, 202], ["AVGACVLCN", "PROTEIN", 203, 212], ["SARS-CoV", "SPECIES", 117, 125], ["various coronaviruses", "PROBLEM", 81, 102], ["the nsp12", "TEST", 158, 167]]], ["The peptide was dissolved in distilled water and used to measure the activity of the protease.", [["protease", "PROTEIN", 85, 93], ["The peptide", "TREATMENT", 0, 11], ["the protease", "TREATMENT", 81, 93]]], ["Initial velocity for enzymatic activity using 1 \u03bcM 3CLPro protease and 0\u201310 \u03bcM of peptide substrate in 20 mM HEPES, pH 7.0 was plotted as a function of fluorescence intensity arbitrary unit and peptide concentration.", [["HEPES", "CHEMICAL", 109, 114], ["1 \u03bcM 3CLPro protease", "PROTEIN", 46, 66], ["Initial velocity", "TEST", 0, 16], ["enzymatic activity", "TEST", 21, 39], ["1 \u03bcM 3CLPro protease", "TREATMENT", 46, 66], ["peptide substrate in 20 mM HEPES", "TREATMENT", 82, 114], ["pH", "TEST", 116, 118], ["fluorescence intensity arbitrary unit and peptide concentration", "TREATMENT", 152, 215]]], ["The rate of proteolytic activity was determined by measuring the increase in fluorescence intensity of enzymatic reactions in 500 \u03bcl volume conducted in a fluorescence cuvette.", [["enzymatic reactions", "PROBLEM", 103, 122], ["a fluorescence cuvette", "TREATMENT", 153, 175], ["proteolytic activity", "OBSERVATION", 12, 32], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["fluorescence cuvette", "OBSERVATION", 155, 175]]], ["The relative fluorescent unit (RFU) is linearly proportional to the amount of AVGACVLCN-EDANS generated by protease activity.", [["AVGACVLCN-EDANS", "SIMPLE_CHEMICAL", 78, 93], ["AVGACVLCN", "PROTEIN", 78, 87], ["EDANS", "PROTEIN", 88, 93], ["protease", "PROTEIN", 107, 115], ["amount", "OBSERVATION_MODIFIER", 68, 74]]], ["The slope of the curve was used for enzymatic activity of enzyme for the FRET peptide substrate.Protease activity using specific substrate ::: Activity inhibition assay ::: Materials and methodsIn the FRET assay for determination of kinetic parameters, 1 \u03bcM of 3CLPro enzyme was incubated with varied concentration (2.5\u2013100 \u03bcM) of the peptide substrate DABCYL-MYTPHTVLQ\u2193AVGACVLCN-EDANS for an 1 h at 25 \u00b0C and the intensity of fluorescence was measured.", [["Protease", "GENE_OR_GENE_PRODUCT", 96, 104], ["enzyme", "PROTEIN", 58, 64], ["3CLPro enzyme", "PROTEIN", 261, 274], ["the curve", "TREATMENT", 13, 22], ["enzymatic activity of enzyme", "TREATMENT", 36, 64], ["the FRET peptide substrate", "TREATMENT", 69, 95], ["the FRET assay", "TEST", 197, 211], ["kinetic parameters", "TEST", 233, 251], ["3CLPro enzyme", "TREATMENT", 261, 274], ["the peptide substrate DABCYL", "TEST", 331, 359]]], ["The excitation and emission parameters for measurement were kept as 330 nm and 500 nm, respectively, using Cary Eclipse fluorescence spectrophotometer (Agilent Technologies).", [["emission parameters", "TEST", 19, 38], ["measurement", "TEST", 43, 54], ["Cary Eclipse fluorescence spectrophotometer (Agilent Technologies", "TREATMENT", 107, 172]]], ["All reactions were performed at 25 \u00b0C in temperature-controlled conditions.", [["All reactions", "PROBLEM", 0, 13]]], ["The initial velocity slope was used for the fluorescence intensity rate calculation and plotted against varied substrate concentrations for the determination of the kinetic parameters including Km, Vmax, kcat and kcat/Km values.Protease activity using specific substrate ::: Activity inhibition assay ::: Materials and methodsFor the inhibitor assay, the above experiment was conducted with 1 \u03bcM of 3CLPro in 20 mM HEPES, pH 7.0 buffer incubated with varying inhibitor concentrations and 50 \u03bcM of peptide substrate in 500 \u03bcl, incubated at 25 \u00b0C for an hour before the measurements.", [["3CLPro", "CHEMICAL", 399, 405], ["3CLPro", "CHEMICAL", 399, 405], ["HEPES", "CHEMICAL", 415, 420], ["Protease", "GENE_OR_GENE_PRODUCT", 228, 236], ["3CLPro", "SIMPLE_CHEMICAL", 399, 405], ["The initial velocity slope", "TEST", 0, 26], ["the fluorescence intensity rate calculation", "TEST", 40, 83], ["varied substrate concentrations", "TREATMENT", 104, 135], ["the determination", "TEST", 140, 157], ["the kinetic parameters", "TEST", 161, 183], ["Km", "TEST", 194, 196], ["Vmax", "TEST", 198, 202], ["kcat", "TEST", 204, 208], ["kcat/Km values", "TEST", 213, 227], ["methods", "TREATMENT", 319, 326], ["the inhibitor assay", "TEST", 330, 349], ["3CLPro", "TREATMENT", 399, 405], ["20 mM HEPES", "TREATMENT", 409, 420], ["pH", "TEST", 422, 424], ["varying inhibitor concentrations", "TREATMENT", 451, 483], ["peptide substrate", "TREATMENT", 497, 514], ["the measurements", "TEST", 564, 580], ["velocity slope", "OBSERVATION", 12, 26]]], ["The enzyme inhibitory potential IC50 value was calculated by fitting the curve of normalised residual activity with inhibitor concentration.", [["The enzyme inhibitory", "TEST", 0, 21], ["IC50 value", "TEST", 32, 42], ["the curve", "TEST", 69, 78], ["inhibitor concentration", "TREATMENT", 116, 139], ["residual activity", "OBSERVATION", 93, 110]]], ["The reactions for each set were performed in triplicates.Protease activity using casein substrate ::: Activity inhibition assay ::: Materials and methodsThrough the sequence analysis, we found that casein substrate has some cleavage junction peptides matching with the consensus cleavage sequences of 3CLPro of SARS-CoV-2.", [["SARS", "DISEASE", 311, 315], ["Protease", "GENE_OR_GENE_PRODUCT", 57, 65], ["casein substrate", "SIMPLE_CHEMICAL", 81, 97], ["casein", "GENE_OR_GENE_PRODUCT", 198, 204], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 311, 321], ["casein substrate", "PROTEIN", 198, 214], ["consensus cleavage sequences", "DNA", 269, 297], ["3CLPro", "PROTEIN", 301, 307], ["SARS-CoV", "SPECIES", 311, 319], ["the sequence analysis", "TEST", 161, 182], ["casein substrate", "TREATMENT", 198, 214], ["some cleavage junction peptides", "PROBLEM", 219, 250]]], ["Hence, we have used the casein substrate also for the protease activity measurements.", [["protease", "PROTEIN", 54, 62], ["the casein substrate", "TREATMENT", 20, 40], ["the protease activity measurements", "TREATMENT", 50, 84]]], ["The protease activity of 3CLPro was previously established by using casein substrate [14,15] by the measurement of tyrosine liberated as a result of enzymatic activity.", [["tyrosine", "CHEMICAL", 115, 123], ["tyrosine", "CHEMICAL", 115, 123], ["3CLPro", "SIMPLE_CHEMICAL", 25, 31], ["tyrosine", "AMINO_ACID", 115, 123], ["protease", "PROTEIN", 4, 12], ["3CLPro", "PROTEIN", 25, 31], ["The protease activity of 3CLPro", "TREATMENT", 0, 31], ["casein substrate", "TREATMENT", 68, 84], ["tyrosine liberated", "TREATMENT", 115, 133], ["enzymatic activity", "OBSERVATION", 149, 167]]], ["A calibration curve was prepared from absorbance measurements at 280 nm with standard L-tyrosine solutions and a slope was obtained.", [["-tyrosine", "CHEMICAL", 87, 96], ["A calibration curve", "TEST", 0, 19], ["absorbance measurements", "TEST", 38, 61], ["standard L-tyrosine solutions", "TREATMENT", 77, 106]]], ["The activity of 3CLPro was estimated by using 1 \u03bcM of enzyme with different casein concentrations in 400 \u03bcl phosphate buffer pH 7.5 incubated at 37 \u00b0C for an hour before terminating the reaction with 200 \u03bcl of 1.7% trichloro-acetic acid.", [["phosphate", "CHEMICAL", 108, 117], ["trichloro-acetic acid", "CHEMICAL", 215, 236], ["phosphate", "CHEMICAL", 108, 117], ["trichloro-acetic acid", "CHEMICAL", 215, 236], ["3CLPro", "SIMPLE_CHEMICAL", 16, 22], ["casein", "SIMPLE_CHEMICAL", 76, 82], ["trichloro-acetic acid", "SIMPLE_CHEMICAL", 215, 236], ["enzyme", "TREATMENT", 54, 60], ["different casein concentrations", "TREATMENT", 66, 97], ["phosphate buffer pH", "TEST", 108, 127], ["1.7% trichloro-acetic acid", "TREATMENT", 210, 236]]], ["The reaction was centrifuged at 15,000 \u00d7g for 10 min and tyrosine concentration was monitored in cuvette at 280 nm using Beckman Coulter DU 800 spectrophotometer.", [["tyrosine", "CHEMICAL", 57, 65], ["tyrosine", "CHEMICAL", 57, 65], ["tyrosine", "AMINO_ACID", 57, 65], ["The reaction", "PROBLEM", 0, 12], ["tyrosine concentration", "TREATMENT", 57, 79]]], ["The amount of tyrosine liberated was calculated using tyrosine standard slope, plotted as a function of substrate concentration and fitted with Michaelis-Menten equation.", [["tyrosine", "CHEMICAL", 14, 22], ["tyrosine", "CHEMICAL", 54, 62], ["tyrosine", "CHEMICAL", 14, 22], ["tyrosine", "CHEMICAL", 54, 62], ["tyrosine", "AMINO_ACID", 14, 22], ["tyrosine", "AMINO_ACID", 54, 62], ["tyrosine standard slope", "TREATMENT", 54, 77], ["a function of substrate concentration", "TREATMENT", 90, 127], ["Michaelis", "TEST", 144, 153], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["tyrosine liberated", "OBSERVATION", 14, 32]]], ["Further, the Lineweaver-Burk plot was used to determine the kinetic parameters Km, Vmax, Kcat and catalytic efficiency Kcat/Km.", [["Kcat", "GENE_OR_GENE_PRODUCT", 89, 93], ["the Lineweaver-Burk plot", "TREATMENT", 9, 33], ["the kinetic parameters", "TEST", 56, 78], ["Vmax", "TEST", 83, 87], ["Kcat", "TEST", 89, 93]]], ["In the compound inhibition study, 1 \u03bcM of 3CLPro was incubated with varying inhibitor concentration for an hour followed by addition of 135 \u03bcM of casein in 400 \u03bcl phosphate buffer at pH 7.5, incubated at 37 \u00b0C for an hour before terminating the reaction with 200 \u03bcl of 1.7% trichloro-acetic acid and absorbance measurements was done as above.", [["3CLPro", "CHEMICAL", 42, 48], ["casein", "CHEMICAL", 146, 152], ["phosphate", "CHEMICAL", 163, 172], ["trichloro-acetic acid", "CHEMICAL", 274, 295], ["3CLPro", "CHEMICAL", 42, 48], ["phosphate", "CHEMICAL", 163, 172], ["trichloro-acetic acid", "CHEMICAL", 274, 295], ["3CLPro", "SIMPLE_CHEMICAL", 42, 48], ["casein", "SIMPLE_CHEMICAL", 146, 152], ["trichloro-acetic acid", "SIMPLE_CHEMICAL", 274, 295], ["the compound inhibition study", "TEST", 3, 32], ["3CLPro", "TREATMENT", 42, 48], ["varying inhibitor concentration", "TREATMENT", 68, 99], ["casein", "TREATMENT", 146, 152], ["phosphate buffer", "TREATMENT", 163, 179], ["pH", "TEST", 183, 185], ["acetic acid", "TEST", 284, 295], ["absorbance measurements", "TEST", 300, 323]]], ["The enzyme inhibitory potential IC50 value was calculated by fitting the curve of percentage residual activity with inhibitor concentration.Studying protein-drug interaction studies using fluorescence spectroscopy ::: Materials and methodsFluorescence quenching is routinely used to ascertain the effect of a particular drug on the target protein.", [["target protein", "PROTEIN", 332, 346], ["The enzyme inhibitory", "TEST", 0, 21], ["IC50 value", "TEST", 32, 42], ["inhibitor concentration", "TREATMENT", 116, 139], ["fluorescence spectroscopy", "TEST", 188, 213], ["Materials", "TREATMENT", 218, 227], ["methodsFluorescence quenching", "TREATMENT", 232, 261], ["residual activity", "OBSERVATION", 93, 110]]], ["The impact of the drug on the protein can be dynamic due to collisions between the fluorophore (protein) and the quencher (drug), or it may be static, owing to the protein and the quencher forming a complex at ground-state [16,17].", [["the protein", "TREATMENT", 26, 37], ["the fluorophore (protein)", "TREATMENT", 79, 104], ["the quencher (drug", "TREATMENT", 109, 127]]], ["An intense quenching of the fluorescence marked an unvarying local dielectric environment.", [["the fluorescence", "TEST", 24, 40], ["intense", "OBSERVATION_MODIFIER", 3, 10], ["quenching", "OBSERVATION", 11, 20], ["local", "OBSERVATION_MODIFIER", 61, 66], ["dielectric environment", "OBSERVATION", 67, 89]]], ["The tertiary structure perturbations post-interaction to ligands were assessed using the principle of intrinsic fluorescence of 3CLPro which has three tryptophan residues which contribute to its hydrophobicity and fluorescence properties.", [["3CLPro", "CHEMICAL", 128, 134], ["tryptophan", "CHEMICAL", 151, 161], ["3CLPro", "CHEMICAL", 128, 134], ["tryptophan", "CHEMICAL", 151, 161], ["3CLPro", "SIMPLE_CHEMICAL", 128, 134], ["The tertiary structure perturbations", "PROBLEM", 0, 36], ["intrinsic fluorescence of 3CLPro", "TREATMENT", 102, 134], ["three tryptophan residues", "TREATMENT", 145, 170], ["its hydrophobicity and fluorescence properties", "PROBLEM", 191, 237], ["tertiary", "OBSERVATION_MODIFIER", 4, 12], ["tryptophan residues", "OBSERVATION", 151, 170], ["hydrophobicity", "OBSERVATION_MODIFIER", 195, 209]]], ["In the fluorescence quenching experiment 1 \u03bcM of 3CLPro was allowed to interact with varying concentrations of drugs.", [["3CLPro", "CHEMICAL", 49, 55], ["3CLPro", "CHEMICAL", 49, 55], ["3CLPro", "SIMPLE_CHEMICAL", 49, 55], ["3CLPro", "TREATMENT", 49, 55], ["drugs", "TREATMENT", 111, 116]]], ["Fluorescence signals were monitored at 295 nm excitation with emission scan between 310 and 400 nm using Cary Eclipse fluorescence spectrophotometer (Agilent technologies).Bimolecular interaction by surface plasmon resonance spectroscopy ::: Materials and methodsThe binding between 3CLPro and Teicoplanin was measured using surface plasmon resonance spectroscopy (SPR) Biacore 3000 (GE Healthcare.).", [["Teicoplanin", "CHEMICAL", 294, 305], ["3CLPro", "CHEMICAL", 283, 289], ["Teicoplanin", "CHEMICAL", 294, 305], ["3CLPro", "SIMPLE_CHEMICAL", 283, 289], ["Teicoplanin", "SIMPLE_CHEMICAL", 294, 305], ["Fluorescence signals", "TEST", 0, 20], ["emission scan", "TEST", 62, 75], ["Cary Eclipse fluorescence spectrophotometer (Agilent technologies", "TREATMENT", 105, 170], ["surface plasmon resonance spectroscopy", "TEST", 199, 237], ["3CLPro and Teicoplanin", "TREATMENT", 283, 305], ["surface plasmon resonance spectroscopy", "TREATMENT", 325, 363]]], ["For our SPR experiments, 3CLPro protein (10 mg/mL) solution in PBS buffer pH 7.4 was first immobilized to a CM5 gold chip using EDC-NHS coupling and the binding of varying concentrations of Teicoplanin was tested.", [["3CLPro", "CHEMICAL", 25, 31], ["EDC-NHS", "CHEMICAL", 128, 135], ["Teicoplanin", "CHEMICAL", 190, 201], ["Teicoplanin", "CHEMICAL", 190, 201], ["3CLPro", "SIMPLE_CHEMICAL", 25, 31], ["EDC-NHS", "SIMPLE_CHEMICAL", 128, 135], ["Teicoplanin", "SIMPLE_CHEMICAL", 190, 201], ["3CLPro protein", "PROTEIN", 25, 39], ["our SPR experiments", "TREATMENT", 4, 23], ["3CLPro protein", "TREATMENT", 25, 39], ["PBS buffer pH", "TEST", 63, 76], ["NHS coupling", "TREATMENT", 132, 144], ["Teicoplanin", "TREATMENT", 190, 201]]], ["The resultant sensorgram was analysed using BIA evaluation software to determine the binding constants.Thermofluor\u00ae assay ::: Materials and methodsBimolecular interactions of 3CLPro and Teicoplanin were measured by Thermofluor\u00ae assay [18].", [["3CLPro", "CHEMICAL", 175, 181], ["Teicoplanin", "CHEMICAL", 186, 197], ["3CLPro", "CHEMICAL", 175, 181], ["Teicoplanin", "CHEMICAL", 186, 197], ["3CLPro", "SIMPLE_CHEMICAL", 175, 181], ["Teicoplanin", "SIMPLE_CHEMICAL", 186, 197], ["The resultant sensorgram", "TEST", 0, 24], ["BIA evaluation software", "TEST", 44, 67], ["the binding constants", "PROBLEM", 81, 102], ["3CLPro and Teicoplanin", "TREATMENT", 175, 197]]], ["3CLPro enzyme was incubated with Teicoplanin and 20\u00d7 SYPRO\u00ae Orange Protein Gel Stain (S5692) in buffer and thermal scanning was performed from 25 \u00b0C to 99 \u00b0C at an interval of 0.5 \u00b0C/min with hold of 0.5 min at each measurement.", [["Teicoplanin", "CHEMICAL", 33, 44], ["Teicoplanin", "CHEMICAL", 33, 44], ["3CLPro", "GENE_OR_GENE_PRODUCT", 0, 6], ["Teicoplanin", "SIMPLE_CHEMICAL", 33, 44], ["3CLPro enzyme", "PROTEIN", 0, 13], ["3CLPro enzyme", "TEST", 0, 13], ["Teicoplanin", "TREATMENT", 33, 44], ["Protein Gel Stain", "TEST", 67, 84], ["thermal scanning", "TEST", 107, 123]]], ["The shift in melting curve was plotted and analysed.In-silico analysis of molecular interaction between Teicoplanin and 3CLPro ::: Materials and methodsThe backbone chain without water or other drugs of 3CLPro (PDB: 6LU7) was used for docking studies using ParDOCK+.", [["3CLPro", "CHEMICAL", 203, 209], ["ParDOCK", "CHEMICAL", 257, 264], ["Teicoplanin", "CHEMICAL", 104, 115], ["3CLPro", "CHEMICAL", 120, 126], ["3CLPro", "CHEMICAL", 203, 209], ["Teicoplanin", "SIMPLE_CHEMICAL", 104, 115], ["3CLPro", "SIMPLE_CHEMICAL", 120, 126], ["water", "SIMPLE_CHEMICAL", 179, 184], ["3CLPro", "SIMPLE_CHEMICAL", 203, 209], ["ParDOCK+", "SIMPLE_CHEMICAL", 257, 265], ["ParDOCK", "PROTEIN", 257, 264], ["melting curve", "TEST", 13, 26], ["Teicoplanin", "TREATMENT", 104, 115], ["The backbone chain", "TREATMENT", 152, 170], ["3CLPro (PDB", "TREATMENT", 203, 214], ["docking studies", "TEST", 235, 250], ["ParDOCK", "TEST", 257, 264], ["shift", "OBSERVATION_MODIFIER", 4, 9], ["backbone", "OBSERVATION_MODIFIER", 156, 164], ["chain", "OBSERVATION_MODIFIER", 165, 170]]], ["The best prediction coordinates were in agreement with the reported active sites i.e. His41 and Cys145.", [["Cys145", "CHEMICAL", 96, 102], ["His41", "CHEMICAL", 86, 91], ["Cys", "CHEMICAL", 96, 99], ["His41", "SIMPLE_CHEMICAL", 86, 91], ["Cys145", "AMINO_ACID", 96, 102], ["Cys", "TEST", 96, 99]]], ["The coordinate near the active site was fixed and subjected to site-specific docking by ParDOCK+.", [["ParDOCK", "CHEMICAL", 88, 95], ["ParDOCK+", "SIMPLE_CHEMICAL", 88, 96], ["active site", "DNA", 24, 35], ["ParDOCK", "PROTEIN", 88, 95], ["active", "OBSERVATION_MODIFIER", 24, 30], ["site", "OBSERVATION_MODIFIER", 31, 35]]], ["The 3-Dimensional structure of Teicoplanin (Pubchem ID: 16152170) was used as a ligand for docking.", [["Teicoplanin", "CHEMICAL", 31, 42], ["Pubchem ID: 16152170", "CHEMICAL", 44, 64], ["Teicoplanin", "CHEMICAL", 31, 42], ["Pubchem ID: 16152170", "CHEMICAL", 44, 64], ["Teicoplanin", "SIMPLE_CHEMICAL", 31, 42]]], ["The partial charge model used was AM1BCC with minimization cycles of 2500.", [["The partial charge model", "TREATMENT", 0, 24], ["minimization cycles", "TREATMENT", 46, 65]]], ["The four best poses were received and analysed.Purification and validation of 3CLPro ::: ResultsThe protein 3CLPro was cloned in pET28a vector and purified using affinity, ion exchange and SEC (Fig. 1).", [["3CLPro", "SIMPLE_CHEMICAL", 78, 84], ["3CLPro", "GENE_OR_GENE_PRODUCT", 108, 114], ["pET28a", "GENE_OR_GENE_PRODUCT", 129, 135], ["protein 3CLPro", "PROTEIN", 100, 114], ["pET28a vector", "DNA", 129, 142], ["The protein 3CLPro", "TREATMENT", 96, 114], ["ion exchange", "TREATMENT", 172, 184]]], ["The protein identity was confirmed with western blot using FLAG antibody (DYKDDDDK, # 2368 Cell Signaling Technology).Inhibition of 3CLPro enzymatic activity with inhibitors ::: ResultsFRET-based assay and casein assay was employed for the protease activity measurement.", [["FLAG", "GENE_OR_GENE_PRODUCT", 59, 63], ["3CLPro", "SIMPLE_CHEMICAL", 132, 138], ["FLAG antibody", "PROTEIN", 59, 72], ["DYKDDDDK", "PROTEIN", 74, 82], ["3CLPro", "PROTEIN", 132, 138], ["ResultsFRET", "PROTEIN", 178, 189], ["protease", "PROTEIN", 240, 248], ["The protein identity", "TEST", 0, 20], ["western blot", "TEST", 40, 52], ["FLAG antibody", "TEST", 59, 72], ["DYKDDDDK", "TEST", 74, 82], ["3CLPro enzymatic activity with inhibitors", "TREATMENT", 132, 173], ["casein assay", "TEST", 206, 218], ["the protease activity measurement", "TREATMENT", 236, 269]]], ["The relative fluorescence units were calculated for the correlation of fluorescence intensity and enzymatic activity.", [["The relative fluorescence units", "TREATMENT", 0, 31], ["fluorescence intensity", "TEST", 71, 93], ["enzymatic activity", "OBSERVATION", 98, 116]]], ["Initial velocity for enzymatic activity was plotted as a function of time which shows the typical fluorescence profile for the hydrolysis of the substrate.", [["Initial velocity", "TEST", 0, 16], ["enzymatic activity", "PROBLEM", 21, 39], ["velocity", "OBSERVATION_MODIFIER", 8, 16], ["enzymatic activity", "OBSERVATION", 21, 39]]], ["For calibration curve, 1 \u03bcM of enzyme was used with varied concentrations (from 0 to 10 \u03bcM) of substrate in a final volume of 500 \u03bcL reaction buffer, incubated for an hour.", [["calibration curve", "TEST", 4, 21], ["enzyme", "TEST", 31, 37], ["varied concentrations", "PROBLEM", 52, 73]]], ["Initial velocities were determined from the linear section of the curve, slope obtained is 4.1 RFU per hour (or 0.00114 RFU per sec), and the corresponding relative fluorescence units per unit of time (RFU/s) was converted to the amount of the cleaved substrate by fitting to the calibration curve (Fig. S1A).", [["Initial velocities", "TEST", 0, 18], ["slope", "TEST", 73, 78], ["the cleaved substrate", "PROBLEM", 240, 261], ["the calibration curve", "TEST", 276, 297], ["velocities", "OBSERVATION_MODIFIER", 8, 18]]], ["The kinetic parameter was calculated using 1 \u03bcM enzyme in 500 \u03bcl volume by varying the peptide substrate concentrations (0\u2013100 \u03bcM) and fitted with the Michaelis-Menten equation as well as Lineweaver-Burk plot (Fig. S1B and C).", [["S1B", "GENE_OR_GENE_PRODUCT", 215, 218], ["C", "GENE_OR_GENE_PRODUCT", 223, 224], ["1 \u03bcM enzyme", "TREATMENT", 43, 54], ["varying the peptide substrate concentrations", "TREATMENT", 75, 119], ["the Michaelis", "TEST", 147, 160]]], ["From the double reciprocal plot, ignoring the outlier points, parameters obtained are as: Km = (17.2 \u00b1 1.7) \u00d7 10\u22126 M, kcat = (0.51 \u00b1 0.05) s\u22121, kcat/Km = (29,316 \u00b1 2990) M\u22121 s\u22121.", [["M", "TEST", 115, 116], ["kcat", "TEST", 118, 122], ["s", "TEST", 139, 140], ["kcat/Km", "TEST", 144, 151], ["M\u22121 s", "TEST", 170, 175]]], ["The activity parameters are in consistent with recent findings where a different substrate Mca\u2013AVLQ\u2193SGFRK(Dnp)K was used, the catalytic efficiency (kcat/Km) for SARS-CoV-2 Mpro was measured to be 28,500 M\u22121 s\u22121, which is slightly higher than that for SARS-CoV Mpro (kcat/Km = 26,500 M\u22121 s\u22121) [19].Inhibition of 3CLPro enzymatic activity with inhibitors ::: ResultsFurther, we tried to find out and correlate with the previously reported kinetic parameters for 3CLpro of SARS-CoV-2 as well as SARS-CoV, as they share a high-level of sequence similarity, and have tabulated this information in Supplementary Table S1 [[19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]].", [["Dnp", "CHEMICAL", 106, 109], ["K", "CHEMICAL", 110, 111], ["SARS", "DISEASE", 470, 474], ["SGFRK(Dnp)K", "CHEMICAL", 100, 111], ["Dnp)K", "GENE_OR_GENE_PRODUCT", 106, 111], ["3CLPro", "SIMPLE_CHEMICAL", 311, 317], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 470, 480], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 492, 500], ["[19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]]", "SIMPLE_CHEMICAL", 616, 723], ["Mca\u2013AVLQ", "PROTEIN", 91, 99], ["SGFRK(Dnp)K", "PROTEIN", 100, 111], ["3CLPro", "PROTEIN", 311, 317], ["SARS-CoV", "SPECIES", 251, 259], ["SARS-CoV", "SPECIES", 470, 478], ["SARS-CoV", "SPECIES", 492, 500], ["The activity parameters", "TEST", 0, 23], ["a different substrate Mca\u2013AVLQ", "TEST", 69, 99], ["K", "TEST", 110, 111], ["the catalytic efficiency", "TEST", 122, 146], ["kcat/Km)", "TEST", 148, 156], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["SARS", "TEST", 251, 255], ["CoV Mpro", "TEST", 256, 264], ["kcat", "TEST", 266, 270], ["Km", "TEST", 271, 273], ["M\u22121 s", "TEST", 283, 288], ["3CLPro enzymatic activity with inhibitors", "TREATMENT", 311, 352], ["SARS", "PROBLEM", 470, 474], ["CoV", "TEST", 475, 478], ["slightly", "OBSERVATION_MODIFIER", 221, 229], ["higher", "OBSERVATION_MODIFIER", 230, 236]]], ["The reason behind the huge variations in the kinetic parameter like kcat/Km values is unclear, as to whether it is because of the differences in experimental conditions, length of substrate, FRET pairs, peptide-substrate preparations, buffer compositions, or other assay methods.", [["kcat/Km", "GENE_OR_GENE_PRODUCT", 68, 75], ["the huge variations", "PROBLEM", 18, 37], ["the kinetic parameter", "TEST", 41, 62], ["kcat/Km values", "TEST", 68, 82], ["experimental conditions", "PROBLEM", 145, 168], ["substrate preparations", "TREATMENT", 211, 233], ["buffer compositions", "TREATMENT", 235, 254], ["other assay methods", "TEST", 259, 278], ["huge", "OBSERVATION_MODIFIER", 22, 26], ["variations", "OBSERVATION", 27, 37]]], ["It is well documented that the protein preparations are very crucial for the enzymatically-active form of 3CLPro, compared in past, in the presence and absence of histidine tag, as it exists in monomer and dimer mixed states.", [["3CLPro", "CHEMICAL", 106, 112], ["histidine", "CHEMICAL", 163, 172], ["3CLPro", "CHEMICAL", 106, 112], ["histidine", "CHEMICAL", 163, 172], ["3CLPro", "SIMPLE_CHEMICAL", 106, 112], ["histidine", "AMINO_ACID", 163, 172], ["3CLPro", "PROTEIN", 106, 112], ["histidine tag", "PROTEIN", 163, 176], ["the protein preparations", "TREATMENT", 27, 51], ["3CLPro", "TREATMENT", 106, 112], ["histidine tag", "PROBLEM", 163, 176], ["histidine tag", "OBSERVATION", 163, 176], ["mixed", "OBSERVATION_MODIFIER", 212, 217]]], ["The dimer of the 3C-like proteinase is the active form of the enzyme and predomination of the inactive monomeric form with low concentrations of the active dimers in the experiment might be a major reason for these observations.Inhibition of 3CLPro enzymatic activity with inhibitors ::: ResultsWe also used a non-specific casein substrate for determining the proteolytic activity of 3CLPro.", [["3CLPro", "SIMPLE_CHEMICAL", 242, 248], ["3CLPro", "SIMPLE_CHEMICAL", 384, 390], ["3C-like proteinase", "PROTEIN", 17, 35], ["enzyme", "PROTEIN", 62, 68], ["inactive monomeric form", "PROTEIN", 94, 117], ["3CLPro", "PROTEIN", 242, 248], ["3CLPro", "PROTEIN", 384, 390], ["the enzyme", "TEST", 58, 68], ["low concentrations of the active dimers", "PROBLEM", 123, 162], ["3CLPro enzymatic activity with inhibitors", "TREATMENT", 242, 283], ["a non-specific casein substrate", "TREATMENT", 308, 339], ["3CLPro", "TREATMENT", 384, 390], ["active", "OBSERVATION_MODIFIER", 43, 49], ["low concentrations", "OBSERVATION_MODIFIER", 123, 141], ["active dimers", "OBSERVATION", 149, 162]]], ["The slope of the tyrosine standard plot (0.0011 Absorbance Unit 280 nm per \u03bcM) (Fig. S1D) was used for calculating the enzyme activity of 3CLPro, as a measure of tyrosine liberated from casein upon hydrolysis.", [["tyrosine", "CHEMICAL", 17, 25], ["tyrosine", "CHEMICAL", 162, 170], ["tyrosine", "CHEMICAL", 17, 25], ["3CLPro", "CHEMICAL", 138, 144], ["tyrosine", "CHEMICAL", 162, 170], ["tyrosine", "AMINO_ACID", 17, 25], ["3CLPro", "SIMPLE_CHEMICAL", 138, 144], ["tyrosine", "AMINO_ACID", 162, 170], ["casein", "GENE_OR_GENE_PRODUCT", 186, 192], ["the tyrosine standard plot", "TREATMENT", 13, 39], ["nm per \u03bcM) (Fig. S1D)", "TREATMENT", 68, 89], ["3CLPro", "TREATMENT", 138, 144]]], ["The kinetic parameters for the enzyme were obtained by fitting the observed values in Michaelis-Menten equation and Lineweaver-Burk plot (Fig. S1E and F).", [["S1E", "PROTEIN", 143, 146], ["The kinetic parameters", "TEST", 0, 22], ["the enzyme", "TEST", 27, 37], ["Michaelis", "TEST", 86, 95], ["Menten equation", "TEST", 96, 111], ["Lineweaver", "TEST", 116, 126]]], ["From the double reciprocal plot, the values obtained were as follows: Km = (116 \u00b1 12) \u00d7 10\u22126 M, kcat = (0.46 \u00b1 0.05) s\u22121, kcat/Km = (3917 \u00b1 470) M\u22121 s\u22121.", [["the double reciprocal plot", "TEST", 5, 31], ["Km", "TEST", 70, 72], ["M", "TEST", 93, 94], ["kcat", "TEST", 96, 100], ["s", "TEST", 117, 118], ["kcat/Km", "TEST", 122, 129], ["M\u22121 s", "TEST", 145, 150]]], ["The catalytic efficiency of 3CLPro towards specific peptide substrate DABCYL-MYTPHTVLQ\u2193AVGACVLCN-EDANS was found to be about 7.5 fold higher than broad specificity casein substrate possessing multiple cleavage sites.Inhibition of 3CLPro enzymatic activity with inhibitors ::: ResultsFrom literature search and some computational studies, we have prepared a list of about 100 potential molecules.", [["3CLPro", "CHEMICAL", 28, 34], ["3CLPro", "CHEMICAL", 28, 34], ["3CLPro", "SIMPLE_CHEMICAL", 28, 34], ["3CLPro", "SIMPLE_CHEMICAL", 230, 236], ["MYTPHTVLQ", "PROTEIN", 77, 86], ["AVGACVLCN", "PROTEIN", 87, 96], ["EDANS", "PROTEIN", 97, 102], ["multiple cleavage sites", "PROTEIN", 192, 215], ["3CLPro", "PROTEIN", 230, 236], ["The catalytic efficiency", "TREATMENT", 0, 24], ["3CLPro", "TREATMENT", 28, 34], ["specific peptide substrate DABCYL", "TEST", 43, 76], ["AVGACVLCN", "TEST", 87, 96], ["broad specificity casein substrate", "TREATMENT", 146, 180], ["multiple cleavage sites", "PROBLEM", 192, 215], ["3CLPro enzymatic activity with inhibitors", "TREATMENT", 230, 271], ["literature search", "TEST", 288, 305], ["some computational studies", "TEST", 310, 336], ["multiple", "OBSERVATION_MODIFIER", 192, 200], ["cleavage sites", "OBSERVATION", 201, 215]]], ["We found only 23 drugs in our initial screening which has some effect on protease activity and finalised 11 drugs for our further studies based on based on their inhibition profile under similar experimental conditions using 16 \u03bcM of inhibitors (Table 1).", [["protease", "PROTEIN", 73, 81], ["our initial screening", "TEST", 26, 47], ["protease activity", "TREATMENT", 73, 90], ["our further studies", "TEST", 118, 137], ["16 \u03bcM of inhibitors", "TREATMENT", 225, 244], ["23 drugs", "OBSERVATION_MODIFIER", 14, 22]]], ["The effect of selected 11 inhibitors on the enzymatic activity of 3CLPro was monitored by peptide substrate and casein substrate (Fig. 2A\u2013D).", [["3CLPro", "CHEMICAL", 66, 72], ["3CLPro", "SIMPLE_CHEMICAL", 66, 72], ["casein substrate", "SIMPLE_CHEMICAL", 112, 128], ["casein substrate", "PROTEIN", 112, 128], ["selected 11 inhibitors", "TREATMENT", 14, 36], ["3CLPro", "TREATMENT", 66, 72]]], ["Teicoplanin emerged as the best inhibitor in our studies with an IC50 value of 1.61 \u00b1 0.09 \u03bcM and 1.46 \u00b1 0.05 \u03bcM with peptide and casein substrate respectively (Fig. 2E, F).", [["Teicoplanin", "CHEMICAL", 0, 11], ["Teicoplanin", "CHEMICAL", 0, 11], ["Teicoplanin", "SIMPLE_CHEMICAL", 0, 11], ["casein substrate", "SIMPLE_CHEMICAL", 130, 146], ["Teicoplanin", "TREATMENT", 0, 11], ["our studies", "TEST", 45, 56], ["an IC50 value", "TEST", 62, 75], ["peptide and casein substrate", "TREATMENT", 118, 146]]], ["Teicoplanin was found to be more effective among the currently used/proposed anti-COVID19 drugs such as lopinavir, Hydroxychloroquine, Chloroquine, Atazanavir, Azithromycin.Studying protein-ligand interactions by fluorescence spectroscopy ::: ResultsThe fluorescence quenching spectra of 3CLPro protease titrated to increasing concentrations of various molecules are shown in Fig. 3.", [["Teicoplanin", "CHEMICAL", 0, 11], ["lopinavir", "CHEMICAL", 104, 113], ["Hydroxychloroquine", "CHEMICAL", 115, 133], ["Chloroquine", "CHEMICAL", 135, 146], ["Atazanavir", "CHEMICAL", 148, 158], ["Azithromycin", "CHEMICAL", 160, 172], ["Teicoplanin", "CHEMICAL", 0, 11], ["lopinavir", "CHEMICAL", 104, 113], ["Hydroxychloroquine", "CHEMICAL", 115, 133], ["Chloroquine", "CHEMICAL", 135, 146], ["Atazanavir", "CHEMICAL", 148, 158], ["Azithromycin", "CHEMICAL", 160, 172], ["Teicoplanin", "SIMPLE_CHEMICAL", 0, 11], ["anti-COVID19", "SIMPLE_CHEMICAL", 77, 89], ["lopinavir", "SIMPLE_CHEMICAL", 104, 113], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 115, 133], ["Chloroquine", "SIMPLE_CHEMICAL", 135, 146], ["Atazanavir", "SIMPLE_CHEMICAL", 148, 158], ["Azithromycin", "SIMPLE_CHEMICAL", 160, 172], ["3CLPro protease", "GENE_OR_GENE_PRODUCT", 288, 303], ["3CLPro protease", "PROTEIN", 288, 303], ["Teicoplanin", "TREATMENT", 0, 11], ["proposed anti-COVID19 drugs", "TREATMENT", 68, 95], ["lopinavir", "TREATMENT", 104, 113], ["Hydroxychloroquine", "TREATMENT", 115, 133], ["Chloroquine", "TREATMENT", 135, 146], ["Atazanavir", "TREATMENT", 148, 158], ["Azithromycin", "TREATMENT", 160, 172], ["fluorescence spectroscopy", "TEST", 213, 238], ["The fluorescence quenching spectra", "TREATMENT", 250, 284], ["3CLPro protease", "TREATMENT", 288, 303], ["increasing concentrations of various molecules", "PROBLEM", 316, 362]]], ["The overall structural perturbations on the 3CLPro with ligands were assessed by fluorescence quenching.", [["3CLPro", "CHEMICAL", 44, 50], ["3CLPro", "SIMPLE_CHEMICAL", 44, 50], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["structural perturbations", "OBSERVATION", 12, 36]]], ["Upon titration with Teicoplanin there was a gradual decrease in fluorescence intensity with concentration (Fig. 3A).", [["Teicoplanin", "CHEMICAL", 20, 31], ["Teicoplanin", "CHEMICAL", 20, 31], ["Teicoplanin", "SIMPLE_CHEMICAL", 20, 31], ["Teicoplanin", "TREATMENT", 20, 31], ["a gradual decrease in fluorescence intensity", "PROBLEM", 42, 86], ["gradual", "OBSERVATION_MODIFIER", 44, 51], ["decrease", "OBSERVATION_MODIFIER", 52, 60]]], ["A significant quenching of the 3CLPro fluorescence emission was observed with Teicoplanin.", [["Teicoplanin", "CHEMICAL", 78, 89], ["Teicoplanin", "CHEMICAL", 78, 89], ["3CLPro", "SIMPLE_CHEMICAL", 31, 37], ["Teicoplanin", "SIMPLE_CHEMICAL", 78, 89], ["the 3CLPro fluorescence emission", "TREATMENT", 27, 59], ["Teicoplanin", "TREATMENT", 78, 89], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["quenching", "OBSERVATION", 14, 23]]], ["This observation indicates the probable involvement of Trp residues of protein in the conformational dynamics.", [["Trp", "CHEMICAL", 55, 58], ["Trp", "AMINO_ACID", 55, 58], ["This observation", "TEST", 0, 16], ["Trp residues of protein", "PROBLEM", 55, 78], ["Trp residues", "OBSERVATION", 55, 67]]], ["The concentration-dependent quenching was also observed in case of lopinavir, hydroxychloroquine and chloroquine (Fig. 3B\u2013D).", [["lopinavir", "CHEMICAL", 67, 76], ["hydroxychloroquine", "CHEMICAL", 78, 96], ["chloroquine", "CHEMICAL", 101, 112], ["lopinavir", "CHEMICAL", 67, 76], ["hydroxychloroquine", "CHEMICAL", 78, 96], ["chloroquine", "CHEMICAL", 101, 112], ["Fig. 3B\u2013D", "CHEMICAL", 114, 123], ["lopinavir", "SIMPLE_CHEMICAL", 67, 76], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 78, 96], ["chloroquine", "SIMPLE_CHEMICAL", 101, 112], ["Fig. 3B\u2013D", "SIMPLE_CHEMICAL", 114, 123], ["The concentration-dependent quenching", "TREATMENT", 0, 37], ["lopinavir", "TREATMENT", 67, 76], ["hydroxychloroquine", "TREATMENT", 78, 96], ["chloroquine", "TREATMENT", 101, 112]]], ["The interaction of 3CLPro with hydroxychloroquine and chloroquine led to protein conformation changes from native state to unfolded state (332 nm to 360 nm peak transitions).", [["3CLPro", "CHEMICAL", 19, 25], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["chloroquine", "CHEMICAL", 54, 65], ["3CLPro", "CHEMICAL", 19, 25], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["chloroquine", "CHEMICAL", 54, 65], ["3CLPro", "SIMPLE_CHEMICAL", 19, 25], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["chloroquine", "SIMPLE_CHEMICAL", 54, 65], ["3CLPro", "TREATMENT", 19, 25], ["hydroxychloroquine", "TREATMENT", 31, 49], ["chloroquine", "TREATMENT", 54, 65], ["protein conformation changes", "PROBLEM", 73, 101], ["unfolded state", "PROBLEM", 123, 137]]], ["This depicts that three tryptophan residues in 3CLPro are exposed more in unfolded state with hydroxychloroquine and chloroquine.", [["tryptophan", "CHEMICAL", 24, 34], ["3CLPro", "CHEMICAL", 47, 53], ["hydroxychloroquine", "CHEMICAL", 94, 112], ["chloroquine", "CHEMICAL", 117, 128], ["tryptophan", "CHEMICAL", 24, 34], ["3CLPro", "CHEMICAL", 47, 53], ["hydroxychloroquine", "CHEMICAL", 94, 112], ["chloroquine", "CHEMICAL", 117, 128], ["3CLPro", "SIMPLE_CHEMICAL", 47, 53], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 94, 112], ["chloroquine", "SIMPLE_CHEMICAL", 117, 128], ["three tryptophan residues", "PROBLEM", 18, 43], ["hydroxychloroquine", "TREATMENT", 94, 112], ["chloroquine", "TREATMENT", 117, 128], ["tryptophan residues", "OBSERVATION", 24, 43]]], ["The other drugs like aciclovir, famciclovir, atazanavir, and azithromycin displayed some quenching (Fig. 3E\u2013H).", [["aciclovir", "CHEMICAL", 21, 30], ["famciclovir", "CHEMICAL", 32, 43], ["atazanavir", "CHEMICAL", 45, 55], ["azithromycin", "CHEMICAL", 61, 73], ["aciclovir", "CHEMICAL", 21, 30], ["famciclovir", "CHEMICAL", 32, 43], ["atazanavir", "CHEMICAL", 45, 55], ["azithromycin", "CHEMICAL", 61, 73], ["aciclovir", "SIMPLE_CHEMICAL", 21, 30], ["famciclovir", "SIMPLE_CHEMICAL", 32, 43], ["atazanavir", "SIMPLE_CHEMICAL", 45, 55], ["azithromycin", "SIMPLE_CHEMICAL", 61, 73], ["The other drugs", "TREATMENT", 0, 15], ["aciclovir", "TREATMENT", 21, 30], ["famciclovir", "TREATMENT", 32, 43], ["atazanavir", "TREATMENT", 45, 55], ["azithromycin", "TREATMENT", 61, 73]]], ["Rest of the drugs were not able to display any observable changes in the protein (Fig. 3I\u2013K).Studying protein-ligand interactions by fluorescence spectroscopy ::: ResultsThe fluorescence quenching is usually described by the linear Stern\u2013Volmer equations [19].F0/F=1+KSVQwhere F0 and F are the intrinsic fluorescence intensities of 3CLPro (fluorophore) in the absence or presence of the quencher respectively.", [["3CLPro", "CHEMICAL", 332, 338], ["3CLPro", "SIMPLE_CHEMICAL", 332, 338], ["fluorophore", "SIMPLE_CHEMICAL", 340, 351], ["3I\u2013K", "CELL_LINE", 87, 91], ["any observable changes in the protein", "PROBLEM", 43, 80], ["fluorescence spectroscopy", "TEST", 133, 158], ["The fluorescence quenching", "PROBLEM", 170, 196], ["3CLPro (fluorophore", "TREATMENT", 332, 351]]], ["[Q] is the concentration of the quencher, and KSV is the Stern\u2013Volmer quenching constant.Studying protein-ligand interactions by fluorescence spectroscopy ::: ResultsThe maximum fluorescence intensity at 333 nm was used for all KSV calculations.", [["KSV", "SIMPLE_CHEMICAL", 46, 49], ["fluorescence spectroscopy", "TEST", 129, 154], ["all KSV calculations", "TEST", 224, 244], ["maximum", "OBSERVATION_MODIFIER", 170, 177]]], ["The Stern\u2013Volmer plots for fluorescence quenching by all inhibitors are shown in Fig. 3L.", [["The Stern\u2013Volmer plots", "TREATMENT", 0, 22], ["fluorescence quenching", "TREATMENT", 27, 49], ["all inhibitors", "TREATMENT", 53, 67]]], ["The magnitude of KSV Stern\u2013Volmer quenching constant for Teicoplanin was estimated 2.5 \u00d7 105 L\u00b7mol\u22121 (Table 2), which suggests a relatively high affinity between Teicoplanin and 3CLPro protease.", [["Teicoplanin", "CHEMICAL", 57, 68], ["Teicoplanin", "CHEMICAL", 162, 173], ["Teicoplanin", "CHEMICAL", 57, 68], ["Teicoplanin", "CHEMICAL", 162, 173], ["Teicoplanin", "SIMPLE_CHEMICAL", 57, 68], ["Teicoplanin", "SIMPLE_CHEMICAL", 162, 173], ["3CLPro protease", "GENE_OR_GENE_PRODUCT", 178, 193], ["Teicoplanin", "PROTEIN", 162, 173], ["3CLPro protease", "PROTEIN", 178, 193], ["KSV", "TEST", 17, 20], ["Teicoplanin", "TREATMENT", 57, 68], ["a relatively high affinity", "PROBLEM", 127, 153], ["Teicoplanin", "TREATMENT", 162, 173], ["3CLPro protease", "TREATMENT", 178, 193], ["high affinity", "OBSERVATION", 140, 153]]], ["The strongest effect was observed with Teicoplanin while the others show a diminished effect.Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsSurface plasmon resonance was employed to monitor the molecular interactions in real-time between 3CLPro and the identified ligand molecule.", [["Teicoplanin", "CHEMICAL", 39, 50], ["Teicoplanin", "CHEMICAL", 39, 50], ["3CLPro", "CHEMICAL", 138, 144], ["Teicoplanin", "CHEMICAL", 149, 160], ["3CLPro", "CHEMICAL", 270, 276], ["Teicoplanin", "SIMPLE_CHEMICAL", 39, 50], ["3CLPro", "SIMPLE_CHEMICAL", 138, 144], ["Teicoplanin", "SIMPLE_CHEMICAL", 149, 160], ["3CLPro", "SIMPLE_CHEMICAL", 270, 276], ["3CLPro", "PROTEIN", 270, 276], ["Teicoplanin", "TREATMENT", 39, 50], ["a diminished effect", "PROBLEM", 73, 92], ["ResultsSurface plasmon resonance", "TEST", 165, 197], ["3CLPro", "TREATMENT", 270, 276], ["diminished", "OBSERVATION", 75, 85], ["bimolecular interactions", "OBSERVATION", 105, 129], ["ligand molecule", "OBSERVATION", 296, 311]]], ["SPR is generally used to determine the binding specificity of molecules, including rates of association and dissociation between drug molecules and target proteins.Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsIn this study, the SARS-CoV 3CLPro was immobilized on a sensor chip, and the identified molecule Teicoplanin was passed over the sensor's surface.", [["surface", "ANATOMY", 381, 388], ["SARS", "DISEASE", 262, 266], ["Teicoplanin", "CHEMICAL", 340, 351], ["3CLPro", "CHEMICAL", 209, 215], ["Teicoplanin", "CHEMICAL", 220, 231], ["Teicoplanin", "CHEMICAL", 340, 351], ["3CLPro", "SIMPLE_CHEMICAL", 209, 215], ["Teicoplanin", "SIMPLE_CHEMICAL", 220, 231], ["Teicoplanin", "SIMPLE_CHEMICAL", 340, 351], ["surface", "CELLULAR_COMPONENT", 381, 388], ["drug molecules", "PROTEIN", 129, 143], ["target proteins", "PROTEIN", 148, 163], ["SARS-CoV 3CLPro", "DNA", 262, 277], ["SARS-CoV", "SPECIES", 262, 270], ["dissociation between drug molecules", "PROBLEM", 108, 143], ["target proteins", "PROBLEM", 148, 163], ["this study", "TEST", 246, 256], ["the SARS", "TEST", 258, 266], ["a sensor chip", "TREATMENT", 297, 310], ["the identified molecule Teicoplanin", "TREATMENT", 316, 351], ["bimolecular interactions", "OBSERVATION", 176, 200], ["molecule Teicoplanin", "OBSERVATION", 331, 351]]], ["The SPR sensorgram of the compound was recorded at varying concentrations of analyte molecule.", [["The SPR sensorgram", "TEST", 0, 18], ["analyte molecule", "OBSERVATION", 77, 93]]], ["The real-time binding kinetics and affinity of 3CLPro were measured for Teicoplanin.", [["Teicoplanin", "CHEMICAL", 72, 83], ["Teicoplanin", "CHEMICAL", 72, 83], ["3CLPro", "SIMPLE_CHEMICAL", 47, 53], ["Teicoplanin", "SIMPLE_CHEMICAL", 72, 83], ["3CLPro", "TREATMENT", 47, 53], ["Teicoplanin", "TREATMENT", 72, 83]]], ["For 3CLPro, the molecule Teicoplanin increased the SPR sensorgram significantly and in a dose-dependent manner (Fig. 4A).Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsThe association constant (kon) was recorded as 7.8 \u00d7 103 (1/Ms) and the dissociation rate constant (koff) was found to be 0.012 (1/s).", [["Teicoplanin", "CHEMICAL", 25, 36], ["Teicoplanin", "CHEMICAL", 177, 188], ["Teicoplanin", "CHEMICAL", 25, 36], ["3CLPro", "CHEMICAL", 166, 172], ["Teicoplanin", "CHEMICAL", 177, 188], ["3CLPro", "SIMPLE_CHEMICAL", 4, 10], ["Teicoplanin", "SIMPLE_CHEMICAL", 25, 36], ["3CLPro", "SIMPLE_CHEMICAL", 166, 172], ["Teicoplanin", "SIMPLE_CHEMICAL", 177, 188], ["3CLPro", "TREATMENT", 4, 10], ["the molecule Teicoplanin", "TREATMENT", 12, 36], ["the SPR sensorgram", "TEST", 47, 65], ["the dissociation rate", "TEST", 268, 289], ["Teicoplanin", "OBSERVATION_MODIFIER", 25, 36], ["bimolecular interactions", "OBSERVATION", 133, 157]]], ["The dissociation constant KD (koff/kon) was calculated by globally fitting the kinetic data at various concentrations of Teicoplanin according to fitting model \u201c1:1 (Langmuir binding)\u201d.", [["Teicoplanin", "CHEMICAL", 121, 132], ["Teicoplanin", "CHEMICAL", 121, 132], ["Teicoplanin", "SIMPLE_CHEMICAL", 121, 132], ["The dissociation", "PROBLEM", 0, 16], ["Teicoplanin", "TREATMENT", 121, 132]]], ["The equilibrium rate constant (KD) was calculated by the formulaKD=koff/konMwhere, K is the equilibrium dissociation constant, kon is association rate constant, and koff is dissociation rate constant.", [["K", "CHEMICAL", 83, 84], ["The equilibrium rate", "TEST", 0, 20], ["the equilibrium dissociation", "PROBLEM", 88, 116]]], ["The KD was recorded as 1.6 \u00d7 10\u22126 M defining a good interaction between the immobilized 3CLPro and Teicoplanin (Fig. 4A).Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsWe tested various concentrations of Teicoplanin over 3CLPro and recorded the corresponding response units.", [["Teicoplanin", "CHEMICAL", 99, 110], ["Teicoplanin", "CHEMICAL", 236, 247], ["3CLPro", "CHEMICAL", 88, 94], ["Teicoplanin", "CHEMICAL", 99, 110], ["3CLPro", "CHEMICAL", 166, 172], ["Teicoplanin", "CHEMICAL", 177, 188], ["Teicoplanin", "CHEMICAL", 236, 247], ["3CLPro", "SIMPLE_CHEMICAL", 88, 94], ["Teicoplanin", "SIMPLE_CHEMICAL", 99, 110], ["3CLPro", "SIMPLE_CHEMICAL", 166, 172], ["Teicoplanin", "SIMPLE_CHEMICAL", 177, 188], ["Teicoplanin", "SIMPLE_CHEMICAL", 236, 247], ["3CLPro", "SIMPLE_CHEMICAL", 253, 259], ["The KD", "TEST", 0, 6], ["the immobilized 3CLPro", "TREATMENT", 72, 94], ["Teicoplanin", "TREATMENT", 99, 110], ["Teicoplanin", "TREATMENT", 236, 247], ["3CLPro", "TREATMENT", 253, 259], ["bimolecular interactions", "OBSERVATION", 133, 157], ["response units", "OBSERVATION", 291, 305]]], ["We tried lower concentrations of Teicoplanin and found 1:1 binding at those concentrations.", [["Teicoplanin", "CHEMICAL", 33, 44], ["Teicoplanin", "CHEMICAL", 33, 44], ["Teicoplanin", "SIMPLE_CHEMICAL", 33, 44], ["Teicoplanin", "TREATMENT", 33, 44]]], ["When we increased the concentrations of the Teicoplanin, the saturation level was not achieved, suggesting for multiple binding sites on 3CLPro with the analyte molecules.", [["Teicoplanin", "CHEMICAL", 44, 55], ["Teicoplanin", "CHEMICAL", 44, 55], ["3CLPro", "CHEMICAL", 137, 143], ["Teicoplanin", "SIMPLE_CHEMICAL", 44, 55], ["3CLPro", "SIMPLE_CHEMICAL", 137, 143], ["the Teicoplanin", "TREATMENT", 40, 55], ["the saturation level", "TEST", 57, 77], ["multiple binding sites", "PROBLEM", 111, 133], ["3CLPro", "TREATMENT", 137, 143], ["the analyte molecules", "TREATMENT", 149, 170]]], ["These promiscuous binding are seen when more molecule is available for binding to non-specific sites after the active sites are saturated with the molecule.Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsThe effect of Teicoplanin on the 3CLPro protein was analysed using Thermofluor assay\u00ae which relies upon the binding of SYPRO\u00ae dye to exposed hydrophobic patches on heating.", [["Teicoplanin", "CHEMICAL", 249, 260], ["SYPRO\u00ae dye", "CHEMICAL", 354, 364], ["3CLPro", "CHEMICAL", 201, 207], ["Teicoplanin", "CHEMICAL", 212, 223], ["Teicoplanin", "CHEMICAL", 249, 260], ["3CLPro", "SIMPLE_CHEMICAL", 201, 207], ["Teicoplanin", "SIMPLE_CHEMICAL", 212, 223], ["Teicoplanin", "SIMPLE_CHEMICAL", 249, 260], ["3CLPro", "GENE_OR_GENE_PRODUCT", 268, 274], ["SYPRO\u00ae dye", "SIMPLE_CHEMICAL", 354, 364], ["3CLPro protein", "PROTEIN", 268, 282], ["These promiscuous binding", "PROBLEM", 0, 25], ["binding to non-specific sites", "PROBLEM", 71, 100], ["the active sites", "PROBLEM", 107, 123], ["Teicoplanin", "TREATMENT", 249, 260], ["the 3CLPro protein", "TREATMENT", 264, 282], ["Thermofluor assay\u00ae", "TREATMENT", 302, 320], ["SYPRO\u00ae dye", "TREATMENT", 354, 364], ["promiscuous binding", "OBSERVATION", 6, 25], ["active", "OBSERVATION_MODIFIER", 111, 117], ["saturated", "OBSERVATION_MODIFIER", 128, 137], ["bimolecular interactions", "OBSERVATION", 168, 192], ["hydrophobic patches", "OBSERVATION", 376, 395]]], ["The melting temperature (TM) of native protein was recorded ~57 \u00b0C, whereas the same for the Teicoplanin-3CLPro complex was found ~49 \u00b0C (Fig. 4B).", [["Teicoplanin", "CHEMICAL", 93, 104], ["Teicoplanin-3CLPro", "CHEMICAL", 93, 111], ["Teicoplanin-3CLPro", "GENE_OR_GENE_PRODUCT", 93, 111], ["native protein", "PROTEIN", 32, 46], ["Teicoplanin", "PROTEIN", 93, 104], ["3CLPro complex", "PROTEIN", 105, 119], ["The melting temperature", "TEST", 0, 23], ["native protein", "TEST", 32, 46], ["the Teicoplanin", "TEST", 89, 104]]], ["The interaction of inhibitors shifts the melting temperature which is a signature of protein stability.", [["inhibitors", "TREATMENT", 19, 29], ["the melting temperature", "PROBLEM", 37, 60], ["protein stability", "OBSERVATION", 85, 102]]], ["The binding doesn't alter the monomeric conformation of 3CLPro as depicted by SEC (Fig. 4C).Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsOur docking analysis using PARDock revealed that the ligand drug Teicoplanin fits perfectly in the active site pocket (Fig. 4D) and the binding energy obtained for this binding is about \u22128 kcal/mol.", [["Teicoplanin", "CHEMICAL", 236, 247], ["3CLPro", "CHEMICAL", 56, 62], ["3CLPro", "CHEMICAL", 137, 143], ["Teicoplanin", "CHEMICAL", 148, 159], ["Teicoplanin", "CHEMICAL", 236, 247], ["3CLPro", "SIMPLE_CHEMICAL", 56, 62], ["3CLPro", "SIMPLE_CHEMICAL", 137, 143], ["Teicoplanin", "SIMPLE_CHEMICAL", 148, 159], ["Teicoplanin", "SIMPLE_CHEMICAL", 236, 247], ["3CLPro", "PROTEIN", 56, 62], ["SEC", "PROTEIN", 78, 81], ["active site pocket", "PROTEIN", 270, 288], ["3CLPro", "TREATMENT", 56, 62], ["Our docking analysis", "TEST", 171, 191], ["PARDock", "TEST", 198, 205], ["the ligand drug Teicoplanin", "TREATMENT", 220, 247], ["bimolecular interactions", "OBSERVATION", 104, 128], ["active", "OBSERVATION_MODIFIER", 270, 276], ["site", "OBSERVATION_MODIFIER", 277, 281], ["pocket", "OBSERVATION_MODIFIER", 282, 288]]], ["The cavity is lined by the active site amino acids i.e. histidine 41 and cysteine 145 (Fig. 4E).", [["amino acids", "CHEMICAL", 39, 50], ["histidine 41 and cysteine 145", "CHEMICAL", 56, 85], ["amino acids", "CHEMICAL", 39, 50], ["histidine", "CHEMICAL", 56, 65], ["cysteine", "CHEMICAL", 73, 81], ["amino acids", "AMINO_ACID", 39, 50], ["histidine 41", "AMINO_ACID", 56, 68], ["cysteine", "AMINO_ACID", 73, 81], ["145", "AMINO_ACID", 82, 85], ["amino acids", "TEST", 39, 50], ["histidine", "TEST", 56, 65], ["cysteine", "TEST", 73, 81], ["cavity", "OBSERVATION", 4, 10], ["lined", "OBSERVATION", 14, 19], ["active", "OBSERVATION_MODIFIER", 27, 33]]], ["The residues His41 and Cys145 form the catalytic dyad, form the substrate binding region and are located at the cleft of domain I and II in which His acts as a proton acceptor while Cys behaves as a nucleophile.", [["Cys", "CHEMICAL", 182, 185], ["His41", "CHEMICAL", 13, 18], ["Cys145", "CHEMICAL", 23, 29], ["His", "CHEMICAL", 146, 149], ["Cys", "CHEMICAL", 182, 185], ["His41", "GENE_OR_GENE_PRODUCT", 13, 18], ["Cys145", "AMINO_ACID", 23, 29], ["Cys", "AMINO_ACID", 182, 185], ["catalytic dyad", "PROTEIN", 39, 53], ["substrate binding region", "PROTEIN", 64, 88], ["domain I and II", "PROTEIN", 121, 136], ["The residues His41", "TEST", 0, 18], ["the catalytic dyad", "PROBLEM", 35, 53], ["a proton acceptor", "TREATMENT", 158, 175], ["a nucleophile", "TREATMENT", 197, 210], ["cleft", "OBSERVATION", 112, 117]]], ["Previously, it is reported that Teicoplanin is well docked with SARS-CoV-2 main protease using AutoDock4, AutoDock Vina and Dock6 docking programs, which also revealed that docked Teicoplanin is well accommodated within the inhibitor binding cavity in a manner similar a Michael acceptor inhibitor\u2014known as N3 which is a potent and irreversible inhibitor of SARS-CoV-2 [20].Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsTeicoplanin displays a bonding with the protein at the molecular level, via hydrophobic interactions, hydrogen bonding and halogen bonding.", [["Teicoplanin", "CHEMICAL", 32, 43], ["Teicoplanin", "CHEMICAL", 180, 191], ["N3", "CHEMICAL", 307, 309], ["Teicoplanin", "CHEMICAL", 453, 464], ["Teicoplanin", "CHEMICAL", 32, 43], ["Teicoplanin", "CHEMICAL", 180, 191], ["N3", "CHEMICAL", 307, 309], ["3CLPro", "CHEMICAL", 419, 425], ["Teicoplanin", "CHEMICAL", 430, 441], ["Teicoplanin", "CHEMICAL", 453, 464], ["hydrogen", "CHEMICAL", 555, 563], ["halogen", "CHEMICAL", 576, 583], ["Teicoplanin", "SIMPLE_CHEMICAL", 32, 43], ["AutoDock4", "GENE_OR_GENE_PRODUCT", 95, 104], ["Dock6", "GENE_OR_GENE_PRODUCT", 124, 129], ["Teicoplanin", "GENE_OR_GENE_PRODUCT", 180, 191], ["N3", "SIMPLE_CHEMICAL", 307, 309], ["3CLPro", "SIMPLE_CHEMICAL", 419, 425], ["Teicoplanin", "SIMPLE_CHEMICAL", 430, 441], ["Teicoplanin", "SIMPLE_CHEMICAL", 453, 464], ["hydrogen", "SIMPLE_CHEMICAL", 555, 563], ["halogen", "SIMPLE_CHEMICAL", 576, 583], ["SARS-CoV-2 main protease", "PROTEIN", 64, 88], ["AutoDock4", "PROTEIN", 95, 104], ["Teicoplanin", "TREATMENT", 32, 43], ["CoV", "TEST", 69, 72], ["AutoDock4", "TREATMENT", 95, 104], ["AutoDock Vina", "TREATMENT", 106, 119], ["Dock6 docking programs", "TREATMENT", 124, 146], ["docked Teicoplanin", "TREATMENT", 173, 191], ["a Michael acceptor", "TREATMENT", 269, 287], ["a potent and irreversible inhibitor of SARS", "PROBLEM", 319, 362], ["CoV", "TEST", 363, 366], ["Teicoplanin", "TREATMENT", 453, 464], ["docked Teicoplanin", "OBSERVATION", 173, 191], ["bimolecular interactions", "OBSERVATION", 386, 410]]], ["The hydrophobic interactions are seen with Asp187 and Glu166 (Fig. 4F).", [["Asp187", "CHEMICAL", 43, 49], ["Glu166", "CHEMICAL", 54, 60], ["Asp", "CHEMICAL", 43, 46], ["Glu", "CHEMICAL", 54, 57], ["Asp187", "AMINO_ACID", 43, 49], ["Glu166", "AMINO_ACID", 54, 60], ["Asp", "TEST", 43, 46], ["Glu", "TEST", 54, 57], ["hydrophobic interactions", "OBSERVATION", 4, 28]]], ["These two residues are also involved in the formation of hydrogen bonds.", [["hydrogen", "CHEMICAL", 57, 65], ["hydrogen bonds", "SIMPLE_CHEMICAL", 57, 71], ["hydrogen bonds", "OBSERVATION", 57, 71]]], ["The involvement of H-bond donors and acceptors around hydrophobic sites compel the Teicoplanin molecule to interact within the inhibitor binding pocket of the 3CLPro protease.", [["Teicoplanin", "CHEMICAL", 83, 94], ["H", "CHEMICAL", 19, 20], ["H", "SIMPLE_CHEMICAL", 19, 20], ["Teicoplanin molecule", "GENE_OR_GENE_PRODUCT", 83, 103], ["3CLPro protease", "GENE_OR_GENE_PRODUCT", 159, 174], ["hydrophobic sites", "PROTEIN", 54, 71], ["Teicoplanin molecule", "PROTEIN", 83, 103], ["inhibitor binding pocket", "PROTEIN", 127, 151], ["3CLPro protease", "PROTEIN", 159, 174], ["H-bond donors and acceptors", "TREATMENT", 19, 46], ["hydrophobic sites", "PROBLEM", 54, 71], ["the Teicoplanin molecule", "TREATMENT", 79, 103], ["the 3CLPro protease", "TREATMENT", 155, 174], ["Teicoplanin", "OBSERVATION", 83, 94]]], ["The formation of extensive hydrogen bonds with active site residues has been observed previously with Arg40 and Gly170 residues.", [["hydrogen", "CHEMICAL", 27, 35], ["Arg40", "CHEMICAL", 102, 107], ["Gly170", "CHEMICAL", 112, 118], ["Arg40", "GENE_OR_GENE_PRODUCT", 102, 107], ["Arg40", "PROTEIN", 102, 107], ["extensive hydrogen bonds", "PROBLEM", 17, 41], ["active site residues", "PROBLEM", 47, 67], ["Arg40 and Gly170 residues", "TREATMENT", 102, 127], ["extensive", "OBSERVATION_MODIFIER", 17, 26], ["hydrogen bonds", "OBSERVATION", 27, 41], ["active", "OBSERVATION_MODIFIER", 47, 53], ["site residues", "OBSERVATION", 54, 67]]], ["In a recent MD simulation study, it was reported that Teicoplanin in complex with SARS-CoV-2 main protease has stable ligand-protein complex and intermolecular interactions during the simulated trajectory [21].Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsFurther our careful analysis revealed that the Leu141 and Ser144 residues of 3CLPro form a halogen bond with the Teicoplanin molecule.", [["Teicoplanin", "CHEMICAL", 54, 65], ["SARS", "DISEASE", 82, 86], ["3CLPro", "CHEMICAL", 366, 372], ["Teicoplanin", "CHEMICAL", 402, 413], ["Teicoplanin", "CHEMICAL", 54, 65], ["3CLPro", "CHEMICAL", 255, 261], ["Teicoplanin", "CHEMICAL", 266, 277], ["Leu141", "CHEMICAL", 336, 342], ["Ser144", "CHEMICAL", 347, 353], ["3CLPro", "CHEMICAL", 366, 372], ["halogen", "CHEMICAL", 380, 387], ["Teicoplanin", "CHEMICAL", 402, 413], ["Teicoplanin", "SIMPLE_CHEMICAL", 54, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["3CLPro", "SIMPLE_CHEMICAL", 255, 261], ["Teicoplanin", "SIMPLE_CHEMICAL", 266, 277], ["Leu141", "GENE_OR_GENE_PRODUCT", 336, 342], ["3CLPro", "SIMPLE_CHEMICAL", 366, 372], ["Teicoplanin molecule", "SIMPLE_CHEMICAL", 402, 422], ["Teicoplanin", "PROTEIN", 54, 65], ["SARS-CoV-2 main protease", "PROTEIN", 82, 106], ["protein complex", "PROTEIN", 125, 140], ["Leu141 and Ser144 residues", "PROTEIN", 336, 362], ["3CLPro", "PROTEIN", 366, 372], ["Teicoplanin molecule", "PROTEIN", 402, 422], ["a recent MD simulation study", "TEST", 3, 31], ["Teicoplanin", "TREATMENT", 54, 65], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["main protease", "TREATMENT", 93, 106], ["our careful analysis", "TEST", 297, 317], ["the Teicoplanin molecule", "TREATMENT", 398, 422], ["bimolecular interactions", "OBSERVATION", 222, 246], ["Teicoplanin molecule", "OBSERVATION", 402, 422]]], ["It has been established that the halogen bond interactions are critical for the potential activity of the protease inhibitors.", [["halogen", "CHEMICAL", 33, 40], ["the halogen bond interactions", "TREATMENT", 29, 58], ["the protease inhibitors", "TREATMENT", 102, 125]]], ["The halogen bond interaction characteristic of an inhibitor compound makes it more promising candidate as a novel anti-viral therapeutic [22].Analysis of bimolecular interactions between 3CLPro and Teicoplanin ::: ResultsWe observed quite significant and different kinds of interactions between the Teicoplanin molecule and the 3CLPro protein suggesting that Teicoplanin can act as a good inhibitor of 3CLPro.", [["Teicoplanin", "CHEMICAL", 359, 370], ["halogen", "CHEMICAL", 4, 11], ["3CLPro", "CHEMICAL", 187, 193], ["Teicoplanin", "CHEMICAL", 198, 209], ["Teicoplanin", "CHEMICAL", 299, 310], ["Teicoplanin", "CHEMICAL", 359, 370], ["3CLPro", "SIMPLE_CHEMICAL", 187, 193], ["Teicoplanin", "SIMPLE_CHEMICAL", 198, 209], ["Teicoplanin molecule", "GENE_OR_GENE_PRODUCT", 299, 319], ["3CLPro", "GENE_OR_GENE_PRODUCT", 328, 334], ["Teicoplanin", "SIMPLE_CHEMICAL", 359, 370], ["3CLPro", "SIMPLE_CHEMICAL", 402, 408], ["Teicoplanin molecule", "PROTEIN", 299, 319], ["3CLPro protein", "PROTEIN", 328, 342], ["3CLPro", "PROTEIN", 402, 408], ["an inhibitor compound", "PROBLEM", 47, 68], ["the Teicoplanin molecule", "TREATMENT", 295, 319], ["the 3CLPro protein", "TREATMENT", 324, 342], ["Teicoplanin", "TREATMENT", 359, 370], ["3CLPro", "TREATMENT", 402, 408], ["bimolecular interactions", "OBSERVATION", 154, 178], ["significant", "OBSERVATION_MODIFIER", 239, 250]]], ["These interactions around and at the active site amino acids most probably hinder the proton transfer and binding of substrate to the active site, leading to disruption in the protease activity.Relative efficacy of drugs to inhibit 3CLPro ::: ResultsThe relative efficacy of the drugs to inhibit the protease activity of main protease of SARS-CoV-2 was analysed using protease assay.", [["amino acids", "CHEMICAL", 49, 60], ["amino acids", "CHEMICAL", 49, 60], ["amino acids", "AMINO_ACID", 49, 60], ["proton", "SIMPLE_CHEMICAL", 86, 92], ["3CLPro", "SIMPLE_CHEMICAL", 232, 238], ["SARS-CoV-2", "ORGANISM", 338, 348], ["protease", "PROTEIN", 176, 184], ["protease", "PROTEIN", 300, 308], ["protease", "PROTEIN", 326, 334], ["protease", "PROTEIN", 368, 376], ["SARS-CoV", "SPECIES", 338, 346], ["the active site amino acids", "TREATMENT", 33, 60], ["the proton transfer", "TREATMENT", 82, 101], ["the protease activity", "TREATMENT", 172, 193], ["drugs", "TREATMENT", 215, 220], ["the drugs", "TREATMENT", 275, 284], ["the protease activity", "TREATMENT", 296, 317], ["CoV", "TEST", 343, 346], ["protease assay", "TREATMENT", 368, 382]]], ["Teicoplanin emerged as the most potent inhibitor in our involving 23 drugs (Table 1).", [["Teicoplanin", "CHEMICAL", 0, 11], ["Teicoplanin", "CHEMICAL", 0, 11], ["Teicoplanin", "SIMPLE_CHEMICAL", 0, 11], ["Teicoplanin", "TREATMENT", 0, 11], ["the most potent inhibitor", "TREATMENT", 23, 48]]], ["As compared to Teicoplanin with IC50 value at 1.5 \u03bcM as 100%, lopinavir displayed only 9.12% activity inhibition and hydroxychloroquine showed 4.56% inhibition (Fig. 5).", [["Teicoplanin", "CHEMICAL", 15, 26], ["lopinavir", "CHEMICAL", 62, 71], ["hydroxychloroquine", "CHEMICAL", 117, 135], ["Teicoplanin", "CHEMICAL", 15, 26], ["lopinavir", "CHEMICAL", 62, 71], ["hydroxychloroquine", "CHEMICAL", 117, 135], ["Teicoplanin", "SIMPLE_CHEMICAL", 15, 26], ["lopinavir", "SIMPLE_CHEMICAL", 62, 71], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 117, 135], ["Teicoplanin", "TREATMENT", 15, 26], ["IC50 value", "TEST", 32, 42], ["lopinavir", "TREATMENT", 62, 71], ["hydroxychloroquine", "TREATMENT", 117, 135]]], ["The other drugs showed less than 5% inhibition.Relative efficacy of drugs to inhibit 3CLPro ::: ResultsIn this study, we have used a wide variety of drugs indicated in different infectious diseases such as retroviral HIV infections, bacterial infections, etc. and have used biochemical and biophysical analysis to compare these 23 drugs in terms of activity on the casein substrate, FRET peptide substrate as well as drug-protein interactions using fluorescence quenching.", [["infectious diseases", "DISEASE", 178, 197], ["retroviral HIV infections", "DISEASE", 206, 231], ["bacterial infections", "DISEASE", 233, 253], ["3CLPro", "SIMPLE_CHEMICAL", 85, 91], ["retroviral", "ORGANISM", 206, 216], ["casein", "GENE_OR_GENE_PRODUCT", 365, 371], ["FRET", "SIMPLE_CHEMICAL", 383, 387], ["casein substrate", "PROTEIN", 365, 381], ["HIV", "SPECIES", 217, 220], ["HIV", "SPECIES", 217, 220], ["The other drugs", "TEST", 0, 15], ["drugs", "TREATMENT", 68, 73], ["this study", "TEST", 106, 116], ["a wide variety of drugs", "TREATMENT", 131, 154], ["different infectious diseases", "PROBLEM", 168, 197], ["retroviral HIV infections", "PROBLEM", 206, 231], ["bacterial infections", "PROBLEM", 233, 253], ["biochemical and biophysical analysis", "TEST", 274, 310], ["these 23 drugs", "TREATMENT", 322, 336], ["the casein substrate", "TREATMENT", 361, 381], ["FRET peptide substrate", "TREATMENT", 383, 405], ["drug-protein interactions", "TREATMENT", 417, 442], ["infectious", "OBSERVATION", 178, 188], ["bacterial", "OBSERVATION_MODIFIER", 233, 242], ["infections", "OBSERVATION", 243, 253]]], ["We have found that under similar laboratory conditions, Teicoplanin was found to be a much stronger inhibitor of 3CLPro as compared to the other drugs like hydroxychloroquine, lopinavir, chloroquine, azithromycin, atazanavir etc.DiscussionThe COVID-19 pandemic has become a major challenge for healthcare workers and governments of the world.", [["Teicoplanin", "CHEMICAL", 56, 67], ["3CLPro", "CHEMICAL", 113, 119], ["hydroxychloroquine", "CHEMICAL", 156, 174], ["lopinavir", "CHEMICAL", 176, 185], ["chloroquine", "CHEMICAL", 187, 198], ["azithromycin", "CHEMICAL", 200, 212], ["atazanavir", "CHEMICAL", 214, 224], ["Teicoplanin", "CHEMICAL", 56, 67], ["3CLPro", "CHEMICAL", 113, 119], ["hydroxychloroquine", "CHEMICAL", 156, 174], ["lopinavir", "CHEMICAL", 176, 185], ["chloroquine", "CHEMICAL", 187, 198], ["azithromycin", "CHEMICAL", 200, 212], ["atazanavir", "CHEMICAL", 214, 224], ["Teicoplanin", "SIMPLE_CHEMICAL", 56, 67], ["3CLPro", "SIMPLE_CHEMICAL", 113, 119], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 156, 174], ["lopinavir", "SIMPLE_CHEMICAL", 176, 185], ["chloroquine", "SIMPLE_CHEMICAL", 187, 198], ["azithromycin", "SIMPLE_CHEMICAL", 200, 212], ["atazanavir", "SIMPLE_CHEMICAL", 214, 224], ["Teicoplanin", "TREATMENT", 56, 67], ["3CLPro", "TREATMENT", 113, 119], ["hydroxychloroquine", "TREATMENT", 156, 174], ["lopinavir", "TREATMENT", 176, 185], ["chloroquine", "TREATMENT", 187, 198], ["azithromycin", "TREATMENT", 200, 212], ["atazanavir", "TREATMENT", 214, 224]]], ["The current treatment options are targeting symptoms of the disease which involve pulmonary complications including localized lesions, pneumonia, bronchiolitis.", [["pulmonary", "ANATOMY", 82, 91], ["lesions", "ANATOMY", 126, 133], ["pulmonary complications", "DISEASE", 82, 105], ["pneumonia", "DISEASE", 135, 144], ["bronchiolitis", "DISEASE", 146, 159], ["pulmonary", "ORGAN", 82, 91], ["lesions", "PATHOLOGICAL_FORMATION", 126, 133], ["The current treatment options", "TREATMENT", 0, 29], ["targeting symptoms", "PROBLEM", 34, 52], ["the disease", "PROBLEM", 56, 67], ["pulmonary complications", "PROBLEM", 82, 105], ["localized lesions", "PROBLEM", 116, 133], ["pneumonia", "PROBLEM", 135, 144], ["bronchiolitis", "PROBLEM", 146, 159], ["pulmonary", "ANATOMY", 82, 91], ["complications", "OBSERVATION", 92, 105], ["localized", "OBSERVATION_MODIFIER", 116, 125], ["lesions", "OBSERVATION", 126, 133], ["pneumonia", "OBSERVATION", 135, 144], ["bronchiolitis", "OBSERVATION", 146, 159]]], ["The virus infects the lung endothelial cells and promotes the development of a pathological state akin to lymphocytic endothelialitis and inflammatory cell invasion.", [["lung endothelial cells", "ANATOMY", 22, 44], ["lymphocytic endothelialitis", "ANATOMY", 106, 133], ["cell", "ANATOMY", 151, 155], ["endothelialitis", "DISEASE", 118, 133], ["lung endothelial cells", "CELL", 22, 44], ["inflammatory cell", "CELL", 138, 155], ["lung endothelial cells", "CELL_TYPE", 22, 44], ["The virus infects the lung endothelial cells", "PROBLEM", 0, 44], ["lymphocytic endothelialitis", "PROBLEM", 106, 133], ["inflammatory cell invasion", "PROBLEM", 138, 164], ["virus infects", "OBSERVATION", 4, 17], ["lung", "ANATOMY", 22, 26], ["endothelial cells", "OBSERVATION", 27, 44], ["lymphocytic endothelialitis", "OBSERVATION", 106, 133], ["inflammatory cell invasion", "OBSERVATION", 138, 164]]], ["The lack of a specific treatment has resulted in major loss of life and economy.", [["a specific treatment", "TREATMENT", 12, 32]]], ["Drug discovery usually takes a long time with proper validation to ensure the safety and efficacy of the drug.", [["proper validation", "TREATMENT", 46, 63], ["the drug", "TREATMENT", 101, 109]]], ["In these circumstances, drug-repositioning confers an edge along with 3CLPro as an attractive drug target of SARS-CoV-2.", [["SARS", "DISEASE", 109, 113], ["3CLPro", "SIMPLE_CHEMICAL", 70, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["drug-repositioning", "TREATMENT", 24, 42], ["3CLPro", "TREATMENT", 70, 76]]], ["The sessile sequences of 3CLPro do not match with the protein sequences of human proteases and hence a number of different strategies are being used to inhibit the activity of this protease, to halt the viral replication with minimal toxicity.DiscussionThere are many approved drugs for other viral infections such as Ebola, HIV and Influenza suggested for tackling COVID-19.", [["toxicity", "DISEASE", 234, 242], ["viral infections", "DISEASE", 293, 309], ["Ebola, HIV and Influenza", "DISEASE", 318, 342], ["human", "ORGANISM", 75, 80], ["Ebola", "ORGANISM", 318, 323], ["3CLPro", "PROTEIN", 25, 31], ["human proteases", "PROTEIN", 75, 90], ["protease", "PROTEIN", 181, 189], ["human", "SPECIES", 75, 80], ["HIV", "SPECIES", 325, 328], ["human", "SPECIES", 75, 80], ["HIV", "SPECIES", 325, 328], ["The sessile sequences", "TEST", 0, 21], ["the protein sequences", "TEST", 50, 71], ["human proteases", "TREATMENT", 75, 90], ["different strategies", "TREATMENT", 113, 133], ["this protease", "TREATMENT", 176, 189], ["the viral replication", "TREATMENT", 199, 220], ["minimal toxicity", "PROBLEM", 226, 242], ["drugs", "TREATMENT", 277, 282], ["other viral infections", "PROBLEM", 287, 309], ["Ebola", "PROBLEM", 318, 323], ["HIV", "PROBLEM", 325, 328], ["Influenza", "PROBLEM", 333, 342], ["tackling COVID", "TEST", 357, 371], ["sessile", "OBSERVATION_MODIFIER", 4, 11], ["viral replication", "OBSERVATION", 203, 220], ["minimal", "OBSERVATION_MODIFIER", 226, 233], ["toxicity", "OBSERVATION", 234, 242]]], ["The secondary infections resulting from the COVID-19 infection is also contributing to fatality [23].", [["infections", "DISEASE", 14, 24], ["infection", "DISEASE", 53, 62], ["COVID-19", "ORGANISM", 44, 52], ["COVID-19", "SPECIES", 44, 52], ["The secondary infections", "PROBLEM", 0, 24], ["the COVID-19 infection", "PROBLEM", 40, 62], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["infections", "OBSERVATION", 14, 24], ["infection", "OBSERVATION", 53, 62]]], ["Therefore, searching for drugs with antiviral properties with minimum side effects would be an ideal solution.", [["drugs", "TREATMENT", 25, 30], ["antiviral properties", "TREATMENT", 36, 56], ["minimum side effects", "TREATMENT", 62, 82]]], ["Teicoplanin is an effective glycopeptide antibiotic with reported anti-MERS CoV activity [24,25].", [["Teicoplanin", "CHEMICAL", 0, 11], ["Teicoplanin", "CHEMICAL", 0, 11], ["Teicoplanin", "SIMPLE_CHEMICAL", 0, 11], ["anti-MERS CoV", "GENE_OR_GENE_PRODUCT", 66, 79], ["Teicoplanin", "TREATMENT", 0, 11], ["an effective glycopeptide antibiotic", "TREATMENT", 15, 51]]], ["We report Teicoplanin as an effective drug against 3CLPro which works at a micromolar concentration of 1.5 \u03bcM (Fig. 2) and acts by blocking the active site of the protease (Fig. 4F).DiscussionWe studied protein-drug interactions in order to decipher the working of the drug and mechanism of inhibition at the molecular level.", [["Teicoplanin", "CHEMICAL", 10, 21], ["3CLPro", "CHEMICAL", 51, 57], ["Teicoplanin", "CHEMICAL", 10, 21], ["Teicoplanin", "SIMPLE_CHEMICAL", 10, 21], ["3CLPro", "SIMPLE_CHEMICAL", 51, 57], ["Fig. 4F", "GENE_OR_GENE_PRODUCT", 173, 180], ["protease", "PROTEIN", 163, 171], ["Fig. 4F", "PROTEIN", 173, 180], ["Teicoplanin", "TREATMENT", 10, 21], ["3CLPro", "TREATMENT", 51, 57], ["a micromolar concentration", "TREATMENT", 73, 99], ["the drug", "TREATMENT", 265, 273]]], ["The protein-drug interaction shows fluorescence quenching by monitoring the intrinsic fluorescence, Teicoplanin interaction is gradual however the interaction of hydroxychloroquine and chloroquine is perturbing the conformational dynamics as depicted by wavelength shifts (Fig. 3).", [["Teicoplanin", "CHEMICAL", 100, 111], ["hydroxychloroquine", "CHEMICAL", 162, 180], ["chloroquine", "CHEMICAL", 185, 196], ["Teicoplanin", "CHEMICAL", 100, 111], ["hydroxychloroquine", "CHEMICAL", 162, 180], ["chloroquine", "CHEMICAL", 185, 196], ["Teicoplanin", "SIMPLE_CHEMICAL", 100, 111], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 162, 180], ["chloroquine", "SIMPLE_CHEMICAL", 185, 196], ["The protein", "TEST", 0, 11], ["fluorescence quenching", "PROBLEM", 35, 57], ["Teicoplanin interaction", "TREATMENT", 100, 123], ["hydroxychloroquine", "TREATMENT", 162, 180], ["chloroquine", "TREATMENT", 185, 196]]], ["The SPR finding suggests that the good affinity of Teicoplanin with 3CLPro (Fig. 4A).", [["Teicoplanin", "CHEMICAL", 51, 62], ["Teicoplanin", "CHEMICAL", 51, 62], ["3CLPro", "CHEMICAL", 68, 74], ["Teicoplanin", "SIMPLE_CHEMICAL", 51, 62], ["Teicoplanin", "TREATMENT", 51, 62], ["3CLPro (Fig. 4A", "TREATMENT", 68, 83]]], ["Lopinavir is another anti-retroviral drug that acts by targeting HIV protease.", [["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["HIV protease", "GENE_OR_GENE_PRODUCT", 65, 77], ["HIV protease", "PROTEIN", 65, 77], ["HIV", "SPECIES", 65, 68], ["Lopinavir", "TREATMENT", 0, 9], ["another anti-retroviral drug", "TREATMENT", 13, 41], ["HIV protease", "TREATMENT", 65, 77]]], ["It was under clinical trial for COVID-19 which concluded that its beneficial effects were minimal [26].", [["COVID-19", "CHEMICAL", 32, 40], ["COVID", "TEST", 32, 37]]], ["Hydroxychloroquine is in an ongoing drug trial and is currently included in the prime regimen of drugs used in the management of COVID-19.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 129, 137], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["an ongoing drug trial", "TREATMENT", 25, 46], ["drugs", "TREATMENT", 97, 102], ["COVID", "TEST", 129, 134]]], ["The proposed mechanism of action of the drug is the alteration in the pH of endosome thereby preventing the uncapping of capsid and genome release [27,28].", [["endosome", "ANATOMY", 76, 84], ["endosome", "CELLULAR_COMPONENT", 76, 84], ["genome", "CELLULAR_COMPONENT", 132, 138], ["capsid and genome release", "TREATMENT", 121, 146]]], ["We found that the relative potency of lopinavir and hydroxychloroquine to inhibit the SARS-CoV-2 main protease was 9.12% and 4.56%, respectively (Fig. 5).", [["lopinavir", "CHEMICAL", 38, 47], ["hydroxychloroquine", "CHEMICAL", 52, 70], ["SARS", "DISEASE", 86, 90], ["lopinavir", "CHEMICAL", 38, 47], ["hydroxychloroquine", "CHEMICAL", 52, 70], ["lopinavir", "SIMPLE_CHEMICAL", 38, 47], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 52, 70], ["SARS-CoV-2 main protease", "PROTEIN", 86, 110], ["lopinavir", "TREATMENT", 38, 47], ["hydroxychloroquine", "TREATMENT", 52, 70], ["the SARS", "TEST", 82, 90], ["CoV", "TEST", 91, 94]]], ["The activity of other drugs was found negligible or undetectable.", [["other drugs", "TREATMENT", 16, 27]]], ["These drugs have already proven their potential in the treatment of different DNA and RNA virus diseases which further supports their anti-viral capabilities.DiscussionIn our study, Teicoplanin showed significant reduction of the proteolytic activity of 3CLPro.", [["Teicoplanin", "CHEMICAL", 182, 193], ["Teicoplanin", "CHEMICAL", 182, 193], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["Teicoplanin", "SIMPLE_CHEMICAL", 182, 193], ["3CLPro", "SIMPLE_CHEMICAL", 254, 260], ["3CLPro", "PROTEIN", 254, 260], ["These drugs", "TREATMENT", 0, 11], ["different DNA", "PROBLEM", 68, 81], ["RNA virus diseases", "PROBLEM", 86, 104], ["our study", "TEST", 171, 180], ["Teicoplanin", "TREATMENT", 182, 193], ["3CLPro", "TREATMENT", 254, 260], ["RNA virus diseases", "OBSERVATION", 86, 104], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["reduction", "OBSERVATION_MODIFIER", 213, 222]]], ["As this protein is essential to the replication cycle of the virus, due to its irreplaceable role in the processing of viral polyproteins, which the virus needs to complete its life cycle, we propose that this reduction may contribute to its anti-SARS-CoV-2 effect via inhibition of the viral replication.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 242, 257], ["viral polyproteins", "PROTEIN", 119, 137], ["the virus", "PROBLEM", 57, 66], ["viral polyproteins", "PROBLEM", 119, 137], ["the virus", "PROBLEM", 145, 154], ["this reduction", "TREATMENT", 205, 219], ["its anti-SARS", "PROBLEM", 238, 251], ["CoV", "PROBLEM", 252, 255], ["the viral replication", "TREATMENT", 283, 304], ["viral polyproteins", "OBSERVATION", 119, 137], ["viral replication", "OBSERVATION", 287, 304]]], ["We also observed some inhibitory activity in other drugs that we tested but as Teicoplanin was found most potent among them.", [["Teicoplanin", "CHEMICAL", 79, 90], ["Teicoplanin", "CHEMICAL", 79, 90], ["Teicoplanin", "SIMPLE_CHEMICAL", 79, 90], ["other drugs", "TREATMENT", 45, 56], ["Teicoplanin", "TREATMENT", 79, 90], ["inhibitory activity", "OBSERVATION", 22, 41]]], ["Further experiments in higher validation systems are required to establish the efficacy of the molecule.", [["Further experiments in higher validation systems", "PROBLEM", 0, 48]]], ["We advocate the expedited systematic investigation in primate models and trials in terminally ill patients suffering from COVID-19.DiscussionRecently, the effect of Teicoplanin with respect to SARS-CoV-2 has been observed by other groups as well.", [["terminally ill", "DISEASE", 83, 97], ["Teicoplanin", "CHEMICAL", 165, 176], ["SARS", "DISEASE", 193, 197], ["COVID-19", "CHEMICAL", 122, 130], ["Teicoplanin", "CHEMICAL", 165, 176], ["primate", "ORGANISM", 54, 61], ["patients", "ORGANISM", 98, 106], ["Teicoplanin", "SIMPLE_CHEMICAL", 165, 176], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 193, 203], ["patients", "SPECIES", 98, 106], ["the expedited systematic investigation", "TEST", 12, 50], ["COVID", "TEST", 122, 127], ["Teicoplanin", "TREATMENT", 165, 176], ["SARS", "PROBLEM", 193, 197]]], ["For example, according to Zhou et al. [29], Teicoplanin acts on an early stage of the viral life cycle in coronaviruses by inhibiting the low-pH cleavage of the viral spike protein by cathepsin L in the late endosomes, thereby preventing the release of genomic viral RNA and continuation of the virus replication cycle.", [["late endosomes", "ANATOMY", 203, 217], ["Teicoplanin", "CHEMICAL", 44, 55], ["Teicoplanin", "SIMPLE_CHEMICAL", 44, 55], ["coronaviruses", "ORGANISM", 106, 119], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 184, 195], ["late endosomes", "CELLULAR_COMPONENT", 203, 217], ["viral spike protein", "PROTEIN", 161, 180], ["cathepsin L", "PROTEIN", 184, 195], ["genomic viral RNA", "RNA", 253, 270], ["Teicoplanin acts", "TREATMENT", 44, 60], ["the viral life cycle", "TREATMENT", 82, 102], ["coronaviruses", "PROBLEM", 106, 119], ["the low-pH cleavage", "PROBLEM", 134, 153], ["the viral spike protein", "PROBLEM", 157, 180], ["cathepsin L", "TREATMENT", 184, 195], ["genomic viral RNA", "PROBLEM", 253, 270], ["the virus replication cycle", "TREATMENT", 291, 318], ["viral spike", "OBSERVATION", 161, 172], ["viral RNA", "OBSERVATION", 261, 270]]], ["In a recent study, J. Zhang et al. [30] showed that Teicoplanin blocked virus entry by specifically inhibiting the activity of cathepsin L in SARS-CoV-2 virus.", [["Teicoplanin", "CHEMICAL", 52, 63], ["Teicoplanin", "CHEMICAL", 52, 63], ["Teicoplanin", "SIMPLE_CHEMICAL", 52, 63], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 127, 138], ["SARS-CoV-2 virus", "ORGANISM", 142, 158], ["cathepsin L", "PROTEIN", 127, 138], ["CoV-2 virus", "SPECIES", 147, 158], ["SARS-CoV-2 virus", "SPECIES", 142, 158], ["a recent study", "TEST", 3, 17], ["Teicoplanin blocked virus entry", "TREATMENT", 52, 83], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150]]], ["They identified that Teicoplanin inhibited the entry of SARS-CoV-2 pseudovirus, which provides a possible strategy for the prophylaxis and treatment for SARS-CoV-2 infection.", [["Teicoplanin", "CHEMICAL", 21, 32], ["SARS-CoV-2 infection", "DISEASE", 153, 173], ["Teicoplanin", "CHEMICAL", 21, 32], ["Teicoplanin", "SIMPLE_CHEMICAL", 21, 32], ["SARS-CoV-2", "ORGANISM", 56, 66], ["pseudovirus", "ORGANISM", 67, 78], ["SARS-CoV-2", "ORGANISM", 153, 163], ["CoV-2 pseudovirus", "SPECIES", 61, 78], ["SARS-CoV-2 pseudovirus", "SPECIES", 56, 78], ["SARS-CoV-2", "SPECIES", 153, 163], ["Teicoplanin", "TREATMENT", 21, 32], ["SARS", "PROBLEM", 56, 60], ["CoV-2 pseudovirus", "TREATMENT", 61, 78], ["strategy", "TREATMENT", 106, 114], ["the prophylaxis", "TREATMENT", 119, 134], ["treatment", "TREATMENT", 139, 148], ["SARS", "PROBLEM", 153, 157], ["CoV", "PROBLEM", 158, 161], ["2 infection", "PROBLEM", 162, 173], ["infection", "OBSERVATION", 164, 173]]], ["They proposed that Teicoplanin may prevent virus infection and amplification at a very early stage.", [["Teicoplanin", "CHEMICAL", 19, 30], ["infection", "DISEASE", 49, 58], ["Teicoplanin", "CHEMICAL", 19, 30], ["Teicoplanin", "SIMPLE_CHEMICAL", 19, 30], ["Teicoplanin", "TREATMENT", 19, 30], ["virus infection", "PROBLEM", 43, 58]]], ["Their result indicates that the potential antiviral activity of Teicoplanin could be utilized for the treatment of SARS-CoV-2 virus infection [29,30].DiscussionFurther, recently there has been a clinical study carried out with Teicoplanin as reported by Intensive Care COVID-19 Study Group of Sapienza University.", [["Teicoplanin", "CHEMICAL", 64, 75], ["SARS-CoV-2 virus infection", "DISEASE", 115, 141], ["Teicoplanin", "CHEMICAL", 227, 238], ["Teicoplanin", "CHEMICAL", 64, 75], ["Teicoplanin", "CHEMICAL", 227, 238], ["Teicoplanin", "SIMPLE_CHEMICAL", 64, 75], ["SARS-CoV-2 virus", "ORGANISM", 115, 131], ["Teicoplanin", "SIMPLE_CHEMICAL", 227, 238], ["CoV-2 virus", "SPECIES", 120, 131], ["SARS-CoV-2 virus", "SPECIES", 115, 131], ["Teicoplanin", "TREATMENT", 64, 75], ["SARS", "PROBLEM", 115, 119], ["CoV-2 virus infection", "PROBLEM", 120, 141], ["a clinical study", "TEST", 193, 209], ["Teicoplanin", "TREATMENT", 227, 238]]], ["They recruited a cohort of 21 patients affected by severe COVID-19 symptoms such as lung involvement, who were hospitalized in intensive care units (ICUs) of a hospital in Italy, Rome, and complementarily treated with Teicoplanin.", [["lung", "ANATOMY", 84, 88], ["COVID", "DISEASE", 58, 63], ["lung involvement", "DISEASE", 84, 100], ["Teicoplanin", "CHEMICAL", 218, 229], ["Teicoplanin", "CHEMICAL", 218, 229], ["patients", "ORGANISM", 30, 38], ["lung", "ORGAN", 84, 88], ["Teicoplanin", "SIMPLE_CHEMICAL", 218, 229], ["patients", "SPECIES", 30, 38], ["severe COVID-19 symptoms", "PROBLEM", 51, 75], ["lung involvement", "PROBLEM", 84, 100], ["Teicoplanin", "TREATMENT", 218, 229], ["lung", "ANATOMY", 84, 88], ["involvement", "OBSERVATION", 89, 100]]], ["On ICU admission, the patients received Teicoplanin in doses of 6 mg/kg every 24 h.", [["Teicoplanin", "CHEMICAL", 40, 51], ["Teicoplanin", "CHEMICAL", 40, 51], ["patients", "ORGANISM", 22, 30], ["Teicoplanin", "SIMPLE_CHEMICAL", 40, 51], ["patients", "SPECIES", 22, 30], ["Teicoplanin", "TREATMENT", 40, 51]]], ["The median duration of Teicoplanin therapy was 10 days (range 7\u201312 days).", [["Teicoplanin", "CHEMICAL", 23, 34], ["Teicoplanin", "CHEMICAL", 23, 34], ["Teicoplanin", "SIMPLE_CHEMICAL", 23, 34], ["Teicoplanin therapy", "TREATMENT", 23, 42]]], ["The ICU mortality rate was only 14.3% (3/21 patients).", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["The ICU mortality rate", "TEST", 0, 22]]], ["None of the patients had any adverse effects related to Teicoplanin [31].DiscussionAlthough this study has many obvious limitations, including its non-comparative retrospective observational nature, small sample size and short follow-up.", [["Teicoplanin", "CHEMICAL", 56, 67], ["Teicoplanin", "CHEMICAL", 56, 67], ["patients", "ORGANISM", 12, 20], ["Teicoplanin", "SIMPLE_CHEMICAL", 56, 67], ["patients", "SPECIES", 12, 20], ["any adverse effects", "PROBLEM", 25, 44], ["Teicoplanin", "TREATMENT", 56, 67], ["this study", "TEST", 92, 102], ["small sample size", "PROBLEM", 199, 216], ["small", "OBSERVATION_MODIFIER", 199, 204], ["size", "OBSERVATION_MODIFIER", 212, 216]]], ["But most importantly, their observations were investigated on critically ill patients.", [["critically ill", "DISEASE", 62, 76], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85]]], ["However, this is the first clinical report on the use of Teicoplanin in-vivo in subjects affected by COVID-19 and the results appear fairly acceptable when compared with other medications.", [["Teicoplanin", "CHEMICAL", 57, 68], ["Teicoplanin", "CHEMICAL", 57, 68], ["Teicoplanin", "SIMPLE_CHEMICAL", 57, 68], ["Teicoplanin", "TREATMENT", 57, 68], ["COVID", "TEST", 101, 106], ["other medications", "TREATMENT", 170, 187]]], ["However, a more detailed clinical investigation is required on large cohort, in different stages mild, moderate and critically ill patients to conclude the definite role of Teicoplanin against COVID-19.DiscussionIn a nutshell, all these studies support each other that Teicoplanin might be a potential therapeutic option against COVID-19.ConclusionThe approved drug Teicoplanin has already been tested for toxicity in human beings over a period of time.", [["critically ill", "DISEASE", 116, 130], ["Teicoplanin", "CHEMICAL", 173, 184], ["COVID-19", "CHEMICAL", 193, 201], ["Teicoplanin", "CHEMICAL", 269, 280], ["Teicoplanin", "CHEMICAL", 366, 377], ["toxicity", "DISEASE", 406, 414], ["Teicoplanin", "CHEMICAL", 173, 184], ["COVID-19", "CHEMICAL", 193, 201], ["Teicoplanin", "CHEMICAL", 269, 280], ["Teicoplanin", "CHEMICAL", 366, 377], ["patients", "ORGANISM", 131, 139], ["Teicoplanin", "SIMPLE_CHEMICAL", 173, 184], ["Teicoplanin", "SIMPLE_CHEMICAL", 269, 280], ["Teicoplanin", "SIMPLE_CHEMICAL", 366, 377], ["human", "ORGANISM", 418, 423], ["patients", "SPECIES", 131, 139], ["human", "SPECIES", 418, 423], ["human", "SPECIES", 418, 423], ["Teicoplanin", "TREATMENT", 173, 184], ["COVID", "TEST", 193, 198], ["Teicoplanin", "TREATMENT", 269, 280], ["COVID", "TEST", 329, 334], ["The approved drug Teicoplanin", "TREATMENT", 348, 377], ["toxicity", "PROBLEM", 406, 414], ["different stages", "OBSERVATION_MODIFIER", 80, 96], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["moderate", "OBSERVATION_MODIFIER", 103, 111]]], ["We propose Teicoplanin as an effective drug against SARS CoV-2.", [["Teicoplanin", "CHEMICAL", 11, 22], ["SARS", "DISEASE", 52, 56], ["Teicoplanin", "CHEMICAL", 11, 22], ["Teicoplanin", "SIMPLE_CHEMICAL", 11, 22], ["CoV-2", "ORGANISM", 57, 62], ["SARS CoV", "SPECIES", 52, 60], ["Teicoplanin", "TREATMENT", 11, 22], ["SARS CoV", "TEST", 52, 60]]], ["The study paves the path for an expedited research to an effective treatment of COVID-19.", [["COVID-19", "CHEMICAL", 80, 88], ["The study", "TEST", 0, 9], ["an effective treatment", "TREATMENT", 54, 76], ["COVID", "TEST", 80, 85]]], ["We also propose immediate attention for the randomized clinical trials for this drug to reduce infections and to help the society, as it has a proven mechanism of action and efficacy as compared to other recommended drugs for COVID-19.ConclusionThe following are the supplementary data related to this article.", [["infections", "DISEASE", 95, 105], ["COVID-19", "CHEMICAL", 226, 234], ["the randomized clinical trials", "TREATMENT", 40, 70], ["this drug", "TREATMENT", 75, 84], ["infections", "PROBLEM", 95, 105], ["drugs", "TREATMENT", 216, 221], ["COVID", "TEST", 226, 231], ["infections", "OBSERVATION", 95, 105]]]], "782b54270d7d6097cb791aa17cbad57ada9d884f": [["OUTBREAK OF HUMAN METAPNEUMOVIRUS INFECTION IN ELDERLY INPATIENTS IN JAPANTo the Editor: Human metapneumovirus (hMPV), a newly discovered pneumovirus of the Paramyxoviridae family, has been isolated from young children with acute respiratory tract illness (RTI) in the Netherlands.", [["Human metapneumovirus (hMPV)", "DISEASE", 89, 117], ["acute respiratory tract illness", "DISEASE", 224, 255], ["RTI", "DISEASE", 257, 260], ["Human metapneumovirus", "ORGANISM", 89, 110], ["hMPV", "ORGANISM", 112, 116], ["pneumovirus", "CANCER", 138, 149], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 157, 172], ["children", "ORGANISM", 210, 218], ["tract", "ORGANISM_SUBDIVISION", 242, 247], ["Human", "SPECIES", 89, 94], ["hMPV", "SPECIES", 112, 116], ["children", "SPECIES", 210, 218], ["Human metapneumovirus", "SPECIES", 89, 110], ["hMPV", "SPECIES", 112, 116], ["HUMAN METAPNEUMOVIRUS INFECTION", "PROBLEM", 12, 43], ["Human metapneumovirus (hMPV", "PROBLEM", 89, 116], ["acute respiratory tract illness", "PROBLEM", 224, 255], ["HUMAN METAPNEUMOVIRUS INFECTION", "OBSERVATION", 12, 43], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["respiratory tract", "ANATOMY", 230, 247]]], ["1 Serological analyses have indicated that the prevalence of hMPV in the Dutch population is high, because virtually all children became seropositive before the age of 6, 1 indicating that hMPV is a common and ubiquitous human pathogen.", [["hMPV", "DISEASE", 61, 65], ["hMPV", "DISEASE", 189, 193], ["hMPV", "ORGANISM", 61, 65], ["children", "ORGANISM", 121, 129], ["hMPV", "ORGANISM", 189, 193], ["human", "ORGANISM", 221, 226], ["children", "SPECIES", 121, 129], ["human", "SPECIES", 221, 226], ["hMPV", "SPECIES", 61, 65], ["hMPV", "SPECIES", 189, 193], ["human", "SPECIES", 221, 226], ["Serological analyses", "TEST", 2, 22], ["hMPV", "PROBLEM", 61, 65], ["seropositive", "PROBLEM", 137, 149], ["hMPV", "PROBLEM", 189, 193], ["a common and ubiquitous human pathogen", "PROBLEM", 197, 235], ["hMPV", "OBSERVATION", 61, 65], ["high", "OBSERVATION_MODIFIER", 93, 97], ["hMPV", "OBSERVATION", 189, 193]]], ["Subjects aged 65 and older were reported to account for 45.9% of Canadian patients with community-acquired hMPV infection hospitalized for RTI.", [["hMPV infection", "DISEASE", 107, 121], ["RTI", "DISEASE", 139, 142], ["Subjects", "ORGANISM", 0, 8], ["patients", "ORGANISM", 74, 82], ["hMPV", "ORGANISM", 107, 111], ["patients", "SPECIES", 74, 82], ["hMPV", "SPECIES", 107, 111], ["community-acquired hMPV infection", "PROBLEM", 88, 121], ["RTI", "PROBLEM", 139, 142], ["infection", "OBSERVATION", 112, 121]]], ["2 Between January 18 and 31, 2005, a cluster of eight inpatients (mean age 79; range 65-89; 6 male, 2 female) developed RTI in a 23-bed ward in a hospital for older people in Japan.", [["RTI", "DISEASE", 120, 123], ["inpatients", "ORGANISM", 54, 64], ["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171], ["RTI", "PROBLEM", 120, 123]]], ["Two patients had bronchiolitis (Cases 1 and 7), five bronchitis (Cases 2-5 and 8), and one upper RTI (Case 6) based on the clinical symptoms and chest roentgenograms.", [["chest", "ANATOMY", 145, 150], ["bronchiolitis", "DISEASE", 17, 30], ["bronchitis", "DISEASE", 53, 63], ["RTI", "DISEASE", 97, 100], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["bronchiolitis", "PROBLEM", 17, 30], ["five bronchitis", "PROBLEM", 48, 63], ["Cases", "TEST", 65, 70], ["the clinical symptoms", "PROBLEM", 119, 140], ["chest roentgenograms", "TEST", 145, 165], ["bronchiolitis", "OBSERVATION", 17, 30], ["bronchitis", "OBSERVATION", 53, 63], ["upper RTI", "ANATOMY", 91, 100], ["chest", "ANATOMY", 145, 150]]], ["Mean duration of exothermic reaction (437.01C) was 4 days (range 0-6).", [["exothermic reaction", "PROBLEM", 17, 36], ["exothermic reaction", "OBSERVATION", 17, 36]]], ["Wheezing and dyspnea were observed in only two subjects; coryza and productive cough were observed in all.", [["Wheezing", "DISEASE", 0, 8], ["dyspnea", "DISEASE", 13, 20], ["cough", "DISEASE", 79, 84], ["Wheezing", "PROBLEM", 0, 8], ["dyspnea", "PROBLEM", 13, 20], ["coryza", "PROBLEM", 57, 63], ["productive cough", "PROBLEM", 68, 84], ["dyspnea", "OBSERVATION", 13, 20], ["productive", "OBSERVATION_MODIFIER", 68, 78], ["cough", "OBSERVATION", 79, 84]]], ["White blood cell count (mean 4.1 \u00c2 10 9 cells/L, range 2.3-6.5 \u00c2 10 9 ), and C-reactive protein blood levels (25.7 mg/ L, range 1.7-52.9) remained low.", [["blood cell", "ANATOMY", 6, 16], ["cells", "ANATOMY", 40, 45], ["blood", "ANATOMY", 96, 101], ["White blood cell", "CELL", 0, 16], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 77, 95], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["White blood cell count", "TEST", 0, 22], ["mean", "TEST", 24, 28], ["cells", "TEST", 40, 45], ["L", "TEST", 46, 47], ["range", "TEST", 49, 54], ["C", "TEST", 77, 78], ["blood levels", "TEST", 96, 108], ["range", "TEST", 122, 127], ["low", "OBSERVATION_MODIFIER", 147, 150]]], ["Treatment for RTI included aminophylline, oxygen supplementation, antibiotics, and acetaminophen.", [["RTI", "DISEASE", 14, 17], ["aminophylline", "CHEMICAL", 27, 40], ["oxygen", "CHEMICAL", 42, 48], ["acetaminophen", "CHEMICAL", 83, 96], ["aminophylline", "CHEMICAL", 27, 40], ["oxygen", "CHEMICAL", 42, 48], ["acetaminophen", "CHEMICAL", 83, 96], ["aminophylline", "SIMPLE_CHEMICAL", 27, 40], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["acetaminophen", "SIMPLE_CHEMICAL", 83, 96], ["Treatment", "TREATMENT", 0, 9], ["RTI", "PROBLEM", 14, 17], ["aminophylline", "TREATMENT", 27, 40], ["oxygen supplementation", "TREATMENT", 42, 64], ["antibiotics", "TREATMENT", 66, 77], ["acetaminophen", "TREATMENT", 83, 96]]], ["All subjects showed recovery from acute RTI, although two patients newly developed asthma and secondary pneumonia (Klebsiella pneumoniae identified in sputum).OUTBREAK OF HUMAN METAPNEUMOVIRUS INFECTION IN ELDERLY INPATIENTS IN JAPANhMPV fusion gene was detected using reverse-transcription polymerase chain reaction (RT-PCR) 3 in nasal swabs from all subjects at onset.", [["sputum", "ANATOMY", 151, 157], ["nasal swabs", "ANATOMY", 331, 342], ["RTI", "DISEASE", 40, 43], ["asthma", "DISEASE", 83, 89], ["pneumonia", "DISEASE", 104, 113], ["Klebsiella pneumoniae", "DISEASE", 115, 136], ["patients", "ORGANISM", 58, 66], ["Klebsiella pneumoniae", "ORGANISM", 115, 136], ["sputum", "ORGANISM_SUBSTANCE", 151, 157], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 331, 342], ["ELDERLY INPATIENTS IN JAPANhMPV fusion gene", "DNA", 206, 249], ["patients", "SPECIES", 58, 66], ["Klebsiella pneumoniae", "SPECIES", 115, 136], ["Klebsiella pneumoniae", "SPECIES", 115, 136], ["acute RTI", "PROBLEM", 34, 43], ["asthma", "PROBLEM", 83, 89], ["secondary pneumonia", "PROBLEM", 94, 113], ["Klebsiella pneumoniae", "PROBLEM", 115, 136], ["sputum", "PROBLEM", 151, 157], ["HUMAN METAPNEUMOVIRUS INFECTION", "PROBLEM", 171, 202], ["JAPANhMPV fusion gene", "TREATMENT", 228, 249], ["RT-PCR)", "TREATMENT", 318, 325], ["nasal swabs", "TEST", 331, 342], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["RTI", "OBSERVATION", 40, 43], ["asthma", "OBSERVATION", 83, 89], ["secondary", "OBSERVATION_MODIFIER", 94, 103], ["pneumonia", "OBSERVATION", 104, 113], ["Klebsiella pneumoniae", "OBSERVATION", 115, 136], ["HUMAN METAPNEUMOVIRUS INFECTION", "OBSERVATION", 171, 202], ["nasal", "ANATOMY", 331, 336]]], ["The genotype of the amplified products from every specimen was identical to that of the prototype strain (designated NL/1/99, Gene Bank accession no. AY525843), which belongs to genetic lineage B1.", [["specimen", "ANATOMY", 50, 58], ["AY525843", "CHEMICAL", 150, 158], ["AY525843", "GENE_OR_GENE_PRODUCT", 150, 158], ["the amplified products", "TREATMENT", 16, 38], ["the prototype strain", "PROBLEM", 84, 104]]], ["4 The results of other viral cultures, antigen tests (influenza virus A/B, adenovirus, and respiratory syncytial virus (RSV)), and RT-PCR (RSV, parainfluenza virus (types 1-4), coronavirus, and rhinovirus) were all negative. hMPV was not found in swabs from other inpatients without RTI (n 5 6) in the same ward or the care workers (n 5 4).OUTBREAK OF HUMAN METAPNEUMOVIRUS INFECTION IN ELDERLY INPATIENTS IN JAPANImmunoglobulin (Ig) G antibody to hMPV with indirect immunofluorescence assay 1,5,6 was already present in serum from eight hMPV-infected patients and 10 control individuals in the acute phase.", [["swabs", "ANATOMY", 247, 252], ["serum", "ANATOMY", 521, 526], ["respiratory syncytial virus", "DISEASE", 91, 118], ["parainfluenza virus", "DISEASE", 144, 163], ["RTI", "DISEASE", 283, 286], ["hMPV-infected", "DISEASE", 538, 551], ["influenza virus A/B", "ORGANISM", 54, 73], ["adenovirus", "ORGANISM", 75, 85], ["respiratory syncytial virus", "ORGANISM", 91, 118], ["RSV", "ORGANISM", 120, 123], ["RSV", "ORGANISM", 139, 142], ["parainfluenza virus", "ORGANISM", 144, 163], ["types 1-4", "ORGANISM", 165, 174], ["coronavirus", "ORGANISM", 177, 188], ["rhinovirus", "ORGANISM", 194, 204], ["hMPV", "ORGANISM", 225, 229], ["JAPANImmunoglobulin (Ig) G antibody", "GENE_OR_GENE_PRODUCT", 409, 444], ["hMPV", "ORGANISM", 448, 452], ["serum", "ORGANISM_SUBSTANCE", 521, 526], ["hMPV", "ORGANISM", 538, 542], ["patients", "ORGANISM", 552, 560], ["JAPANImmunoglobulin (Ig) G antibody", "PROTEIN", 409, 444], ["influenza virus", "SPECIES", 54, 69], ["respiratory syncytial virus", "SPECIES", 91, 118], ["parainfluenza virus", "SPECIES", 144, 163], ["coronavirus", "SPECIES", 177, 188], ["patients", "SPECIES", 552, 560], ["adenovirus", "SPECIES", 75, 85], ["respiratory syncytial virus", "SPECIES", 91, 118], ["RSV", "SPECIES", 120, 123], ["RSV", "SPECIES", 139, 142], ["parainfluenza virus", "SPECIES", 144, 163], ["hMPV", "SPECIES", 225, 229], ["hMPV", "SPECIES", 448, 452], ["other viral cultures", "TEST", 17, 37], ["antigen tests", "TEST", 39, 52], ["influenza virus A/B", "TEST", 54, 73], ["adenovirus", "PROBLEM", 75, 85], ["respiratory syncytial virus", "TEST", 91, 118], ["RSV", "TEST", 120, 123], ["RT-PCR", "TEST", 131, 137], ["RSV", "TEST", 139, 142], ["parainfluenza virus (types", "TEST", 144, 170], ["coronavirus", "PROBLEM", 177, 188], ["rhinovirus", "PROBLEM", 194, 204], ["hMPV", "PROBLEM", 225, 229], ["RTI", "PROBLEM", 283, 286], ["HUMAN METAPNEUMOVIRUS INFECTION", "PROBLEM", 352, 383], ["JAPANImmunoglobulin", "TEST", 409, 428], ["G antibody", "TEST", 434, 444], ["hMPV", "TEST", 448, 452], ["indirect immunofluorescence assay", "TEST", 458, 491], ["serum", "TEST", 521, 526], ["eight hMPV", "TEST", 532, 542], ["respiratory syncytial", "ANATOMY", 91, 112], ["parainfluenza virus", "OBSERVATION", 144, 163], ["HUMAN METAPNEUMOVIRUS INFECTION", "OBSERVATION", 352, 383], ["acute phase", "OBSERVATION_MODIFIER", 595, 606]]], ["The IgG titers in six hMPVinfected subjects except Cases 4 and 7 were more than four times as high in the convalescent phase, and the titers in one of the controls were more than four times as high as in the convalescent phase.", [["IgG", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgG", "PROTEIN", 4, 7], ["The IgG titers", "TEST", 0, 14], ["Cases", "TEST", 51, 56], ["the titers", "TEST", 130, 140], ["convalescent phase", "OBSERVATION_MODIFIER", 106, 124]]], ["Two months after recovery of the final patient, purified protein derivative (PPD) reaction was retrospectively investigated in the hMPV-infected subjects (n 5 8), the controls (n 5 8), and the care workers (n 5 9).", [["hMPV-infected", "DISEASE", 131, 144], ["patient", "ORGANISM", 39, 46], ["hMPV", "ORGANISM", 131, 135], ["patient", "SPECIES", 39, 46], ["purified protein derivative (PPD) reaction", "PROBLEM", 48, 90], ["the hMPV", "TEST", 127, 135]]], ["Seven individuals (87.5%) (all except Case 4) showed a negative reaction, whereas the controls and the workers showed negative rates of 37.5% and 22.2%, respectively.OUTBREAK OF HUMAN METAPNEUMOVIRUS INFECTION IN ELDERLY INPATIENTS IN JAPANThe clinical symptoms induced by hMPV infection in children are similar to those caused by RSV infection, ranging from mild respiratory problems to severe cough, bronchiolitis, and pneumonia.", [["respiratory", "ANATOMY", 364, 375], ["hMPV infection", "DISEASE", 273, 287], ["RSV infection", "DISEASE", 331, 344], ["respiratory problems", "DISEASE", 364, 384], ["cough", "DISEASE", 395, 400], ["bronchiolitis", "DISEASE", 402, 415], ["pneumonia", "DISEASE", 421, 430], ["hMPV", "ORGANISM", 273, 277], ["children", "ORGANISM", 291, 299], ["RSV", "ORGANISM", 331, 334], ["children", "SPECIES", 291, 299], ["hMPV", "SPECIES", 273, 277], ["RSV", "SPECIES", 331, 334], ["Seven individuals", "TEST", 0, 17], ["a negative reaction", "PROBLEM", 53, 72], ["HUMAN METAPNEUMOVIRUS INFECTION", "PROBLEM", 178, 209], ["clinical symptoms", "PROBLEM", 244, 261], ["hMPV infection", "PROBLEM", 273, 287], ["RSV infection", "PROBLEM", 331, 344], ["mild respiratory problems", "PROBLEM", 359, 384], ["severe cough", "PROBLEM", 388, 400], ["bronchiolitis", "PROBLEM", 402, 415], ["pneumonia", "PROBLEM", 421, 430], ["HUMAN METAPNEUMOVIRUS INFECTION", "OBSERVATION", 178, 209], ["hMPV infection", "OBSERVATION", 273, 287], ["RSV", "ANATOMY", 331, 334], ["infection", "OBSERVATION", 335, 344], ["mild", "OBSERVATION_MODIFIER", 359, 363], ["respiratory problems", "OBSERVATION", 364, 384], ["severe", "OBSERVATION_MODIFIER", 388, 394], ["cough", "OBSERVATION", 395, 400], ["bronchiolitis", "OBSERVATION", 402, 415], ["pneumonia", "OBSERVATION", 421, 430]]], ["1 hMPV ribonucleic acid was detected in respiratory samples from hospitalized patients aged 65 and older with RTI, whereas RSV was not found in the same elderly group.", [["respiratory samples", "ANATOMY", 40, 59], ["ribonucleic acid", "CHEMICAL", 7, 23], ["RTI", "DISEASE", 110, 113], ["hMPV", "ORGANISM", 2, 6], ["respiratory samples", "CANCER", 40, 59], ["patients", "ORGANISM", 78, 86], ["RSV", "ORGANISM", 123, 126], ["patients", "SPECIES", 78, 86], ["hMPV", "SPECIES", 2, 6], ["RSV", "SPECIES", 123, 126], ["1 hMPV ribonucleic acid", "TEST", 0, 23], ["RTI", "PROBLEM", 110, 113], ["RSV", "PROBLEM", 123, 126], ["ribonucleic acid", "OBSERVATION", 7, 23]]], ["7 A cluster of eight hMPV-infected cases with RTI was found in a hospital for older people.", [["hMPV-infected", "DISEASE", 21, 34], ["RTI", "DISEASE", 46, 49], ["hMPV", "ORGANISM", 21, 25], ["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90], ["RTI", "PROBLEM", 46, 49]]], ["Thus, hMPV rather than RSV should be considered as a causative pathogen in elderly subjects with RTI.OUTBREAK OF HUMAN METAPNEUMOVIRUS INFECTION IN ELDERLY INPATIENTS IN JAPANOne study 8 has reported detection of hMPV antigens in nasal secretions obtained from 48 hospitalized children with RTIs using an immunofluorescent-antibody test (IFA).", [["nasal secretions", "ANATOMY", 230, 246], ["RTI", "DISEASE", 97, 100], ["RTIs", "DISEASE", 291, 295], ["hMPV", "ORGANISM", 6, 10], ["RSV", "ORGANISM", 23, 26], ["hMPV", "ORGANISM", 213, 217], ["nasal secretions", "ORGANISM_SUBSTANCE", 230, 246], ["children", "ORGANISM", 277, 285], ["hMPV antigens", "PROTEIN", 213, 226], ["children", "SPECIES", 277, 285], ["hMPV", "SPECIES", 6, 10], ["RSV", "SPECIES", 23, 26], ["hMPV", "SPECIES", 213, 217], ["hMPV", "PROBLEM", 6, 10], ["RSV", "PROBLEM", 23, 26], ["a causative pathogen", "PROBLEM", 51, 71], ["RTI", "PROBLEM", 97, 100], ["HUMAN METAPNEUMOVIRUS INFECTION", "PROBLEM", 113, 144], ["JAPANOne study", "TEST", 170, 184], ["hMPV antigens in nasal secretions", "PROBLEM", 213, 246], ["RTIs", "PROBLEM", 291, 295], ["an immunofluorescent-antibody test", "TEST", 302, 336], ["hMPV", "OBSERVATION", 6, 10], ["HUMAN METAPNEUMOVIRUS INFECTION", "OBSERVATION", 113, 144], ["hMPV", "OBSERVATION", 213, 217], ["nasal", "ANATOMY", 230, 235]]], ["IFA is a rapid and useful test for the diagnosis of hMPV infections in children, although the sensitivity of IFA (73.3%) is lower than that of RT-PCR.", [["hMPV infections", "DISEASE", 52, 67], ["hMPV", "ORGANISM", 52, 56], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["hMPV", "SPECIES", 52, 56], ["hMPV infections", "PROBLEM", 52, 67], ["the sensitivity", "TEST", 90, 105], ["IFA", "TEST", 109, 112], ["RT", "TEST", 143, 145], ["PCR", "TEST", 146, 149], ["hMPV", "OBSERVATION", 52, 56]]], ["It is important to establish rapid virus detection assays, including RT-PCR or antigen tests, especially for older people, as are currently applied for diagnosing infections with other viral pathogens, because older people with pneumonia who are infected with hMPV are at risk of death due to respiratory failure.", [["respiratory", "ANATOMY", 293, 304], ["infections", "DISEASE", 163, 173], ["pneumonia", "DISEASE", 228, 237], ["hMPV", "DISEASE", 260, 264], ["death", "DISEASE", 280, 285], ["respiratory failure", "DISEASE", 293, 312], ["people", "ORGANISM", 115, 121], ["people", "ORGANISM", 216, 222], ["hMPV", "ORGANISM", 260, 264], ["people", "SPECIES", 115, 121], ["people", "SPECIES", 216, 222], ["hMPV", "SPECIES", 260, 264], ["rapid virus detection assays", "TEST", 29, 57], ["RT-PCR", "TEST", 69, 75], ["antigen tests", "TEST", 79, 92], ["diagnosing infections", "PROBLEM", 152, 173], ["other viral pathogens", "PROBLEM", 179, 200], ["pneumonia", "PROBLEM", 228, 237], ["hMPV", "PROBLEM", 260, 264], ["death", "PROBLEM", 280, 285], ["respiratory failure", "PROBLEM", 293, 312], ["pneumonia", "OBSERVATION", 228, 237], ["respiratory failure", "OBSERVATION", 293, 312]]], ["2 In addition, a difference was found in the PPD reaction between the hMPV-infected patients and control subjects or care workers, although the reaction was checked retrospectively.", [["hMPV-infected", "DISEASE", 70, 83], ["hMPV", "ORGANISM", 70, 74], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["the PPD reaction", "PROBLEM", 41, 57], ["the reaction", "PROBLEM", 140, 152], ["hMPV", "OBSERVATION", 70, 74], ["infected", "OBSERVATION_MODIFIER", 75, 83]]], ["This observation suggests that a negative PPD reaction, reflecting reduced cellular immunity, is a potential risk factor for hMPV infection, as well as tuberculosis and shingles, in older people.", [["cellular", "ANATOMY", 75, 83], ["hMPV infection", "DISEASE", 125, 139], ["tuberculosis", "DISEASE", 152, 164], ["shingles", "DISEASE", 169, 177], ["cellular", "CELL", 75, 83], ["hMPV", "ORGANISM", 125, 129], ["people", "ORGANISM", 188, 194], ["people", "SPECIES", 188, 194], ["hMPV", "SPECIES", 125, 129], ["This observation", "TEST", 0, 16], ["a negative PPD reaction", "PROBLEM", 31, 54], ["reduced cellular immunity", "PROBLEM", 67, 92], ["hMPV infection", "PROBLEM", 125, 139], ["tuberculosis", "PROBLEM", 152, 164], ["shingles", "PROBLEM", 169, 177], ["reduced", "OBSERVATION_MODIFIER", 67, 74], ["cellular immunity", "OBSERVATION", 75, 92], ["infection", "OBSERVATION", 130, 139], ["tuberculosis", "OBSERVATION", 152, 164], ["shingles", "OBSERVATION", 169, 177]]], ["It is necessary to conduct a wideranging prospective study to better evaluate risk factors that may be associated with hMPV infection.", [["hMPV infection", "DISEASE", 119, 133], ["hMPV", "ORGANISM", 119, 123], ["hMPV", "SPECIES", 119, 123], ["a wideranging prospective study", "TEST", 27, 58], ["risk factors", "PROBLEM", 78, 90], ["hMPV infection", "PROBLEM", 119, 133], ["may be associated with", "UNCERTAINTY", 96, 118], ["hMPV", "OBSERVATION_MODIFIER", 119, 123], ["infection", "OBSERVATION", 124, 133]]], ["Haruhito Honda, Takashi Takahashi, and Shigeto Morimoto prepared the manuscript.OUTBREAK OF HUMAN METAPNEUMOVIRUS INFECTION IN ELDERLY INPATIENTS IN JAPANSponsor's Role: The sponsors had no role in this manuscript.MILD BEHAVIORAL IMPAIRMENT: A PRODROMAL STAGE OF FRONTOTEMPORAL LOBAR DEGENERATIONTo the Editor: Frontotemporal lobar degeneration (FTLD) is the third most common type of dementia after Alzheimer's disease (AD) and dementia with Lewy bodies.", [["Frontotemporal lobar", "ANATOMY", 311, 331], ["Frontotemporal lobar degeneration", "DISEASE", 311, 344], ["FTLD", "DISEASE", 346, 350], ["dementia", "DISEASE", 385, 393], ["Alzheimer's disease", "DISEASE", 400, 419], ["AD", "DISEASE", 421, 423], ["dementia", "DISEASE", 429, 437], ["Lewy bodies", "DISEASE", 443, 454], ["Frontotemporal lobar", "CANCER", 311, 331], ["HUMAN METAPNEUMOVIRUS INFECTION", "PROBLEM", 92, 123], ["MILD BEHAVIORAL IMPAIRMENT", "PROBLEM", 214, 240], ["A PRODROMAL STAGE OF FRONTOTEMPORAL LOBAR DEGENERATIONTo the Editor", "PROBLEM", 242, 309], ["Frontotemporal lobar degeneration", "PROBLEM", 311, 344], ["FTLD", "PROBLEM", 346, 350], ["dementia", "PROBLEM", 385, 393], ["Alzheimer's disease", "PROBLEM", 400, 419], ["AD)", "PROBLEM", 421, 424], ["dementia", "PROBLEM", 429, 437], ["Lewy bodies", "PROBLEM", 443, 454], ["HUMAN METAPNEUMOVIRUS INFECTION", "OBSERVATION", 92, 123], ["BEHAVIORAL", "OBSERVATION_MODIFIER", 219, 229], ["IMPAIRMENT", "OBSERVATION", 230, 240], ["FRONTOTEMPORAL", "ANATOMY_MODIFIER", 263, 277], ["LOBAR", "ANATOMY", 278, 283], ["DEGENERATIONTo", "OBSERVATION", 284, 298], ["Frontotemporal lobar", "ANATOMY", 311, 331], ["degeneration", "OBSERVATION", 332, 344], ["dementia", "OBSERVATION", 385, 393], ["Lewy bodies", "OBSERVATION", 443, 454]]], ["FTLD is a disorder of behavior, social conduct, and executive function and starts between the ages of 40 and 60.", [["FTLD", "DISEASE", 0, 4], ["disorder of behavior", "DISEASE", 10, 30], ["a disorder of behavior", "PROBLEM", 8, 30]]], ["The Neary research criteria define three clinical FTLD syndromes.", [["FTLD", "DISEASE", 50, 54], ["three clinical FTLD syndromes", "PROBLEM", 35, 64], ["FTLD syndromes", "OBSERVATION", 50, 64]]], ["1 The hypothesis that mild cognitive impairment (MCI) represents a transitional state between normal cognitive aging and dementia is widely accepted.", [["cognitive impairment", "DISEASE", 27, 47], ["MCI", "DISEASE", 49, 52], ["cognitive aging", "DISEASE", 101, 116], ["dementia", "DISEASE", 121, 129], ["mild cognitive impairment (MCI", "PROBLEM", 22, 52], ["a transitional state", "PROBLEM", 65, 85], ["dementia", "PROBLEM", 121, 129], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["cognitive", "OBSERVATION_MODIFIER", 27, 36], ["dementia", "OBSERVATION", 121, 129]]], ["Three types are defined (Table 1) : MCI-amnestic; MCI-multiple domains, slightly impaired (for example, vascular cognitive impairment); and MCI-single nonmemory domain.", [["vascular", "ANATOMY", 104, 112], ["MCI", "DISEASE", 36, 39], ["amnestic", "DISEASE", 40, 48], ["MCI", "DISEASE", 50, 53], ["vascular cognitive impairment", "DISEASE", 104, 133], ["MCI", "DISEASE", 140, 143], ["vascular", "MULTI-TISSUE_STRUCTURE", 104, 112], ["nonmemory domain", "PROTEIN", 151, 167], ["MCI", "TEST", 36, 39], ["amnestic", "PROBLEM", 40, 48], ["MCI", "PROBLEM", 50, 53], ["multiple domains", "PROBLEM", 54, 70], ["slightly impaired", "PROBLEM", 72, 89], ["vascular cognitive impairment", "PROBLEM", 104, 133], ["MCI", "TEST", 140, 143], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["slightly", "OBSERVATION_MODIFIER", 72, 80], ["impaired", "OBSERVATION", 81, 89], ["vascular", "ANATOMY", 104, 112]]], ["2 The last presents as impairment in a single cognitive domain other than memory, such as a dysexecutive syndrome.", [["dysexecutive syndrome", "DISEASE", 92, 113], ["a single cognitive domain", "PROBLEM", 37, 62], ["a dysexecutive syndrome", "PROBLEM", 90, 113], ["impairment", "OBSERVATION", 23, 33]]], ["This condition was described as mild behavioral impairment (MBI) and as MCI of the frontotemporal type.", [["behavioral impairment", "DISEASE", 37, 58], ["MCI of the frontotemporal type", "DISEASE", 72, 102], ["mild behavioral impairment", "PROBLEM", 32, 58], ["MBI", "TEST", 60, 63], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["frontotemporal", "ANATOMY_MODIFIER", 83, 97]]], ["3, 4 Three patients referred to the memory clinic are described.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["A 56-year-old man had conflicts at work due to poor judgment.", [["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["poor judgment", "PROBLEM", 47, 60]]], ["He became gradually more aggressive and showed signs of hyperorality and disinhibition.", [["hyperorality", "DISEASE", 56, 68], ["hyperorality", "PROBLEM", 56, 68], ["disinhibition", "PROBLEM", 73, 86], ["hyperorality", "OBSERVATION", 56, 68]]], ["His score was 36 of 72 (cutoff 5 27) on the Frontal Behavioral Inventory (FBI) 5 and 24 of 42 (cutoff 5 14) on the Apathy Scale of Starkstein.", [["Apathy", "DISEASE", 115, 121], ["His score", "TEST", 0, 9], ["cutoff", "TEST", 24, 30], ["cutoff", "TEST", 95, 101]]], ["6 Cerebral single photon emission computed tomography (SPECT) scanning revealed left frontotemporal hypoperfusion.", [["Cerebral", "ANATOMY", 2, 10], ["frontotemporal hypoperfusion", "DISEASE", 85, 113], ["Cerebral single photon emission computed tomography (SPECT) scanning", "TEST", 2, 70], ["left frontotemporal hypoperfusion", "PROBLEM", 80, 113], ["left", "ANATOMY_MODIFIER", 80, 84], ["frontotemporal", "ANATOMY", 85, 99], ["hypoperfusion", "OBSERVATION", 100, 113]]], ["Neuropsychological testing showed impairment on frontal executive tests, but he did not meet the criteria for FTLD, and his wife reported normal activities of daily living (ADLs), instrumental activities of daily living (IADLs), and general functioning.", [["impairment on frontal executive tests", "DISEASE", 34, 71], ["FTLD", "DISEASE", 110, 114], ["Neuropsychological testing", "TEST", 0, 26], ["frontal executive tests", "TEST", 48, 71], ["FTLD", "PROBLEM", 110, 114]]], ["A diagnosis of MBI was made.", [["MBI", "CANCER", 15, 18], ["MBI", "TEST", 15, 18]]], ["He was treated with citalopram, a serotonin-selective reuptake inhibitor (SSRI), and became less disinhibited.", [["citalopram", "CHEMICAL", 20, 30], ["serotonin-selective reuptake inhibitor", "CHEMICAL", 34, 72], ["SSRI", "CHEMICAL", 74, 78], ["citalopram", "CHEMICAL", 20, 30], ["serotonin", "CHEMICAL", 34, 43], ["He", "ORGANISM", 0, 2], ["citalopram", "SIMPLE_CHEMICAL", 20, 30], ["serotonin", "SIMPLE_CHEMICAL", 34, 43], ["citalopram", "TREATMENT", 20, 30], ["a serotonin-selective reuptake inhibitor", "TREATMENT", 32, 72], ["SSRI", "TREATMENT", 74, 78], ["less disinhibited", "PROBLEM", 92, 109]]], ["A 62-year-old male teacher presented with changes in behavior.", [["changes in behavior", "PROBLEM", 42, 61]]], ["He had always been aggressive, but during the previous 2 years showed loss of empathy, impulsivity, hyperorality, inflexibility, and repetitive behavior.", [["loss of empathy", "DISEASE", 70, 85], ["impulsivity", "DISEASE", 87, 98], ["hyperorality", "DISEASE", 100, 112], ["repetitive behavior", "DISEASE", 133, 152], ["loss of empathy", "PROBLEM", 70, 85], ["impulsivity", "PROBLEM", 87, 98], ["hyperorality", "PROBLEM", 100, 112], ["inflexibility", "PROBLEM", 114, 127], ["repetitive behavior", "PROBLEM", 133, 152], ["aggressive", "OBSERVATION_MODIFIER", 19, 29]]], ["He had a high score on the FBI (54).", [["a high score", "PROBLEM", 7, 19], ["the FBI", "TEST", 23, 30]]], ["SPECT scanning showed left temporal hypoperfusion.", [["left temporal hypoperfusion", "DISEASE", 22, 49], ["SPECT scanning", "TEST", 0, 14], ["left temporal hypoperfusion", "PROBLEM", 22, 49], ["left", "ANATOMY_MODIFIER", 22, 26], ["temporal", "ANATOMY_MODIFIER", 27, 35], ["hypoperfusion", "OBSERVATION", 36, 49]]], ["Neuropsychological evaluation revealed some repetitive behavior, loss of insight, and mildly decreased verbal fluency, but he did not meet the criteria for FTLD, and his wife reported normal IADLs/ADLs and general functioning.", [["decreased verbal fluency", "DISEASE", 93, 117], ["FTLD", "DISEASE", 156, 160], ["Neuropsychological evaluation", "TEST", 0, 29], ["some repetitive behavior", "PROBLEM", 39, 63], ["loss of insight", "PROBLEM", 65, 80], ["mildly decreased verbal fluency", "PROBLEM", 86, 117], ["FTLD", "PROBLEM", 156, 160], ["mildly", "OBSERVATION_MODIFIER", 86, 92]]], ["Because of persistent behavioral changes, mild psychiatric symptoms, no memory complaints, and normal functioning, he was diagnosed with MBI.", [["psychiatric", "DISEASE", 47, 58], ["memory complaints", "DISEASE", 72, 89], ["persistent behavioral changes", "PROBLEM", 11, 40], ["mild psychiatric symptoms", "PROBLEM", 42, 67], ["memory complaints", "PROBLEM", 72, 89], ["MBI", "TEST", 137, 140], ["persistent", "OBSERVATION_MODIFIER", 11, 21], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["no", "UNCERTAINTY", 69, 71]]], ["Citalopram improved his aggression slightly.", [["Citalopram", "CHEMICAL", 0, 10], ["aggression", "DISEASE", 24, 34], ["Citalopram", "CHEMICAL", 0, 10], ["Citalopram", "SIMPLE_CHEMICAL", 0, 10], ["Citalopram", "TREATMENT", 0, 10]]], ["A 57year-old man developed apathy, aspontaneity, and behavioral changes with emotional unconcern and inflexibility.", [["apathy", "DISEASE", 27, 33], ["aspontaneity", "DISEASE", 35, 47], ["man", "ORGANISM", 13, 16], ["man", "SPECIES", 13, 16], ["apathy", "PROBLEM", 27, 33], ["aspontaneity", "PROBLEM", 35, 47], ["behavioral changes", "PROBLEM", 53, 71], ["emotional unconcern", "PROBLEM", 77, 96], ["inflexibility", "PROBLEM", 101, 114], ["apathy", "OBSERVATION", 27, 33]]], ["He made repetitive noises, lacked initiative, and showed inappropriate behavior and disinhibition in eating.", [["repetitive noises", "PROBLEM", 8, 25], ["inappropriate behavior", "PROBLEM", 57, 79]]], ["His FBI score was 43.", [["His FBI score", "TEST", 0, 13]]], ["SPECT scanning demonstrated bilateral frontal hypoperfusion.", [["frontal", "ANATOMY", 38, 45], ["frontal hypoperfusion", "DISEASE", 38, 59], ["frontal", "ORGAN", 38, 45], ["SPECT scanning", "TEST", 0, 14], ["bilateral frontal hypoperfusion", "PROBLEM", 28, 59], ["bilateral", "ANATOMY_MODIFIER", 28, 37], ["frontal", "ANATOMY_MODIFIER", 38, 45], ["hypoperfusion", "OBSERVATION", 46, 59]]], ["Neuropsychological examination revealed general slowing, intact memory and orientation, diminished flexibility and self-inhibition, decreased verbal fluency, and mild executive problems, but he did not meet the criteria for FTLD, and his wife reported normal IADLs/ ADLs.", [["decreased verbal fluency", "DISEASE", 132, 156], ["executive problems", "DISEASE", 167, 185], ["FTLD", "DISEASE", 224, 228], ["Neuropsychological examination", "TEST", 0, 30], ["general slowing", "PROBLEM", 40, 55], ["diminished flexibility", "PROBLEM", 88, 110], ["self-inhibition", "PROBLEM", 115, 130], ["decreased verbal fluency", "PROBLEM", 132, 156], ["mild executive problems", "PROBLEM", 162, 185], ["FTLD", "PROBLEM", 224, 228], ["slowing", "OBSERVATION", 48, 55], ["intact memory", "OBSERVATION", 57, 70], ["mild", "OBSERVATION_MODIFIER", 162, 166]]], ["A diagnosis of MBI was made.", [["MBI", "CANCER", 15, 18], ["MBI", "TEST", 15, 18]]], ["A year later, he had developed FTLD.MILD BEHAVIORAL IMPAIRMENT: A PRODROMAL STAGE OF FRONTOTEMPORAL LOBAR DEGENERATIONBy separating clinical and preclinical stages, the importance of disease course is emphasized, which makes it possible to describe various stages of the same disease or, alternatively, to describe one disease-related syndrome that changes its features over time as the disease process continues.", [["FTLD", "DISEASE", 31, 35], ["FTLD", "PROBLEM", 31, 35], ["MILD BEHAVIORAL IMPAIRMENT", "PROBLEM", 36, 62], ["A PRODROMAL STAGE OF FRONTOTEMPORAL LOBAR DEGENERATIONBy separating clinical and preclinical stages", "PROBLEM", 64, 163], ["the same disease", "PROBLEM", 267, 283], ["one disease", "PROBLEM", 315, 326], ["related syndrome", "PROBLEM", 327, 343], ["the disease process", "PROBLEM", 383, 402], ["FTLD", "OBSERVATION", 31, 35], ["BEHAVIORAL", "OBSERVATION_MODIFIER", 41, 51], ["IMPAIRMENT", "OBSERVATION", 52, 62], ["FRONTOTEMPORAL", "OBSERVATION_MODIFIER", 85, 99], ["LOBAR", "OBSERVATION_MODIFIER", 100, 105], ["DEGENERATIONBy", "OBSERVATION", 106, 120], ["disease", "OBSERVATION", 183, 190], ["disease", "OBSERVATION", 387, 394]]], ["Dementia presents with psychiatric symptoms in about 50% of cases.", [["Dementia", "DISEASE", 0, 8], ["psychiatric", "DISEASE", 23, 34], ["Dementia", "PROBLEM", 0, 8], ["psychiatric symptoms", "PROBLEM", 23, 43]]], ["Diagnosis is difficult when symptoms are still mild and atypical.", [["symptoms", "PROBLEM", 28, 36], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["atypical", "OBSERVATION_MODIFIER", 56, 64]]], ["A prospective cohort study of nondemented patients at risk of FTLD was performed; 3 after 3 years 77% had developed into dementia: 7% dementia with Lewy bodies, 25% AD, and 45% FTLD; six of seven patients diagnosed with MCI of the frontotemporal type developed FTLD within a mean AE standard deviation of 1.8 AE 1.0 years.", [["FTLD", "DISEASE", 62, 66], ["dementia", "DISEASE", 121, 129], ["dementia", "DISEASE", 134, 142], ["Lewy bodies", "DISEASE", 148, 159], ["AD", "DISEASE", 165, 167], ["FTLD", "DISEASE", 177, 181], ["MCI of the frontotemporal type", "DISEASE", 220, 250], ["FTLD", "DISEASE", 261, 265], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 196, 204], ["A prospective cohort study", "TEST", 0, 26], ["FTLD", "PROBLEM", 62, 66], ["dementia", "PROBLEM", 121, 129], ["7% dementia", "PROBLEM", 131, 142], ["Lewy bodies", "PROBLEM", 148, 159], ["25% AD", "PROBLEM", 161, 167], ["45% FTLD", "PROBLEM", 173, 181], ["MCI of the frontotemporal type", "PROBLEM", 220, 250], ["FTLD", "PROBLEM", 261, 265], ["dementia", "OBSERVATION", 121, 129], ["Lewy bodies", "OBSERVATION", 148, 159], ["frontotemporal", "ANATOMY_MODIFIER", 231, 245], ["FTLD", "OBSERVATION", 261, 265]]], ["4 In the case with disinhibition as an early symptom, the risk of dementia was more than two and a half times as high.", [["dementia", "DISEASE", 66, 74], ["disinhibition", "PROBLEM", 19, 32], ["an early symptom", "PROBLEM", 36, 52], ["dementia", "PROBLEM", 66, 74], ["dementia", "OBSERVATION", 66, 74]]], ["In the case with a frontotemporal SPECT pattern, the risk of FTLD was three and a half times as high.", [["FTLD", "DISEASE", 61, 65], ["a frontotemporal SPECT pattern", "TEST", 17, 47], ["FTLD", "PROBLEM", 61, 65], ["FTLD", "OBSERVATION", 61, 65]]], ["A normal SPECT decreased the risk of dementia 93%, so functional imaging is a valuable tool.", [["dementia", "DISEASE", 37, 45], ["dementia", "PROBLEM", 37, 45], ["functional imaging", "TEST", 54, 72], ["normal", "OBSERVATION", 2, 8], ["decreased", "OBSERVATION_MODIFIER", 15, 24]]], ["3 If a normally functioning person presents with persistent mild psychiatric symptoms, especially disinhibition, MBI should be considered.", [["psychiatric symptoms", "DISEASE", 65, 85], ["person", "SPECIES", 28, 34], ["persistent mild psychiatric symptoms", "PROBLEM", 49, 85], ["disinhibition", "PROBLEM", 98, 111], ["MBI", "TEST", 113, 116], ["persistent", "OBSERVATION_MODIFIER", 49, 59], ["mild", "OBSERVATION_MODIFIER", 60, 64]]], ["SPECT scanning is recommended.", [["SPECT scanning", "TEST", 0, 14]]], ["In populations without dementia, behavioral symptoms often improve with medications that increase serotonin activity.", [["dementia", "DISEASE", 23, 31], ["behavioral symptoms", "DISEASE", 33, 52], ["serotonin", "CHEMICAL", 98, 107], ["serotonin", "CHEMICAL", 98, 107], ["serotonin", "SIMPLE_CHEMICAL", 98, 107], ["dementia", "PROBLEM", 23, 31], ["behavioral symptoms", "PROBLEM", 33, 52], ["medications", "TREATMENT", 72, 83], ["without", "UNCERTAINTY", 15, 22], ["dementia", "OBSERVATION", 23, 31], ["serotonin activity", "OBSERVATION", 98, 116]]], ["Low serotonin-receptor binding has been reported in FTLD.", [["serotonin", "CHEMICAL", 4, 13], ["FTLD", "DISEASE", 52, 56], ["serotonin", "CHEMICAL", 4, 13], ["serotonin-receptor", "GENE_OR_GENE_PRODUCT", 4, 22], ["Low serotonin-receptor binding", "PROBLEM", 0, 30], ["FTLD", "PROBLEM", 52, 56], ["receptor binding", "OBSERVATION", 14, 30]]], ["Treatment with SSRIs improved behavioral symptoms in at least half of FTLD patients.", [["SSRIs", "CHEMICAL", 15, 20], ["behavioral symptoms", "DISEASE", 30, 49], ["FTLD", "DISEASE", 70, 74], ["SSRIs", "SIMPLE_CHEMICAL", 15, 20], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["SSRIs", "TREATMENT", 15, 20], ["behavioral symptoms", "PROBLEM", 30, 49]]], ["7 It has been reported that paroxetine addressed anxiety and repetitive, ritualistic behaviors.", [["paroxetine", "CHEMICAL", 28, 38], ["anxiety", "DISEASE", 49, 56], ["paroxetine", "CHEMICAL", 28, 38], ["paroxetine", "SIMPLE_CHEMICAL", 28, 38], ["paroxetine", "TREATMENT", 28, 38], ["anxiety", "PROBLEM", 49, 56], ["repetitive, ritualistic behaviors", "PROBLEM", 61, 94]]], ["8 In FTLD, treatment with SSRIs is considered of interest when the target symptoms are disinhibition,", [["FTLD", "DISEASE", 5, 9], ["SSRIs", "CHEMICAL", 26, 31], ["SSRIs", "TREATMENT", 26, 31], ["the target symptoms", "PROBLEM", 63, 82], ["disinhibition", "PROBLEM", 87, 100]]]], "PMC7150084": [["Genetic Variation and its SignificanceUntil the 1960s, it was widely thought that genetic variation was unusual.", [["Genetic Variation", "TEST", 0, 17], ["genetic variation", "PROBLEM", 82, 99]]], ["Following the introduction of allozyme electrophoresis it quickly became clear that most plant and animal populations were highly variable.", [["allozyme electrophoresis", "TREATMENT", 30, 54]]], ["Subsequently, it has become possible to examine DNA sequences directly and large numbers of base pair mutations have been discovered in functional genes of most living organisms studied.", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["DNA sequences", "DNA", 48, 61], ["functional genes", "DNA", 136, 152], ["DNA sequences", "TEST", 48, 61], ["large numbers of base pair mutations", "PROBLEM", 75, 111], ["large", "OBSERVATION_MODIFIER", 75, 80]]], ["Even higher levels of variation occur in the introns and highly repetitive stretches of noncoding \u201cjunk DNA\u201d that lie between eukaryote genes.", [["DNA", "CELLULAR_COMPONENT", 104, 107], ["introns", "DNA", 45, 52], ["noncoding \u201cjunk DNA", "DNA", 88, 107], ["eukaryote genes", "DNA", 126, 141], ["higher", "OBSERVATION_MODIFIER", 5, 11], ["levels", "OBSERVATION_MODIFIER", 12, 18], ["variation", "OBSERVATION_MODIFIER", 22, 31], ["eukaryote genes", "OBSERVATION", 126, 141]]], ["High levels of variability characterize most natural populations of plants and animals and this variability is thought to be both a product of evolutionary agents and a determinant of the future evolvability of a population.", [["most natural", "OBSERVATION_MODIFIER", 40, 52]]], ["Since then, geneticists have studied the effects of the ongoing global reduction of genetic variability on population viability and species persistence.", [["genetic variability", "PROBLEM", 84, 103], ["population viability", "PROBLEM", 107, 127], ["species persistence", "PROBLEM", 132, 151], ["reduction", "OBSERVATION_MODIFIER", 71, 80], ["genetic variability", "OBSERVATION", 84, 103]]], ["Key reviews of the progress made include Schonewald-Cox et al. (1983), Loeschcke et al. (1994), Olney et al. (1994), Frankham (1995), Avise and Hamrick (1996), Smith and Wayne (1996), and Landweber and Dobson (1999).Genetic Variation and its SignificanceEstimates of variability in a population vary with the feature examined and analytical method used.", [["Genetic Variation", "PROBLEM", 216, 233], ["analytical method", "TEST", 330, 347], ["Variation", "OBSERVATION_MODIFIER", 224, 233], ["variability", "OBSERVATION_MODIFIER", 267, 278]]], ["Karyotypic variation is usually low within a species, allozyme variation is high, and DNA sequence variation may be very high in some parts of the genome.", [["DNA", "CELLULAR_COMPONENT", 86, 89], ["Karyotypic variation", "PROBLEM", 0, 20], ["allozyme variation", "TEST", 54, 72], ["DNA sequence variation", "TEST", 86, 108], ["low", "OBSERVATION_MODIFIER", 32, 35], ["high", "OBSERVATION_MODIFIER", 76, 80], ["high", "OBSERVATION_MODIFIER", 121, 125], ["genome", "OBSERVATION", 147, 153]]], ["The principle of high natural variability is perhaps best illustrated by the published surveys of allozyme patterns in plants and animals (Schonewald-Cox et al., 1983).", [["high natural variability", "PROBLEM", 17, 41], ["high", "OBSERVATION_MODIFIER", 17, 21], ["natural variability", "OBSERVATION", 22, 41]]], ["Geneticists typically sample a population of 20 individuals and determine each individual's genotype at 10\u201320 loci.", [["10\u201320 loci", "DNA", 104, 114]]], ["This allows them to calculate the mean number of alleles per locus (A), the mean individual heterozygosity (H), and the proportion of loci in the population that are polymorphic (P).", [["alleles", "DNA", 49, 56], ["polymorphic", "OBSERVATION_MODIFIER", 166, 177]]], ["A few thousand species have been examined to date and variation is typically in the following range: H= 0.05\u20130.15 and P= 0.20\u20130.50.", [["A few thousand species", "PROBLEM", 0, 22], ["P", "TEST", 118, 119], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["Still higher levels of natural variation are found at the DNA sequence level, especially in areas of the genome which are apparently free to mutate.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["genome", "CELLULAR_COMPONENT", 105, 111], ["natural variation", "PROBLEM", 23, 40], ["the DNA sequence level", "TEST", 54, 76], ["higher", "OBSERVATION_MODIFIER", 6, 12], ["levels", "OBSERVATION_MODIFIER", 13, 19], ["natural variation", "OBSERVATION", 23, 40], ["genome", "ANATOMY", 105, 111]]], ["Short repeat sequences (microsatellites) of nuclear DNA, for example, are often 10 times more variable than allozyme loci.", [["nuclear", "ANATOMY", 44, 51], ["nuclear", "CELLULAR_COMPONENT", 44, 51], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["Short repeat sequences", "DNA", 0, 22], ["nuclear DNA", "DNA", 44, 55], ["allozyme loci", "DNA", 108, 121], ["Short repeat sequences", "TEST", 0, 22], ["nuclear DNA", "TEST", 44, 55], ["nuclear DNA", "ANATOMY", 44, 55]]], ["A polymorphic allozyme may have 2 or 3 alleles segregating in a population, whereas a dinucleotide repeat microsatellite may have 10\u201315 alleles (differing in the number of times the motif is repeated) in the same individuals.", [["dinucleotide", "CHEMICAL", 86, 98], ["dinucleotide", "CHEMICAL", 86, 98], ["dinucleotide repeat microsatellite", "DNA", 86, 120], ["10\u201315 alleles", "DNA", 130, 143], ["A polymorphic allozyme", "PROBLEM", 0, 22], ["3 alleles segregating", "PROBLEM", 37, 58], ["a dinucleotide repeat microsatellite", "TEST", 84, 120]]], ["Biochemical and molecular genetics have shown that most living organisms are richly variable.Genetic Variation and its SignificanceMuch of the cryptic variation in natural populations that has been discovered in the past 30 years appears to be selectively neutral or near neutral in its effect on the phenotype.", [["Genetic Variation", "PROBLEM", 93, 110], ["the cryptic variation", "PROBLEM", 139, 160], ["Variation", "OBSERVATION_MODIFIER", 101, 110], ["cryptic variation", "OBSERVATION", 143, 160], ["natural populations", "OBSERVATION", 164, 183]]], ["It is rare to find a single locus genetic trait in which a deleterious condition such as albinism is controlled by a single allelic variant.", [["albinism", "DISEASE", 89, 97], ["a single locus genetic trait", "PROBLEM", 19, 47], ["a deleterious condition", "PROBLEM", 57, 80], ["albinism", "PROBLEM", 89, 97], ["a single allelic variant", "PROBLEM", 115, 139]]], ["Experiments and field observations with a few species have shown that there is a positive relationship between genetic variability and individual growth rate, size at maturity, symmetry of body parts, fecundity, and health as measured by parasite load.", [["body parts", "ANATOMY", 189, 199], ["body", "ORGANISM_SUBDIVISION", 189, 193], ["a positive relationship between genetic variability", "PROBLEM", 79, 130], ["size", "OBSERVATION_MODIFIER", 159, 163]]], ["Fisher's fundamental theorem holds that additive genetic variation in fitness is positively related to a population's ability to respond to natural selection.", [["a population's ability", "PROBLEM", 103, 125], ["natural selection", "TREATMENT", 140, 157]]], ["Evolutionary success, the ability of a species to persist despite changes in climate and exposure to new diseases, predators, and competitors, is somehow related to innate genetic variability.", [["a species", "PROBLEM", 37, 46], ["new diseases", "PROBLEM", 101, 113], ["success", "OBSERVATION", 13, 20], ["new", "OBSERVATION_MODIFIER", 101, 104], ["diseases", "OBSERVATION", 105, 113]]], ["In a world of unpredictable change, alleles that are selectively neutral for thousands of generations may suddenly become lifesavers for the individuals that carry them.", [["unpredictable change", "PROBLEM", 14, 34], ["unpredictable", "OBSERVATION_MODIFIER", 14, 27], ["change", "OBSERVATION", 28, 34]]], ["If evolution is largely dependent on genetic variability, then the conservation of species will sooner or later depend on the conservation of their innate genetic variability (Woodruff, 1989).Genetic Variation and its SignificanceOf course, there are many apparently successful genetically invariant plants and animals.", [["largely", "OBSERVATION_MODIFIER", 16, 23], ["dependent", "OBSERVATION_MODIFIER", 24, 33], ["invariant plants", "OBSERVATION", 290, 306]]], ["There are many known clonal organisms whose descendents are genetically identical to their mothers.", [["clonal organisms", "CELL", 21, 37], ["many known clonal organisms", "PROBLEM", 10, 37], ["clonal organisms", "OBSERVATION", 21, 37]]], ["Such clonal plants, snails, fish, and lizards are genetically invariant even though they may exhibit great ecological success.", [["fish", "ORGANISM_SUBDIVISION", 28, 32], ["clonal plants", "OBSERVATION", 5, 18]]], ["However, they are more likely to go extinct when their environment changes than are closely related sexually reproducing species.", [["more likely", "UNCERTAINTY", 18, 29]]], ["Although meiosis ensures the maintenance of high variability in the sexual species, their asexually reproducing daughter species gradually lose their initial low variability and over time become evolutionary dead ends.Genetic Variation and its SignificanceThere are many different ways of measuring genetic variability, including the examination of karyotypes and single-locus markers (allozymes, mitochondrial and chloroplast DNA restriction fragment length polymorphisms), DNA minisatellite fingerprints, random amplified polymorphic DNA, mtDNA sequences, nuclear DNA sequences, and nDNA microsatellites (simple sequence repeats).", [["mitochondrial", "ANATOMY", 397, 410], ["nuclear", "ANATOMY", 558, 565], ["mitochondrial", "CELLULAR_COMPONENT", 397, 410], ["chloroplast", "CELLULAR_COMPONENT", 415, 426], ["DNA", "CELLULAR_COMPONENT", 427, 430], ["DNA", "CELLULAR_COMPONENT", 475, 478], ["DNA", "CELLULAR_COMPONENT", 536, 539], ["mtDNA", "CELLULAR_COMPONENT", 541, 546], ["nuclear", "CELLULAR_COMPONENT", 558, 565], ["DNA", "CELLULAR_COMPONENT", 566, 569], ["nDNA", "CELLULAR_COMPONENT", 585, 589], ["single-locus markers", "DNA", 364, 384], ["mitochondrial and chloroplast DNA restriction fragment length polymorphisms", "DNA", 397, 472], ["DNA minisatellite fingerprints", "DNA", 475, 505], ["random amplified polymorphic DNA", "DNA", 507, 539], ["mtDNA sequences", "DNA", 541, 556], ["nuclear DNA sequences", "DNA", 558, 579], ["nDNA microsatellites", "DNA", 585, 605], ["meiosis", "PROBLEM", 9, 16], ["high variability", "PROBLEM", 44, 60], ["evolutionary dead ends", "PROBLEM", 195, 217], ["Genetic Variation", "PROBLEM", 218, 235], ["measuring genetic variability", "PROBLEM", 289, 318], ["the examination", "TEST", 330, 345], ["karyotypes", "TEST", 349, 359], ["single-locus markers", "PROBLEM", 364, 384], ["allozymes", "TEST", 386, 395], ["mitochondrial and chloroplast DNA restriction fragment length polymorphisms", "TREATMENT", 397, 472], ["DNA minisatellite fingerprints", "TEST", 475, 505], ["random amplified polymorphic DNA", "TEST", 507, 539], ["mtDNA sequences", "TEST", 541, 556], ["nuclear DNA sequences", "TEST", 558, 579], ["nDNA microsatellites", "TEST", 585, 605], ["simple sequence repeats", "TEST", 607, 630], ["high variability", "OBSERVATION", 44, 60], ["sexual species", "OBSERVATION", 68, 82], ["low variability", "OBSERVATION_MODIFIER", 158, 173], ["dead ends", "OBSERVATION", 208, 217], ["many", "OBSERVATION_MODIFIER", 266, 270], ["different", "OBSERVATION_MODIFIER", 271, 280], ["genetic variability", "OBSERVATION", 299, 318]]], ["Benirschke and Kumamoto (1991) and Smith and Wayne (1996) provide numerous examples of the application of karyotypes and molecular genetic markers, respectively, to conservation.", [["the application of karyotypes", "TREATMENT", 87, 116]]], ["One method, allozyme electrophoresis, is informative with mammals but frustratingly uninformative for birds.", [["birds", "ORGANISM", 102, 107], ["allozyme electrophoresis", "PROBLEM", 12, 36]]], ["The methods also differ greatly in their cost and technical difficulty.", [["The methods", "TREATMENT", 0, 11]]], ["Some relatively inexpensive methods are satisfactory for one-time analyses but the results cannot be built on in subsequent studies.", [["subsequent studies", "TEST", 113, 131], ["relatively", "OBSERVATION_MODIFIER", 5, 15], ["inexpensive", "OBSERVATION_MODIFIER", 16, 27]]], ["Other methods, in contrast, provide genotypes which can be archived in expandable permanent databases such as GenBank for future comparative study of samples collected at other times or places.", [["samples", "ANATOMY", 150, 157], ["samples", "CANCER", 150, 157], ["future comparative study", "TEST", 122, 146]]], ["Although a given method will give comparable results in a study of closely related populations or species, results across unrelated taxa may not be comparable.Genetic Variation and its SignificanceCurrently, nuclear and mitochondrial sequence data are the most informative methods for characterizing variability at or above the level of populations.", [["nuclear", "ANATOMY", 208, 215], ["mitochondrial", "ANATOMY", 220, 233], ["nuclear", "CELLULAR_COMPONENT", 208, 215], ["mitochondrial", "CELLULAR_COMPONENT", 220, 233], ["a study", "TEST", 56, 63], ["species", "PROBLEM", 98, 105], ["Genetic Variation", "TEST", 159, 176], ["nuclear and mitochondrial sequence data", "TEST", 208, 247], ["Variation", "OBSERVATION_MODIFIER", 167, 176]]], ["For studies of variation within populations, hypervariable nuclear microsatellite loci are ideal markers.", [["nuclear", "ANATOMY", 59, 66], ["nuclear", "CELLULAR_COMPONENT", 59, 66], ["hypervariable nuclear microsatellite loci", "DNA", 45, 86], ["studies", "TEST", 4, 11], ["variation within populations", "PROBLEM", 15, 43], ["hypervariable nuclear microsatellite loci", "PROBLEM", 45, 86], ["hypervariable", "OBSERVATION_MODIFIER", 45, 58], ["nuclear", "OBSERVATION_MODIFIER", 59, 66], ["microsatellite loci", "OBSERVATION", 67, 86]]], ["Sequence data and microsatellite genotypes can now be determined directly from minute DNA samples amplified many times by the polymerase chain reaction.", [["samples", "ANATOMY", 90, 97], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["Sequence data", "TEST", 0, 13], ["microsatellite genotypes", "PROBLEM", 18, 42], ["minute DNA samples", "TEST", 79, 97], ["the polymerase chain reaction", "PROBLEM", 122, 151]]], ["Both methods require fully equipped laboratories, trained personnel, and considerable time and money for developing the synthetic DNA primers to amplify the gene sequences of interest in species that have never been studied before.Genetic Variation and its SignificanceNoninvasive genotyping methods involving the extraction of DNA from shed hair and feathers were introduced in 1989 and are now widely used (Morin and Woodruff, 1996).", [["hair", "ANATOMY", 342, 346], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["DNA", "CELLULAR_COMPONENT", 328, 331], ["hair", "MULTI-TISSUE_STRUCTURE", 342, 346], ["feathers", "ORGANISM_SUBDIVISION", 351, 359], ["synthetic DNA primers", "DNA", 120, 141], ["the synthetic DNA primers", "TREATMENT", 116, 141], ["Genetic Variation", "PROBLEM", 231, 248], ["Noninvasive genotyping methods", "TREATMENT", 269, 299], ["the extraction of DNA", "TREATMENT", 310, 331]]], ["Noninvasive (shed tissues, feces, urine, and scent markings) and nondestructive (toe, tail, and ear clips and fish scales) genotyping permits the study of wildlife populations that previously were almost impossible to sample.", [["tissues", "ANATOMY", 18, 25], ["feces", "ANATOMY", 27, 32], ["urine", "ANATOMY", 34, 39], ["tail", "ANATOMY", 86, 90], ["ear", "ANATOMY", 96, 99], ["tissues", "TISSUE", 18, 25], ["feces", "ORGANISM_SUBDIVISION", 27, 32], ["urine", "ORGANISM_SUBSTANCE", 34, 39], ["toe", "ORGANISM_SUBDIVISION", 81, 84], ["tail", "ORGANISM_SUBDIVISION", 86, 90], ["ear", "ORGAN", 96, 99], ["Noninvasive (shed tissues, feces, urine, and scent markings", "TEST", 0, 59], ["nondestructive (toe, tail", "PROBLEM", 65, 90], ["ear clips", "TREATMENT", 96, 105], ["fish scales", "TEST", 110, 121], ["genotyping", "TEST", 123, 133], ["the study", "TEST", 142, 151], ["nondestructive", "OBSERVATION_MODIFIER", 65, 79], ["toe", "ANATOMY", 81, 84], ["tail", "ANATOMY", 86, 90], ["ear", "ANATOMY", 96, 99], ["clips", "OBSERVATION", 100, 105]]], ["Not surprisingly, the DNA extracted from some types of samples may be degraded and very difficult to work with.", [["samples", "ANATOMY", 55, 62], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["samples", "CANCER", 55, 62], ["the DNA", "PROBLEM", 18, 25]]], ["Nevertheless, with technical care and patience it is possible to genotype some animals without actually seeing or handling them.Genetic Variation and its SignificanceConservation geneticists can also genotype museum specimens and determine patterns of variability over periods of decades and sometimes centuries.", [["specimens", "ANATOMY", 216, 225], ["Genetic Variation", "PROBLEM", 128, 145]]], ["Several species that have gone extinct recently, including the dodo, moa, thylacine, and quagga, have been characterized genetically.", [["thylacine", "CHEMICAL", 74, 83], ["moa", "GENE_OR_GENE_PRODUCT", 69, 72], ["thylacine", "GENE_OR_GENE_PRODUCT", 74, 83], ["quagga", "GENE_OR_GENE_PRODUCT", 89, 95], ["Several species", "PROBLEM", 0, 15], ["species", "OBSERVATION", 8, 15]]], ["DNA can also be extracted and sequenced from some fossil remains, but DNA degradation rates are such that fossils more than a few million years old are unlikely to yield reliable sequences.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["DNA", "PROBLEM", 0, 3], ["some fossil", "PROBLEM", 45, 56], ["DNA degradation rates", "PROBLEM", 70, 91]]], ["Although enormously interesting to evolutionary biologists, such ancient DNA cannot be used to recreate extinct organisms.", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["such ancient DNA", "PROBLEM", 60, 76], ["extinct organisms", "PROBLEM", 104, 121]]], ["Conservation geneticists must concentrate on saving existing biodiversity; they cannot fall back on the idea of being able to recreate extinct species from the tiny fragments of DNA (typically less than 0.00001% of an organism's genome) currently under scrutiny.Genetic Variation and its SignificanceGenetic data, once acquired, are used by conservation geneticists to quantify within- and between-population variability.", [["DNA", "CELLULAR_COMPONENT", 178, 181], ["saving existing biodiversity", "TREATMENT", 45, 73], ["extinct species", "PROBLEM", 135, 150], ["the tiny fragments of DNA", "PROBLEM", 156, 181], ["an organism's genome", "TREATMENT", 215, 235], ["Genetic Variation", "TEST", 262, 279], ["its SignificanceGenetic data", "TEST", 284, 312], ["tiny", "OBSERVATION_MODIFIER", 160, 164], ["fragments", "OBSERVATION_MODIFIER", 165, 174]]], ["Variability within populations is used to establish pedigree relations, mating system, sex ratio, and genetic effective population size (Ne).", [["sex ratio", "TEST", 87, 96], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["Interpopulation comparisons reveal spatial structuring and historical patterns of gene flow.", [["Interpopulation comparisons", "TEST", 0, 27], ["spatial structuring", "PROBLEM", 35, 54], ["gene flow", "PROBLEM", 82, 91], ["spatial", "OBSERVATION_MODIFIER", 35, 42], ["structuring", "OBSERVATION", 43, 54], ["gene flow", "OBSERVATION", 82, 91]]], ["Geographic variation is normal within a species and the new field of phylogeography uses genetic information to infer the historical relationships among populations.", [["variation", "OBSERVATION_MODIFIER", 11, 20], ["normal", "OBSERVATION", 24, 30], ["new", "OBSERVATION_MODIFIER", 56, 59]]], ["Single and multilocus genetic differences between kin, populations, subspecies, and species are expressed as genetic distances.", [["genetic", "OBSERVATION_MODIFIER", 22, 29], ["differences", "OBSERVATION_MODIFIER", 30, 41], ["populations", "OBSERVATION_MODIFIER", 55, 66], ["subspecies", "OBSERVATION_MODIFIER", 68, 78]]], ["These metrics and their interpretations are beyond the scope of this review, but it is important to note that the absolute values of genetic distances will vary between different groups of plants and animals and increase over geological time.", [["increase", "OBSERVATION_MODIFIER", 212, 220]]], ["Within a group of related species a major difference in the genetic distances observed within and between taxa can be used to define species and other evolutionarily significant units for conservation management purposes.Genetic Variation and its SignificanceAlthough the previous discussion focused on molecular genetic variation, the growing field of quantitative trait genetics promises to provide a new means of measuring evolutionarily significant population variables (Storfer, 1996).", [["conservation management", "TREATMENT", 188, 211], ["Genetic Variation", "PROBLEM", 221, 238], ["major", "OBSERVATION_MODIFIER", 36, 41], ["difference", "OBSERVATION_MODIFIER", 42, 52], ["significant", "OBSERVATION_MODIFIER", 441, 452], ["population", "OBSERVATION", 453, 463]]], ["Quantitative genetics is concerned with characters such as morphology, behavior, parasite resistance, and physiology that are controlled by several to many genes that work additively, in dominance/recessive relationships, or epistatically.", [["parasite resistance", "PROBLEM", 81, 100], ["parasite resistance", "OBSERVATION", 81, 100]]], ["Such oligogenic and polygenic control, involving quantitative trait loci (QTL), is characteristic of many traits of interest to conservationists\u2014those that effect long-term population persistence and evolvability.", [["Such oligogenic and polygenic control", "PROBLEM", 0, 37], ["quantitative trait loci", "PROBLEM", 49, 72], ["polygenic", "OBSERVATION_MODIFIER", 20, 29]]], ["QTLs affecting body size, hatching date, and predator avoidance behavior (escape speed), for example, are ecologically important and are arguably of greater significance to conservationists than allozyme polymorphism.", [["body", "ANATOMY", 15, 19], ["body", "ORGANISM_SUBDIVISION", 15, 19], ["allozyme polymorphism", "PROBLEM", 195, 216], ["body", "OBSERVATION_MODIFIER", 15, 19], ["size", "OBSERVATION_MODIFIER", 20, 24]]], ["Conservationists are therefore interested in the heritability of such traits that have a direct impact on fitness.", [["such traits", "PROBLEM", 65, 76]]], ["High heritabilities of a QTL indicate that a population has great potential for trait evolution and low heritabilities indicate a more limited ability to respond to environmental change.", [["High heritabilities of a QTL", "PROBLEM", 0, 28], ["trait evolution", "PROBLEM", 80, 95], ["low heritabilities", "PROBLEM", 100, 118], ["low heritabilities", "OBSERVATION_MODIFIER", 100, 118]]], ["Unfortunately, such heritability is difficult to measure because it requires pedigree-level studies conducted over several generations or long-term manipulative experiments such as controlled garden plots.", [["pedigree-level studies", "TEST", 77, 99], ["long-term manipulative experiments", "TREATMENT", 138, 172]]], ["Heritability (h2) is the ratio of the variance of the genetically inherited proportion of a trait (the additive genetic variance, VA) to the total phenotypic variance VP measured in the population.", [["a trait", "PROBLEM", 90, 97], ["the total phenotypic variance VP", "PROBLEM", 137, 169]]], ["VA is one component of genetic variance (VG) which also includes nonadditive genetic variance due to dominance (VD) and epistasis (VI; only VA responds to directional selection.", [["genetic variance (VG", "PROBLEM", 23, 43], ["nonadditive genetic variance", "PROBLEM", 65, 93], ["dominance (VD)", "PROBLEM", 101, 115], ["epistasis (VI", "PROBLEM", 120, 133], ["directional selection", "TREATMENT", 155, 176], ["one component", "OBSERVATION_MODIFIER", 6, 19], ["genetic variance", "OBSERVATION", 23, 39], ["epistasis", "OBSERVATION", 120, 129]]], ["Nevertheless, the preparation of studbooks for captive populations of endangered animals and the comparison of laboratory-raised seedlings of rare plants to their parents in the wild have provided opportunities for the first limited applications of QTL analyses to conservation.", [["QTL analyses", "TEST", 249, 261]]], ["Future technical advances may permit the inclusion of QTL in the conservation geneticist's tool kit of predictors of a population's risk of extinction.Genetic Variation and its SignificanceA major issue requiring resolution is the validity of the widely held relationship between molecular genetic variation and ecological viability and evolutionary potential.", [["extinction", "PROBLEM", 140, 150], ["Genetic Variation", "PROBLEM", 151, 168], ["extinction", "OBSERVATION", 140, 150], ["Variation", "OBSERVATION_MODIFIER", 159, 168], ["ecological viability", "OBSERVATION", 312, 332]]], ["Are single gene markers (those typically surveyed by geneticists) useful indicators of variation at quantitative traits?", [["variation at quantitative traits", "PROBLEM", 87, 119]]], ["Are multilocus allozyme surveys unreliable as predictors of a population's viability since heterozygosity may be only weakly correlated with the additive genetic variation associated with QTLs?", [["multilocus allozyme surveys", "TEST", 4, 31], ["a population's viability", "PROBLEM", 60, 84], ["heterozygosity", "PROBLEM", 91, 105]]], ["In desert topminnows of the genus Poeciliopsis, Vrijenhoek (in Avise and Hamrick, 1996, pp. 367\u2013397) found that rapid losses of heterozygosity in small, isolated populations were associated with a decline in fitness that was manifested as poor competitive ability, growth rate, developmental stability, and resistance to parasites.", [["rapid losses of heterozygosity in small, isolated populations", "PROBLEM", 112, 173], ["a decline in fitness", "PROBLEM", 195, 215], ["poor competitive ability", "PROBLEM", 239, 263], ["developmental stability", "PROBLEM", 278, 301], ["resistance to parasites", "PROBLEM", 307, 330], ["genus Poeciliopsis", "OBSERVATION", 28, 46], ["rapid", "OBSERVATION_MODIFIER", 112, 117], ["losses", "OBSERVATION_MODIFIER", 118, 124], ["small", "OBSERVATION_MODIFIER", 146, 151], ["stability", "OBSERVATION_MODIFIER", 292, 301]]], ["O'Brien (1994), in a remarkable series of genetic studies of captive and wild cheetahs (Acynonyx jubatus), demonstrated a powerful association between low levels of genetic variability and susceptibility to viral diseases.Genetic Variation and its SignificanceThere is no \u201cnormal\u201d level of variation for a population\u2014even as determined with a specific method.", [["viral diseases", "DISEASE", 207, 221], ["wild cheetahs", "ORGANISM", 73, 86], ["Acynonyx jubatus", "ORGANISM", 88, 104], ["cheetahs", "SPECIES", 78, 86], ["Acynonyx jubatus", "SPECIES", 88, 104], ["Acynonyx jubatus", "SPECIES", 88, 104], ["genetic studies", "TEST", 42, 57], ["genetic variability", "PROBLEM", 165, 184], ["viral diseases", "PROBLEM", 207, 221], ["Genetic Variation", "PROBLEM", 222, 239], ["viral diseases", "OBSERVATION", 207, 221], ["no", "UNCERTAINTY", 269, 271], ["normal", "OBSERVATION", 273, 279]]], ["Cheetah, northern elephant seal (Mirounga angustirostris), and European badger (Meles meles) are ecologically successful despite low absolute levels of genetic variation.", [["Mirounga angustirostris", "ORGANISM", 33, 56], ["Meles meles", "ORGANISM", 80, 91], ["Mirounga angustirostris", "SPECIES", 33, 56], ["Meles meles", "SPECIES", 80, 91], ["northern elephant seal", "SPECIES", 9, 31], ["Mirounga angustirostris", "SPECIES", 33, 56], ["European badger", "SPECIES", 63, 78], ["Meles meles", "SPECIES", 80, 91], ["elephant seal", "OBSERVATION", 18, 31], ["genetic variation", "OBSERVATION", 152, 169]]], ["Different types of genetic variability will respond differently to natural selection, inbreeding, population collapse, and range fragmentation.", [["genetic variability", "PROBLEM", 19, 38], ["natural selection", "TREATMENT", 67, 84], ["inbreeding", "PROBLEM", 86, 96], ["population collapse", "PROBLEM", 98, 117], ["range fragmentation", "PROBLEM", 123, 142], ["genetic variability", "OBSERVATION", 19, 38], ["population", "OBSERVATION_MODIFIER", 98, 108], ["collapse", "OBSERVATION", 109, 117], ["range fragmentation", "OBSERVATION", 123, 142]]], ["Conservation geneticists can identify cases in which variation has or is being lost, establish the causes of the loss, and make recommendations to counter its ultimate effects.", [["the loss", "PROBLEM", 109, 117]]], ["Because currently available genetic markers are only proxies for fitness determinants, this underscores the importance of using different markers.", [["genetic markers", "TEST", 28, 43]]], ["It is not the purpose of this review to discuss the technical problems associated with each method or the applicability of the different methods to different groups of plants and animals, but it is important to emphasize that each method has unresolved technical problems (e.g., null alleles, allelic dropout, pseudogenes, and nonreplicable patterns).", [["the technical problems", "PROBLEM", 48, 70], ["technical problems", "PROBLEM", 253, 271], ["null alleles, allelic dropout, pseudogenes", "PROBLEM", 279, 321]]], ["Until molecular and QTL genotyping become routine, conservation geneticists must guard against the natural tendency to overstate the statistical power of their results.Genes ::: Levels of Interest to Conservation GeneticistsLong before the term conservation genetics was coined, the phrase \u201cgenetic conservation\u201d was introduced to describe the science of managing specific genes or phenotypic traits in crop plants, land races and cultivars, bacteria and fungi used in food production, and domesticated animals.", [["QTL genotyping", "TEST", 20, 34], ["phenotypic traits", "PROBLEM", 382, 399], ["cultivars", "PROBLEM", 431, 440], ["bacteria", "PROBLEM", 442, 450], ["fungi", "PROBLEM", 455, 460]]], ["Genetically modified organisms (GMOs) are simply special cases that require even more intensive management for their perpetuation.", [["intensive management", "TREATMENT", 86, 106]]], ["The methods of gene discovery and artificial selection developed for managing microorganisms, plants, and animals are relevant to the far more broadly focused field of conservation genetics, but very few wild species have received such intensive effort.Genes ::: Levels of Interest to Conservation GeneticistsDiscussions of the need to save this or that desired gene in a population are in fact arguments for saving a particular allelic form (variant) of a gene and not the gene itself.", [["gene discovery", "TREATMENT", 15, 29], ["artificial selection", "TREATMENT", 34, 54], ["managing microorganisms", "PROBLEM", 69, 92]]], ["Some alleles are common and others are rare.", [["Some alleles", "PROBLEM", 0, 12], ["alleles", "OBSERVATION", 5, 12], ["common", "OBSERVATION_MODIFIER", 17, 23]]], ["Deleterious alleles (e.g., alleles responsible for albinism or other genetic \u201cdefects\u201d) are typically very rare and have frequencies of less than 0.0001.", [["albinism", "DISEASE", 51, 59], ["Deleterious alleles", "PROBLEM", 0, 19], ["albinism", "PROBLEM", 51, 59], ["other genetic \u201cdefects", "PROBLEM", 63, 85]]], ["Although this argument is reasonable, the maintenance of desirable rare alleles, even if they were identifiable, requires very large population sizes (Ne > 5000) and is simply not possible in most management programs.", [["very", "OBSERVATION_MODIFIER", 122, 126], ["large", "OBSERVATION_MODIFIER", 127, 132], ["population", "OBSERVATION_MODIFIER", 133, 143], ["sizes", "OBSERVATION_MODIFIER", 144, 149], ["not possible", "UNCERTAINTY", 176, 188]]], ["Rare alleles contribute very little to variation in fitness among individuals and are less likely than alleles at relatively high frequency to be the basis of adaptive response to environmental change.Genes ::: Levels of Interest to Conservation GeneticistsIt has been suggested that conservationists should focus on saving diversity at major histocompatibility complex (MHC) genes because they play a role in recognition of infectious agents, disease susceptibility, and defense.", [["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 337, 369], ["major histocompatibility complex (MHC) genes", "DNA", 337, 381], ["Rare alleles", "PROBLEM", 0, 12], ["infectious agents", "TREATMENT", 425, 442], ["disease susceptibility", "PROBLEM", 444, 466], ["alleles", "OBSERVATION", 5, 12], ["very little to variation", "OBSERVATION_MODIFIER", 24, 48]]], ["This recommendation was well intended but rejected because the functional (fitness-related) significance of the large number of alleles at each of the many MHC genes is unknown.", [["MHC genes", "DNA", 156, 165], ["the large number of alleles", "PROBLEM", 108, 135], ["large", "OBSERVATION_MODIFIER", 112, 117], ["MHC genes", "OBSERVATION", 156, 165]]], ["Managing them as a single linkage group would require very large populations or the inevitable loss of variation at other potentially important loci.Populations ::: Levels of Interest to Conservation GeneticistsInterest in the concept of minimum viable populations (Gilpin and Soul\u00e9, 1986) spawned the development of new methods of pedigree analysis and population viability analysis.", [["very large populations", "PROBLEM", 54, 76], ["the inevitable loss of variation", "PROBLEM", 80, 112], ["pedigree analysis", "TEST", 332, 349], ["population viability analysis", "TEST", 354, 383], ["very", "OBSERVATION_MODIFIER", 54, 58], ["large", "OBSERVATION_MODIFIER", 59, 64], ["populations", "OBSERVATION", 65, 76], ["inevitable", "OBSERVATION_MODIFIER", 84, 94], ["loss", "OBSERVATION", 95, 99], ["new", "OBSERVATION_MODIFIER", 317, 320]]], ["Populations have both a census size (N) and a genetic effective population size (Ne); the latter is one of the most important concepts in theoretical conservation biology and is defined in Section III,G and by Lande and Barrowclough (1987).", [["size", "OBSERVATION_MODIFIER", 31, 35], ["effective", "OBSERVATION_MODIFIER", 54, 63], ["population", "OBSERVATION_MODIFIER", 64, 74], ["size", "OBSERVATION_MODIFIER", 75, 79]]], ["The characterization of genetic variation within and among populations enables geneticists to help set conservation priorities.", [["genetic variation", "PROBLEM", 24, 41]]], ["Comparative levels of variation and gene flow (or lack of either) provide clues to a population's viability and extinction proneness.", [["Comparative levels", "TEST", 0, 18], ["gene flow", "TEST", 36, 45], ["extinction proneness", "PROBLEM", 112, 132]]], ["Data on genetic relationships among populations guide translocation decisions and identify well-defined clusters of populations for management as separate entities.Populations ::: Levels of Interest to Conservation GeneticistsPedigree analysis refers to a suite of genetic models for understanding processes in small populations.", [["management", "TREATMENT", 132, 142], ["Pedigree analysis", "TEST", 226, 243], ["small", "OBSERVATION_MODIFIER", 311, 316], ["populations", "OBSERVATION", 317, 328]]], ["First developed for assessing management practices in captive populations, pedigree analysis is also applicable to wild populations of individually monitored organisms.", [["assessing management practices", "TREATMENT", 20, 50], ["pedigree analysis", "TEST", 75, 92]]], ["It is used to establish kinship and individual founder contributions, to identify genetically desirable and undesirable individuals and their descendents, to minimize inbreeding, to describe population structure and mating system, and to choose individuals for reintroduction or translocation.", [["inbreeding", "PROBLEM", 167, 177], ["translocation", "PROBLEM", 279, 292]]], ["Examples of pedigree analysis with the Gene Drop computer program include Haig's (1998) study of the red-cockaded woodpecker, Picoides borealis.", [["Picoides borealis", "ORGANISM", 126, 143], ["Picoides borealis", "SPECIES", 126, 143], ["Picoides borealis", "SPECIES", 126, 143], ["pedigree analysis", "TEST", 12, 29], ["Haig's", "TREATMENT", 74, 80]]], ["Pedigree management programs based on mean kinship or equalizing founder contributions seek to minimize inbreeding in local subpopulations and in the metapopulation as a whole.", [["Pedigree management programs", "TREATMENT", 0, 28]]], ["Captive breeding programs have been successful in slowing the loss of genetic variation and preventing inbreeding depression.Populations ::: Levels of Interest to Conservation GeneticistsPopulation viability analysis (PVA) is the methodology used to assess the ecological and genetic risks facing a wild or captive population and to develop a conservation management plan.", [["inbreeding depression", "DISEASE", 103, 124], ["Captive breeding programs", "TREATMENT", 0, 25], ["inbreeding depression", "PROBLEM", 103, 124], ["viability analysis", "TEST", 198, 216], ["a conservation management plan", "TREATMENT", 341, 371]]], ["PVA refers to a suite of mathematical models that seek to predict the probability of a population's extinction by some time in the future, e.g., 20 or 100 years.", [["PVA", "CHEMICAL", 0, 3], ["PVA", "CHEMICAL", 0, 3]]], ["Early models considered demography (growth rate, present population size, and birth rate) and environmental stochasticity, but Gilpin and Soul\u00e9(1986) broadened the definition to include genetic factors.", [["growth rate", "TEST", 36, 47], ["birth rate", "TEST", 78, 88], ["genetic factors", "PROBLEM", 186, 201], ["size", "OBSERVATION_MODIFIER", 68, 72]]], ["Genetic factors, including genetic drift and fixation of deleterious mutations, are expressed through demographic factors that affect population dynamics.", [["Genetic factors", "PROBLEM", 0, 15], ["genetic drift", "PROBLEM", 27, 40], ["fixation", "TREATMENT", 45, 53], ["deleterious mutations", "PROBLEM", 57, 78], ["deleterious mutations", "OBSERVATION", 57, 78]]], ["The genetic factors thus contribute to extinction probabilities through a very complex and little understood series of interactions affecting fitness.", [["The genetic factors", "PROBLEM", 0, 19], ["extinction probabilities", "PROBLEM", 39, 63]]], ["Most PVAs, in fact, have not included genetic parameters, but this is changing as the significance of genetics in the long-term survival of small populations becomes more widely appreciated (Beissinger and McCullough, 2000).Populations ::: Levels of Interest to Conservation GeneticistsMetapopulations are populations of subpopulations within some defined area, in which dispersal from one local population (subpopulation) to at least some other habitat patches is possible.", [["PVAs", "GENE_OR_GENE_PRODUCT", 5, 9], ["Most PVAs", "PROBLEM", 0, 9], ["genetic parameters", "TEST", 38, 56], ["small populations", "PROBLEM", 140, 157], ["small", "OBSERVATION_MODIFIER", 140, 145], ["populations", "OBSERVATION", 146, 157], ["more widely", "OBSERVATION_MODIFIER", 166, 177], ["subpopulations", "OBSERVATION_MODIFIER", 321, 335], ["some defined", "OBSERVATION_MODIFIER", 343, 355], ["area", "OBSERVATION_MODIFIER", 356, 360], ["habitat patches", "OBSERVATION", 446, 461]]], ["There is significant turnover of local populations, local extinction, and recolonization by dispersal.", [["significant turnover of local populations", "PROBLEM", 9, 50], ["local extinction", "PROBLEM", 52, 68], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["turnover", "OBSERVATION_MODIFIER", 21, 29], ["local", "OBSERVATION_MODIFIER", 33, 38], ["populations", "OBSERVATION_MODIFIER", 39, 50], ["local extinction", "OBSERVATION", 52, 68]]], ["The metapopulation concept is central to much ecology and conservation theory and single-and multiple-species metapopulation dynamics are reviewed by Hanski and Gilpin (1996).", [["metapopulation", "OBSERVATION", 4, 18]]], ["The genetic effective size of a metapopulation is affected by the carrying capacity of the habitat patches, the rates of extirpation and recolonization, the number and source of the founders, the number of local populations, and the rate of gene flow between patches.", [["a metapopulation", "PROBLEM", 30, 46], ["extirpation", "TREATMENT", 121, 132], ["recolonization", "TREATMENT", 137, 151], ["local populations", "TREATMENT", 206, 223], ["gene flow between patches", "TREATMENT", 241, 266], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["metapopulation", "OBSERVATION", 32, 46], ["habitat patches", "OBSERVATION", 91, 106]]], ["It is difficult to establish metapopulation effective size using genetic data because it is strongly affected by extirpation and recolonization dynamics.", [["genetic data", "TEST", 65, 77], ["extirpation", "TREATMENT", 113, 124], ["recolonization dynamics", "PROBLEM", 129, 152], ["extirpation", "OBSERVATION", 113, 124]]], ["As in the case of genetic effective population size of single populations, the metapopulation effective size is 10\u2013100 times less than the census size in many species.", [["single populations", "PROBLEM", 55, 73], ["size", "OBSERVATION_MODIFIER", 47, 51], ["metapopulation", "OBSERVATION_MODIFIER", 79, 93], ["effective", "OBSERVATION_MODIFIER", 94, 103], ["size", "OBSERVATION_MODIFIER", 104, 108], ["size", "OBSERVATION_MODIFIER", 146, 150], ["many", "OBSERVATION_MODIFIER", 154, 158], ["species", "OBSERVATION", 159, 166]]], ["Metapopulation dynamics, with frequent local extinction and recolonization of habitat patches by few founders, can reduce Ne to a small fraction of N, with a resulting loss of genetic variability like that associated with a demographic bottleneck.", [["Metapopulation dynamics", "PROBLEM", 0, 23], ["frequent local extinction", "PROBLEM", 30, 55], ["recolonization of habitat patches", "TREATMENT", 60, 93], ["a resulting loss of genetic variability", "PROBLEM", 156, 195], ["frequent", "OBSERVATION_MODIFIER", 30, 38], ["local", "OBSERVATION_MODIFIER", 39, 44], ["extinction", "OBSERVATION", 45, 55], ["small fraction", "OBSERVATION_MODIFIER", 130, 144], ["loss", "OBSERVATION", 168, 172], ["genetic variability", "OBSERVATION", 176, 195]]], ["Detailed studies of metapopulations are reviewed by Hanski and Gilpin (1997) and include the Glanville fritillary butterfly (Melitaea cinxia) and the red bladder campion (Silene dioica), both in Sweden; the checkerspot butterfly (Euphydryas editha) restricted to serpentine outcrops in California; and the pikas (Ochotona principes), a small mammal restricted to isolated talus slopes in alpine areas.", [["Melitaea cinxia", "ORGANISM", 125, 140], ["bladder", "ORGANISM_SUBDIVISION", 154, 161], ["campion", "ORGANISM", 162, 169], ["Silene dioica", "ORGANISM", 171, 184], ["Euphydryas editha", "ORGANISM", 230, 247], ["Ochotona principes", "ORGANISM", 313, 331], ["Melitaea cinxia", "SPECIES", 125, 140], ["Silene dioica", "SPECIES", 171, 184], ["Euphydryas editha", "SPECIES", 230, 247], ["Ochotona principes", "SPECIES", 313, 331], ["Melitaea cinxia", "SPECIES", 125, 140], ["red bladder campion", "SPECIES", 150, 169], ["Silene dioica", "SPECIES", 171, 184], ["Ochotona principes", "SPECIES", 313, 331], ["the Glanville fritillary butterfly (Melitaea cinxia", "TREATMENT", 89, 140], ["the red bladder campion (Silene dioica)", "TREATMENT", 146, 185], ["the checkerspot butterfly (Euphydryas editha", "TREATMENT", 203, 247], ["the pikas (Ochotona principes", "TREATMENT", 302, 331], ["a small mammal", "PROBLEM", 334, 348], ["isolated talus slopes in alpine areas", "PROBLEM", 363, 400], ["bladder", "ANATOMY", 154, 161], ["serpentine", "OBSERVATION_MODIFIER", 263, 273], ["small", "OBSERVATION_MODIFIER", 336, 341], ["talus slopes", "OBSERVATION", 372, 384], ["alpine areas", "OBSERVATION", 388, 400]]], ["Although the theory of metapopulations is well developed, and the relevance of metapopulation theory to the management of small, semi-isolated populations of threatened species is clear, the empirical testing of the ecological and genetic predictions is only just beginning.Populations ::: Levels of Interest to Conservation GeneticistsUsing molecular markers to characterize mating system, population structure, and phylogeography permits recognition of management units (MUs; sets of populations with shared distinctive alleles frequencies) and evolutionarily significant units (ESUs; sets of populations distinguished by strong phylogenetic structure based on multilocus mtDNA or nDNA variation).", [["mtDNA", "CELLULAR_COMPONENT", 674, 679], ["nDNA", "CELLULAR_COMPONENT", 683, 687], ["metapopulation theory", "TREATMENT", 79, 100], ["the management", "TREATMENT", 104, 118], ["small, semi-isolated populations of threatened species", "PROBLEM", 122, 176], ["the empirical testing", "TEST", 187, 208], ["molecular markers", "TEST", 342, 359], ["management units", "TREATMENT", 455, 471], ["metapopulations", "OBSERVATION", 23, 38], ["small", "OBSERVATION_MODIFIER", 122, 127], ["semi-isolated", "OBSERVATION_MODIFIER", 129, 142], ["populations", "OBSERVATION_MODIFIER", 143, 154], ["threatened species", "OBSERVATION", 158, 176], ["significant", "OBSERVATION_MODIFIER", 562, 573], ["nDNA variation", "OBSERVATION", 683, 697]]], ["Moritz (in Smith and Wayne, 1996, pp. 442\u2013456) describes Australian examples of MUs (the yellow-footed wallaby, Petrogale xanthopus, which is patchily distributed on isolated rock outcrops in southwest Queensland) and ESUs (four ghost bat ESUs previously treated as a single widespread species, Macroderma gigas, whose evolutionary divergence was not apparent until genetic methods were applied).", [["wallaby", "ORGANISM", 103, 110], ["Petrogale xanthopus", "ORGANISM", 112, 131], ["Macroderma gigas", "ORGANISM", 295, 311], ["Petrogale xanthopus", "SPECIES", 112, 131], ["Macroderma gigas", "SPECIES", 295, 311], ["yellow-footed wallaby", "SPECIES", 89, 110], ["Petrogale xanthopus", "SPECIES", 112, 131], ["Macroderma gigas", "SPECIES", 295, 311], ["the yellow-footed wallaby", "PROBLEM", 85, 110], ["Petrogale xanthopus", "PROBLEM", 112, 131], ["a single widespread species", "PROBLEM", 266, 293], ["Macroderma gigas", "PROBLEM", 295, 311], ["genetic methods", "TREATMENT", 366, 381]]], ["Although the criteria used to define these two categories are not agreed upon, ESUs represent deep phylogenetic subdivisions typically within a species or occasionally, as in the case of local endemics, the entire species, and MUs reflect shallower subdivisions within a species which for practical reasons become the focus of management activities.", [["deep phylogenetic subdivisions", "PROBLEM", 94, 124], ["local endemics", "PROBLEM", 187, 201], ["the entire species", "PROBLEM", 203, 221], ["shallower subdivisions", "PROBLEM", 239, 261], ["a species", "PROBLEM", 269, 278], ["management activities", "TREATMENT", 327, 348], ["deep", "ANATOMY_MODIFIER", 94, 98], ["phylogenetic subdivisions", "OBSERVATION", 99, 124]]], ["Translocations between ESUs are typically undesirable.Subspecies ::: Levels of Interest to Conservation GeneticistsSubspecies or local geographic races have been the focus of intense conservation efforts.", [["ESUs", "CANCER", 23, 27]]], ["Although we may recommend trying to preserve every variety of wild tomato or maize in a seed bank, it is difficult to use the same justification to try to conserve all local variants of geographically widespread organisms.Subspecies ::: Levels of Interest to Conservation GeneticistsMany biologists have abandoned the subspecies concept and the associated trinomial nomenclature.", [["tomato", "ORGANISM", 67, 73], ["tomato", "SPECIES", 67, 73], ["maize", "SPECIES", 77, 82], ["tomato", "SPECIES", 67, 73], ["maize", "SPECIES", 77, 82], ["trinomial nomenclature", "OBSERVATION", 356, 378]]], ["To them, the subspecies is an evolutionarily insignificant artificial taxon typically based on a few superficial morphological features.", [["an evolutionarily insignificant artificial taxon", "PROBLEM", 27, 75], ["a few superficial morphological features", "PROBLEM", 95, 135], ["insignificant", "OBSERVATION_MODIFIER", 45, 58], ["artificial taxon", "OBSERVATION", 59, 75], ["few", "OBSERVATION_MODIFIER", 97, 100], ["superficial", "OBSERVATION_MODIFIER", 101, 112], ["morphological features", "OBSERVATION", 113, 135]]], ["There are numerous cases in which genetic studies provide no support for the traditional subspecific taxonomy.", [["genetic studies", "TEST", 34, 49], ["support", "TREATMENT", 61, 68], ["numerous", "OBSERVATION_MODIFIER", 10, 18], ["cases", "OBSERVATION", 19, 24]]], ["Nevertheless, there is much to be learned from the geographic patterns of variation in nature.", [["variation", "OBSERVATION_MODIFIER", 74, 83]]], ["Subspecies were typically defined as geographical races with allopatric or parapatric distributions.", [["geographical", "OBSERVATION_MODIFIER", 37, 49], ["races", "OBSERVATION_MODIFIER", 50, 55], ["allopatric", "OBSERVATION_MODIFIER", 61, 71], ["parapatric distributions", "OBSERVATION", 75, 99]]], ["The observation of significant hybridization without introgression, in the latter cases, led to the development of the semispecies concept which is of relevance to conservation.", [["significant hybridization", "PROBLEM", 19, 44], ["introgression", "PROBLEM", 53, 66], ["the semispecies concept", "PROBLEM", 115, 138], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["hybridization", "OBSERVATION", 31, 44]]], ["Collectively, a group of semispecies comprise a superspecies and each semispecies is treated taxonomically as a full species.", [["semispecies", "CANCER", 25, 36], ["superspecies", "CANCER", 48, 60], ["a group of semispecies", "PROBLEM", 14, 36], ["a superspecies and each semispecies", "PROBLEM", 46, 81]]], ["In this case, geographically defined taxa that used to be treated as subspecies are actually independent evolutionary lineages and therefore as worthy of conservation as other \u201cgood\u201d species.Subspecies ::: Levels of Interest to Conservation GeneticistsConservation geneticists are often asked to advise on proposals to pool individuals from allopatric populations on the argument that it is better to save a generic species than no species.", [["species", "PROBLEM", 432, 439]]], ["Although poorly differentiated subspecies may often be mixed without genetic harm, the pooling of individuals of well-differentiated semispecies or species is likely to have negative genetic consequences.", [["semispecies", "ANATOMY", 133, 144], ["semispecies", "CANCER", 133, 144], ["poorly differentiated subspecies", "PROBLEM", 9, 41], ["genetic harm", "PROBLEM", 69, 81], ["well-differentiated semispecies", "PROBLEM", 113, 144], ["poorly differentiated", "OBSERVATION_MODIFIER", 9, 30], ["harm", "OBSERVATION", 77, 81]]], ["Unfortunately, management decisions are often made before the appropriate genetic data are available.Subspecies ::: Levels of Interest to Conservation GeneticistsGeneticists are often involved in two other situations involving subspecies and local variants.", [["local variants", "OBSERVATION", 242, 256]]], ["The first involves populations on either side of national or state boundaries that may be assigned to different subspecies and can receive radically different levels of protection; a species-wide conservation plan may allocate resources differently and be biologically preferable.", [["radically different levels of protection", "TREATMENT", 139, 179], ["a species", "TREATMENT", 181, 190]]], ["The second situation occurs when peripheral populations of a widespread species become the focus of conservation activities.", [["a widespread species", "PROBLEM", 59, 79], ["widespread", "OBSERVATION_MODIFIER", 61, 71], ["species", "OBSERVATION", 72, 79]]], ["Although such peripheral populations may be at high risk of local extinction, their conservation may not be warranted, especially in cases in which reintroduction is practical.", [["peripheral populations", "CELL", 14, 36], ["such peripheral populations", "PROBLEM", 9, 36], ["local extinction", "PROBLEM", 60, 76], ["local extinction", "OBSERVATION", 60, 76]]], ["On the other hand, some peripheral populations may be critical to a species' long-term survival.", [["peripheral populations", "CELL", 24, 46], ["peripheral populations", "CELL_TYPE", 24, 46], ["some peripheral populations", "PROBLEM", 19, 46], ["a species' long-term survival", "TREATMENT", 66, 95], ["peripheral", "ANATOMY_MODIFIER", 24, 34], ["populations", "OBSERVATION", 35, 46]]], ["Some peripheral populations may be better adapted to changing climatic conditions than central populations even though the latter may be more genetically variable.", [["peripheral populations", "CELL", 5, 27], ["Some peripheral populations", "PROBLEM", 0, 27], ["central populations", "PROBLEM", 87, 106], ["peripheral", "ANATOMY_MODIFIER", 5, 15], ["populations", "OBSERVATION", 16, 27]]], ["At a time of global warming, poleward peripheral populations of a species may be more important than those closest to the equator.Species ::: Levels of Interest to Conservation GeneticistsAs it is thought that half the species of larger vertebrates are at risk of extinction in the next 100 years, most discussions of the conservation of biodiversity focus on species.", [["global warming", "TREATMENT", 13, 27], ["poleward peripheral populations", "TREATMENT", 29, 60], ["a species", "PROBLEM", 64, 73], ["warming", "OBSERVATION_MODIFIER", 20, 27], ["poleward", "OBSERVATION_MODIFIER", 29, 37], ["peripheral populations", "OBSERVATION", 38, 60], ["extinction", "OBSERVATION", 264, 274], ["biodiversity", "OBSERVATION", 338, 350]]], ["Species are fundamental units of evolution and classification (taxonomy).", [["fundamental units", "OBSERVATION_MODIFIER", 12, 29]]], ["However, despite their centrality to the field, conservation geneticists rarely work at the level of whole species and concentrate instead on infraspecific levels of organization.Species ::: Levels of Interest to Conservation GeneticistsErnst Mayr introduced the biological species concept in 1942; species were defined as groups of actually or potentially interbreeding natural populations that are reproductively isolated from other such groups.", [["interbreeding natural populations", "PROBLEM", 357, 390], ["interbreeding", "OBSERVATION_MODIFIER", 357, 370], ["natural populations", "OBSERVATION", 371, 390]]], ["This concept stimulated an enormous amount of research in the second half of the twentieth century.", [["enormous", "OBSERVATION_MODIFIER", 27, 35], ["amount", "OBSERVATION_MODIFIER", 36, 42]]], ["Despite its impact, problems with Mayr's original definition, with its overemphasis on reproductive isolation and its focus on sexually reproducing outcrossing populations over short time spans, led to the development of at least 18 alternative concepts by the end of the century.", [["Mayr's original definition", "PROBLEM", 34, 60], ["its overemphasis", "PROBLEM", 67, 83], ["reproductive isolation", "TREATMENT", 87, 109]]], ["Although some of these have limited operational utility, three newer biological species concepts are of particular relevance to conservation geneticists: Wiley's evolutionary species concept, Templeton's cohesion species concept, and Mallet's genetic cluster species concept.", [["Templeton's cohesion species", "TREATMENT", 192, 220], ["Mallet's genetic cluster species concept", "PROBLEM", 234, 274]]], ["All three concepts, like Mayr's, seek to capture the essential genetic relatedness within, and the genetic distance between, biological species.", [["Mayr's", "TREATMENT", 25, 31]]], ["All allow that the absolute values of observed relatedness and distance will vary with the geological age of a species and will vary in different groups of plants and animals.Species ::: Levels of Interest to Conservation GeneticistsMayr's biological species concept forced researchers to search for reproductive isolating mechanisms between species in nature and to investigate their potential significance in laboratory and greenhouse hybridization experiments.", [["reproductive isolating mechanisms", "PROBLEM", 300, 333], ["greenhouse hybridization", "OBSERVATION", 426, 450]]], ["The introduction of protein electrophoresis and molecular genetic methods of measuring genetic variation has dramatically changed the approach to defining species.", [["protein electrophoresis", "TEST", 20, 43]]], ["It is now possible to quickly establish whether populations exchange genes or whether they are effectively reproductively isolated.", [["populations exchange genes", "PROBLEM", 48, 74]]], ["It is possible to estimate the time since a speciation event and the historical patterns of gene flow within and between taxa.", [["a speciation event", "PROBLEM", 42, 60], ["gene flow", "PROBLEM", 92, 101], ["gene flow", "OBSERVATION", 92, 101]]], ["Our newly found ability to characterize and recognize species genetically does not diminish the value of field and laboratory studies of behavioral ecology, but it does permit geneticists to make powerful contributions to the practice of conservation.Species ::: Levels of Interest to Conservation GeneticistsAlthough it is fortunately still unusual for geneticists to work on the conservation of entire species, there are an increasing number of cases in which every individual in a species has been genotyped to some degree for management purposes.", [["laboratory studies", "TEST", 115, 133], ["behavioral ecology", "TEST", 137, 155], ["management purposes", "TREATMENT", 530, 549], ["increasing", "OBSERVATION_MODIFIER", 426, 436], ["number", "OBSERVATION_MODIFIER", 437, 443]]], ["Such cases include Przewalski's horse (Equus przewalski), San Clemente loggerhead shrike (Lanius ludovicianus mearnsi), whooping crane (Grus americana), and Catalina mahogany (Cerocarpus traskiae).Communities ::: Levels of Interest to Conservation GeneticistsAlthough it is unusual to think of geneticists working at higher levels of organization than species, regional multispecies phylogeographic surveys are useful in defining the historical interactions of whole communities of organisms.", [["whooping crane", "DISEASE", 120, 134], ["horse", "ORGANISM_SUBDIVISION", 32, 37], ["Equus przewalski", "ORGANISM", 39, 55], ["Lanius ludovicianus mearnsi", "ORGANISM", 90, 117], ["Grus americana", "ORGANISM", 136, 150], ["Catalina mahogany", "ORGANISM", 157, 174], ["Cerocarpus traskiae", "ORGANISM", 176, 195], ["horse", "SPECIES", 32, 37], ["Equus przewalski", "SPECIES", 39, 55], ["shrike", "SPECIES", 82, 88], ["Lanius ludovicianus", "SPECIES", 90, 109], ["mearnsi", "SPECIES", 110, 117], ["Grus americana", "SPECIES", 136, 150], ["Catalina mahogany", "SPECIES", 157, 174], ["Cerocarpus traskiae", "SPECIES", 176, 195], ["Equus przewalski", "SPECIES", 39, 55], ["Lanius ludovicianus mearnsi", "SPECIES", 90, 117], ["Grus americana", "SPECIES", 136, 150], ["Catalina mahogany", "SPECIES", 157, 174], ["Cerocarpus traskiae", "SPECIES", 176, 195], ["Przewalski", "TEST", 19, 29], ["regional multispecies phylogeographic surveys", "TEST", 361, 406]]], ["Studies of regional phylogeographic structure, as for example in the southeastern United States or savanna ecosystems of Tanzania, are relevant to the design and maintenance of biodiversity sanctuaries (Avise, 2000).", [["regional", "OBSERVATION_MODIFIER", 11, 19], ["phylogeographic structure", "OBSERVATION", 20, 45]]], ["Elsewhere, populations in ecotonal regions have been found to have higher gene diversity and are thus recommended for higher conservation priority (Smith and Wayne, 1996).Mutation ::: Evolutionary Processes of Interest to Conservation GeneticistsMutations, the occurrence of heritable changes in the genetic material, are typically very rare processes that ultimately provide the raw material of genetic variation upon which the other agents of evolution operate.", [["ecotonal regions", "DNA", 26, 42], ["populations in ecotonal regions", "PROBLEM", 11, 42], ["heritable changes in the genetic material", "PROBLEM", 275, 316], ["populations", "OBSERVATION_MODIFIER", 11, 22], ["heritable", "OBSERVATION_MODIFIER", 275, 284], ["changes", "OBSERVATION", 285, 292]]], ["Mutations span a wide array of phenomena; from single base pair changes in the genetic code to accidental doublings of the number of chromosomes in a gamete.", [["chromosomes", "ANATOMY", 133, 144], ["gamete", "ANATOMY", 150, 156], ["chromosomes", "CELLULAR_COMPONENT", 133, 144], ["gamete", "CELLULAR_COMPONENT", 150, 156], ["chromosomes", "DNA", 133, 144], ["Mutations", "PROBLEM", 0, 9], ["phenomena", "PROBLEM", 31, 40], ["single base pair changes", "PROBLEM", 47, 71], ["wide", "OBSERVATION_MODIFIER", 17, 21]]], ["Many mutations are deleterious or lethal, some are near neutral, and a few may be beneficial to the carrier.", [["Many mutations", "PROBLEM", 0, 14], ["lethal", "PROBLEM", 34, 40], ["mutations", "OBSERVATION", 5, 14], ["deleterious", "OBSERVATION_MODIFIER", 19, 30], ["lethal", "OBSERVATION_MODIFIER", 34, 40]]], ["The vast majority of mutations are completely invisible in the phenotype and can only be detected with an array of genetic techniques.Mutation ::: Evolutionary Processes of Interest to Conservation GeneticistsMutations become of concern to conservationists in a couple of circumstances.", [["mutations", "PROBLEM", 21, 30], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17], ["mutations", "OBSERVATION", 21, 30]]], ["First, the presence of a normally very rare allele of major effect in a remnant or closed captive population can have serious consequences.", [["closed captive population", "PROBLEM", 83, 108], ["major", "OBSERVATION_MODIFIER", 54, 59], ["effect", "OBSERVATION_MODIFIER", 60, 66], ["remnant", "OBSERVATION_MODIFIER", 72, 79], ["closed", "OBSERVATION_MODIFIER", 83, 89], ["captive", "OBSERVATION", 90, 97]]], ["Deleterious traits discussed by Ryder and Fleischer (1996) include hairlessness in red-ruffed lemurs (Varecia variegata ruber), funnel chest in black-and-white ruffed lemurs (Varecia variegata variegata), and congenital diaphragmatic hernia in golden lion tamarin (Leontopithecus rosalia).", [["chest", "ANATOMY", 135, 140], ["diaphragmatic hernia", "ANATOMY", 220, 240], ["hairlessness", "DISEASE", 67, 79], ["congenital diaphragmatic hernia", "DISEASE", 209, 240], ["lemurs", "ORGANISM_SUBDIVISION", 94, 100], ["Varecia variegata ruber", "ORGANISM", 102, 125], ["chest", "ORGANISM_SUBDIVISION", 135, 140], ["lemurs", "ORGANISM", 167, 173], ["Varecia variegata variegata", "ORGANISM", 175, 202], ["diaphragmatic", "ORGAN", 220, 233], ["hernia", "PATHOLOGICAL_FORMATION", 234, 240], ["golden lion tamarin", "ORGANISM", 244, 263], ["Leontopithecus rosalia", "ORGANISM", 265, 287], ["Varecia variegata", "SPECIES", 102, 119], ["Varecia variegata variegata", "SPECIES", 175, 202], ["golden lion tamarin", "SPECIES", 244, 263], ["Leontopithecus rosalia", "SPECIES", 265, 287], ["red-ruffed lemurs", "SPECIES", 83, 100], ["Varecia variegata ruber", "SPECIES", 102, 125], ["white ruffed lemurs", "SPECIES", 154, 173], ["Varecia variegata variegata", "SPECIES", 175, 202], ["golden lion tamarin", "SPECIES", 244, 263], ["Leontopithecus rosalia", "SPECIES", 265, 287], ["Deleterious traits", "PROBLEM", 0, 18], ["hairlessness in red-ruffed lemurs", "PROBLEM", 67, 100], ["funnel chest in black", "TEST", 128, 149], ["white ruffed lemurs", "PROBLEM", 154, 173], ["Varecia variegata variegata", "PROBLEM", 175, 202], ["congenital diaphragmatic hernia", "PROBLEM", 209, 240], ["golden lion tamarin", "TREATMENT", 244, 263], ["chest", "ANATOMY", 135, 140], ["congenital", "OBSERVATION_MODIFIER", 209, 219], ["diaphragmatic", "ANATOMY", 220, 233], ["hernia", "OBSERVATION", 234, 240], ["golden lion", "OBSERVATION", 244, 255]]], ["Second, artificial selection for rare alleles is sometimes the goal of captive breeding programs.", [["artificial selection", "TREATMENT", 8, 28], ["rare alleles", "PROBLEM", 33, 45], ["captive breeding programs", "TREATMENT", 71, 96]]], ["White tigers (Panthera tigris), homozygous for a recessive allele, are beautiful but suffer genetic disease with metabolic, nervous, and developmental consequences.", [["nervous", "ANATOMY", 124, 131], ["metabolic, nervous, and developmental consequences", "DISEASE", 113, 163], ["White tigers", "ORGANISM", 0, 12], ["Panthera tigris", "ORGANISM", 14, 29], ["nervous", "ANATOMICAL_SYSTEM", 124, 131], ["Panthera tigris", "SPECIES", 14, 29], ["White tigers", "SPECIES", 0, 12], ["Panthera tigris", "SPECIES", 14, 29], ["White tigers", "TEST", 0, 12], ["a recessive allele", "PROBLEM", 47, 65], ["genetic disease", "PROBLEM", 92, 107], ["developmental consequences", "PROBLEM", 137, 163]]], ["Selection for such traits in the context of the conservation of an endangered species is unjustified.Mutation ::: Evolutionary Processes of Interest to Conservation GeneticistsAs most populations of conservation concern lose genetic variability, the question arises as to whether new mutations will replace variability lost by population extirpation and genetic erosion.", [["such traits", "PROBLEM", 14, 25], ["an endangered species", "PROBLEM", 64, 85], ["new mutations", "PROBLEM", 280, 293], ["population extirpation", "TREATMENT", 327, 349], ["genetic erosion", "PROBLEM", 354, 369], ["endangered species", "OBSERVATION", 67, 85], ["erosion", "OBSERVATION", 362, 369]]], ["The answer is yes and no. Given that mutation rates are typically on the order of one per 105cell divisions, the time for the accumulation of new variants in a population is on the order of tens of thousands of years.", [["cell", "ANATOMY", 93, 97], ["cell", "CELL", 93, 97], ["mutation rates", "PROBLEM", 37, 51], ["new variants", "PROBLEM", 142, 154], ["new", "OBSERVATION_MODIFIER", 142, 145], ["variants", "OBSERVATION", 146, 154]]], ["Therefore, conservation geneticists are more concerned with the deleterious effects of mutations in small populations than with their very long-term benefits.Mutation ::: Evolutionary Processes of Interest to Conservation GeneticistsExtinction due to genetic causes is almost unknown, but their contribution to the process should not be ignored.", [["mutations in small populations", "PROBLEM", 87, 117], ["genetic causes", "PROBLEM", 251, 265], ["small populations", "OBSERVATION_MODIFIER", 100, 117]]], ["Although natural selection purges deleterious alleles from populations almost immediately, mildly deleterious, near-neutral mutations will gradually increase in frequency and become serious problems when their frequencies exceed 0.05 or 1/(2Ne).", [["deleterious alleles from populations", "PROBLEM", 34, 70], ["mildly deleterious", "PROBLEM", 91, 109], ["neutral mutations", "PROBLEM", 116, 133], ["serious problems", "PROBLEM", 182, 198], ["mildly", "OBSERVATION_MODIFIER", 91, 97], ["deleterious", "OBSERVATION", 98, 109], ["increase", "OBSERVATION_MODIFIER", 149, 157]]], ["Fortunately, this process takes hundreds of generations in all but the smallest isolated populations.", [["smallest", "OBSERVATION_MODIFIER", 71, 79], ["isolated", "OBSERVATION_MODIFIER", 80, 88], ["populations", "OBSERVATION", 89, 100]]], ["Therefore, although such mildly deleterious mutations are rarely considered by wildlife conservationists, they will ultimately diminish the long-term viability of many threatened taxa.", [["such mildly deleterious mutations", "PROBLEM", 20, 53], ["long-term viability", "OBSERVATION_MODIFIER", 140, 159]]], ["On the other hand, managers of captive populations have to recognize this threat from the outset.", [["captive populations", "PROBLEM", 31, 50]]], ["If the goal of a breeding program is to return a captive population to the wild, then managers should maximize genetic variation including mildly deleterious mutants.", [["a captive population", "TREATMENT", 47, 67], ["genetic variation", "PROBLEM", 111, 128], ["mildly deleterious mutants", "PROBLEM", 139, 165], ["mildly", "OBSERVATION_MODIFIER", 139, 145], ["deleterious mutants", "OBSERVATION", 146, 165]]], ["Alternatively, if a population cannot be returned to the wild and must be sustained in captivity for many generations, then managers will need to purge deleterious mutations as they are identified.Mutation ::: Evolutionary Processes of Interest to Conservation GeneticistsMutation rates at near-neutral genes controlling quantitative characters set a lower limit on the population size necessary for future evolution.", [["near-neutral genes", "DNA", 290, 308], ["deleterious mutations", "PROBLEM", 152, 173], ["Mutation rates", "TEST", 272, 286], ["lower limit", "OBSERVATION_MODIFIER", 351, 362]]], ["Harmful mutation rates set lower limits for population sizes for avoiding inbreeding depression and for preventing genetic erosion of fitness by the accumulation of mildly deleterious mutations.", [["inbreeding depression", "DISEASE", 74, 95], ["Harmful mutation rates", "TEST", 0, 22], ["population sizes", "PROBLEM", 44, 60], ["inbreeding depression", "PROBLEM", 74, 95], ["genetic erosion of fitness", "PROBLEM", 115, 141], ["mildly deleterious mutations", "PROBLEM", 165, 193], ["erosion", "OBSERVATION", 123, 130], ["mildly", "OBSERVATION_MODIFIER", 165, 171], ["deleterious mutations", "OBSERVATION", 172, 193]]], ["The suggestion that small populations (Ne < 100) may decline in fitness with the accumulation of mildly deleterious mutations, termed mutational meltdown, is under theoretical and experimental study.Mating System ::: Evolutionary Processes of Interest to Conservation GeneticistsAlthough much population genetic theory is premised on \u201crandom mating,\u201d such behavior is rarely observed in nature.", [["small populations", "PROBLEM", 20, 37], ["mildly deleterious mutations", "PROBLEM", 97, 125], ["experimental study", "TEST", 180, 198], ["small", "OBSERVATION_MODIFIER", 20, 25], ["populations", "OBSERVATION_MODIFIER", 26, 37], ["mildly", "OBSERVATION_MODIFIER", 97, 103], ["deleterious mutations", "OBSERVATION", 104, 125]]], ["Self-fertilization in hermaphroditic organisms and obligate outbreeding in dioecious organisms are the two extreme modes.", [["Self-fertilization", "PROBLEM", 0, 18], ["hermaphroditic organisms", "PROBLEM", 22, 46], ["obligate outbreeding in dioecious organisms", "PROBLEM", 51, 94], ["hermaphroditic organisms", "OBSERVATION", 22, 46]]], ["Conservation managers have to be aware of these differences if they are to mimic a species' natural history.Mating System ::: Evolutionary Processes of Interest to Conservation GeneticistsThe most extreme examples of conservation problems involving mating systems involve cases in which the last surviving individuals in a sexually reproducing population all belong to the same sex.", [["conservation problems", "PROBLEM", 217, 238]]], ["The last passenger pigeon (Ectopistes migratorius) was a female; the last member of one of the 11 surviving subspecies of Galapagos tortoise (Geochelone elephantopsus) is a male, Lonesome George.", [["pigeon", "ORGANISM", 19, 25], ["Ectopistes migratorius", "ORGANISM", 27, 49], ["Galapagos tortoise", "ORGANISM", 122, 140], ["Geochelone elephantopsus", "ORGANISM", 142, 166], ["pigeon", "SPECIES", 19, 25], ["Ectopistes migratorius", "SPECIES", 27, 49], ["Galapagos tortoise", "SPECIES", 122, 140], ["Geochelone elephantopsus", "SPECIES", 142, 166], ["passenger pigeon", "SPECIES", 9, 25], ["Ectopistes migratorius", "SPECIES", 27, 49], ["Galapagos tortoise", "SPECIES", 122, 140], ["Galapagos tortoise", "OBSERVATION", 122, 140]]], ["It is likely that cloning technologies currently under development will be applicable to saving such lineages in the future.Inbreeding ::: Evolutionary Processes of Interest to Conservation GeneticistsInbreeding refers to the mating of close relatives in species that are normally outbreeding.", [["cloning technologies", "TREATMENT", 18, 38], ["is likely", "UNCERTAINTY", 3, 12]]], ["Many species of plants and animals have evolved devices to minimize close inbreeding.", [["evolved devices", "TREATMENT", 40, 55]]], ["Species vary greatly in their tolerance of inbreeding; some trees and dioecious plants are obligate outcrossers.", [["Species", "TREATMENT", 0, 7]]], ["The genetic underpinnings of inbreeding depression are best understood in Drosophila, in which recessive lethal mutations and mildly deleterious mutations are major causes.", [["inbreeding depression", "DISEASE", 29, 50], ["Drosophila", "ORGANISM", 74, 84], ["Drosophila", "SPECIES", 74, 84], ["Drosophila", "SPECIES", 74, 84], ["inbreeding depression", "PROBLEM", 29, 50], ["recessive lethal mutations", "PROBLEM", 95, 121], ["mildly deleterious mutations", "PROBLEM", 126, 154], ["inbreeding depression", "OBSERVATION", 29, 50], ["mildly", "OBSERVATION_MODIFIER", 126, 132]]], ["Gradual inbreeding permits natural selection to purge the former but the partially recessive near-neutral mutations continue to increase in frequency and significance.", [["Gradual inbreeding", "PROBLEM", 0, 18], ["natural selection", "TREATMENT", 27, 44], ["the partially recessive", "PROBLEM", 69, 92], ["neutral mutations", "PROBLEM", 98, 115], ["natural selection", "OBSERVATION", 27, 44], ["neutral mutations", "OBSERVATION", 98, 115], ["increase", "OBSERVATION_MODIFIER", 128, 136]]], ["Outcrossing populations that suddenly decline in numbers usually experience reduced viability and fecundity known as inbreeding depression.", [["inbreeding depression", "DISEASE", 117, 138], ["Outcrossing populations", "PROBLEM", 0, 23], ["reduced viability", "PROBLEM", 76, 93], ["inbreeding depression", "PROBLEM", 117, 138], ["suddenly", "OBSERVATION_MODIFIER", 29, 37], ["decline", "OBSERVATION_MODIFIER", 38, 45]]], ["Inbreeding produces increased homozygosity of recessive partially deleterious mutants and by chance in small populations these alleles become fixed.", [["increased homozygosity of recessive partially deleterious mutants", "PROBLEM", 20, 85], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["homozygosity", "OBSERVATION", 30, 42], ["recessive", "OBSERVATION_MODIFIER", 46, 55], ["partially", "OBSERVATION_MODIFIER", 56, 65], ["deleterious mutants", "OBSERVATION", 66, 85], ["small", "OBSERVATION_MODIFIER", 103, 108], ["populations", "OBSERVATION", 109, 120], ["fixed", "OBSERVATION_MODIFIER", 142, 147]]], ["In the simplest genetic situation of a trait under the control of a lethal recessive allele, there is an increased risk that the offspring of two related healthy but heterozygous individuals will inherit the harmful allele from each parent and die.", [["lethal recessive allele", "DNA", 68, 91], ["allele", "DNA", 216, 222], ["a lethal recessive allele", "PROBLEM", 66, 91], ["heterozygous individuals", "PROBLEM", 166, 190], ["increased", "OBSERVATION_MODIFIER", 105, 114]]], ["Generalizing from this simplest single-locus case, geneticists speak of inbreeding depression as the manifestation of the whole genomic effects of mating of close relatives.", [["inbreeding depression", "DISEASE", 72, 93], ["inbreeding depression", "PROBLEM", 72, 93]]], ["These effects may involve outright genetic disease (congenital abnormalities) but are more often subtle and appear as decreased growth rate, behavioral abnormalities, and reduced fertility and fecundity.", [["genetic disease", "DISEASE", 35, 50], ["congenital abnormalities", "DISEASE", 52, 76], ["behavioral abnormalities", "DISEASE", 141, 165], ["outright genetic disease (congenital abnormalities", "PROBLEM", 26, 76], ["decreased growth rate", "PROBLEM", 118, 139], ["behavioral abnormalities", "PROBLEM", 141, 165], ["reduced fertility and fecundity", "PROBLEM", 171, 202], ["decreased", "OBSERVATION_MODIFIER", 118, 127], ["growth", "OBSERVATION_MODIFIER", 128, 134], ["reduced", "OBSERVATION_MODIFIER", 171, 178], ["fertility", "OBSERVATION_MODIFIER", 179, 188]]], ["Therefore, inbreeding is rare in typically outbreeding populations but becomes a serious problem in small isolated populations.", [["a serious problem", "PROBLEM", 79, 96], ["small isolated populations", "PROBLEM", 100, 126], ["rare", "OBSERVATION_MODIFIER", 25, 29], ["serious", "OBSERVATION_MODIFIER", 81, 88], ["small", "OBSERVATION_MODIFIER", 100, 105], ["isolated", "OBSERVATION_MODIFIER", 106, 114], ["populations", "OBSERVATION_MODIFIER", 115, 126]]], ["In small fragmented populations in nature and in captive populations, inbreeding depression can threaten population viability.", [["inbreeding depression", "DISEASE", 70, 91], ["small fragmented populations", "PROBLEM", 3, 31], ["inbreeding depression", "PROBLEM", 70, 91], ["small", "OBSERVATION_MODIFIER", 3, 8], ["fragmented", "OBSERVATION_MODIFIER", 9, 19], ["populations", "OBSERVATION", 20, 31]]], ["Animal breeders learned these lessons from centuries of experience with artificial selection, and they limit inbreeding rates to less than 2% per generation.", [["artificial selection", "TREATMENT", 72, 92]]], ["The consequences of very close inbreeding are well illustrated by experience with establishing \u201cinbred\u201d strains of laboratory mice; the majority of inbred lines die out within 10 generations.Inbreeding ::: Evolutionary Processes of Interest to Conservation GeneticistsThere is abundant evidence that captive wildlife populations suffer inbreeding depression.", [["inbreeding depression", "DISEASE", 336, 357], ["mice", "ORGANISM", 126, 130], ["inbred lines", "CELL", 148, 160], ["inbred lines", "CELL_LINE", 148, 160], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["inbred lines", "TREATMENT", 148, 160], ["inbreeding depression", "PROBLEM", 336, 357]]], ["Ralls (in Schonewald-Cox et al., 1983, pp. 164\u2013184) was the first to show that even well-intended captive breeding programs subjected small populations to inbreeding depression.", [["inbreeding depression", "DISEASE", 155, 176], ["small populations", "PROBLEM", 134, 151], ["inbreeding depression", "PROBLEM", 155, 176], ["small", "OBSERVATION_MODIFIER", 134, 139], ["populations", "OBSERVATION_MODIFIER", 140, 151], ["inbreeding depression", "OBSERVATION", 155, 176]]], ["She reviewed empirical records for 40 species, mainly ungulates, in zoos and found inbreeding to be a problem in most cases.", [["40 species", "PROBLEM", 35, 45]]], ["Inbreeding is also associated with decreased growth rate and blindness in a captive wolf population in Sweden.", [["blindness", "DISEASE", 61, 70], ["decreased growth rate", "PROBLEM", 35, 56], ["blindness", "PROBLEM", 61, 70], ["decreased", "OBSERVATION_MODIFIER", 35, 44], ["growth", "OBSERVATION_MODIFIER", 45, 51], ["blindness", "OBSERVATION", 61, 70]]], ["In the wild, the final decline of the heath hen (Tympanuchus cupido) on Martha's Vineyard island in 1932 involved inbreeding effects.", [["hen", "ORGANISM_SUBDIVISION", 44, 47], ["Tympanuchus cupido", "ORGANISM", 49, 67], ["hen", "SPECIES", 44, 47], ["Tympanuchus cupido", "SPECIES", 49, 67], ["Tympanuchus cupido", "SPECIES", 49, 67]]], ["Other better documented cases (Hedrick in Smith and Wayne, 1996, pp. 459\u2013477; Lacy, 1997) involving declining or threatened wild populations involve the middle spotted woodpecker (Dendrocopos medius) in Sweden, the Florida panther (Puma concolor coryi), Barrow Island populations of the black-footed rock wallaby (Petrogale lateralis), common shrews (Sorex ananeus) in England, deer mice (Peromyscus polionotus), and Glanville fritillary butterfly (Melitaea cinxia) in the Aland Islands, Finland (Saccheri et al., 1998).Inbreeding ::: Evolutionary Processes of Interest to Conservation GeneticistsIn 1980, Franklin and Soul\u00e9 independently showed, based on theory and experiments, that inbreeding depression can be avoided in the short term if Ne > 50.", [["lateralis", "ANATOMY", 324, 333], ["inbreeding depression", "DISEASE", 685, 706], ["Dendrocopos medius", "ORGANISM", 180, 198], ["Puma concolor coryi", "ORGANISM", 232, 251], ["rock wallaby", "ORGANISM", 300, 312], ["Petrogale lateralis", "ORGANISM", 314, 333], ["shrews", "ORGANISM_SUBDIVISION", 343, 349], ["Sorex ananeus", "ORGANISM", 351, 364], ["deer mice", "ORGANISM", 378, 387], ["Peromyscus polionotus", "ORGANISM", 389, 410], ["Glanville fritillary butterfly", "ORGANISM", 417, 447], ["Melitaea cinxia", "ORGANISM", 449, 464], ["Dendrocopos medius", "SPECIES", 180, 198], ["Puma concolor coryi", "SPECIES", 232, 251], ["Petrogale lateralis", "SPECIES", 314, 333], ["Sorex ananeus", "SPECIES", 351, 364], ["deer", "SPECIES", 378, 382], ["mice", "SPECIES", 383, 387], ["Peromyscus polionotus", "SPECIES", 389, 410], ["fritillary", "SPECIES", 427, 437], ["Melitaea cinxia", "SPECIES", 449, 464], ["Dendrocopos medius", "SPECIES", 180, 198], ["Puma concolor coryi", "SPECIES", 232, 251], ["black-footed rock wallaby", "SPECIES", 287, 312], ["Petrogale lateralis", "SPECIES", 314, 333], ["Sorex ananeus", "SPECIES", 351, 364], ["mice", "SPECIES", 383, 387], ["Peromyscus polionotus", "SPECIES", 389, 410], ["Glanville fritillary butterfly", "SPECIES", 417, 447], ["Melitaea cinxia", "SPECIES", 449, 464], ["common shrews (Sorex ananeus", "PROBLEM", 336, 364], ["Glanville fritillary butterfly", "PROBLEM", 417, 447], ["inbreeding depression", "PROBLEM", 685, 706], ["middle", "ANATOMY_MODIFIER", 153, 159], ["medius", "ANATOMY", 192, 198], ["lateralis", "ANATOMY", 324, 333], ["common shrews", "ANATOMY", 336, 349]]], ["The inbreeding coefficient F increases by 1/2Ne per generation and centuries of animal breeding experience shows that a 1% increase in F per generation is tolerable; thus, an Ne = 50 is necessary to avoid inbreeding depression.", [["depression", "DISEASE", 216, 226], ["inbreeding depression", "PROBLEM", 205, 226]]], ["The theory behind the 50 number is still accepted (Lande, 1999), but it is important to realize that its derivation was based on controlled laboratory experiments; larger Nes are required in nature, where environmental fluctuations are more severe and stressful.Outbreeding ::: Evolutionary Processes of Interest to Conservation GeneticistsOutbreeding, or the crossing of unrelated individuals, is widespread in nature.", [["larger Nes", "PROBLEM", 164, 174], ["larger", "OBSERVATION_MODIFIER", 164, 170], ["unrelated", "OBSERVATION_MODIFIER", 372, 381], ["individuals", "OBSERVATION", 382, 393], ["widespread", "OBSERVATION_MODIFIER", 398, 408]]], ["It is widely believed that sexual reproduction evolved in part because chromosomal crossing over and recombination facilitated by out-breeding produces more genetic variability than do other mating systems.", [["chromosomal", "ANATOMY", 71, 82], ["chromosomal", "CELLULAR_COMPONENT", 71, 82], ["sexual reproduction", "PROBLEM", 27, 46]]], ["Many species of plants and animals have effective immunological and behavioral mechanisms to favor outbreeding.", [["outbreeding", "PROBLEM", 99, 110]]], ["Even in plants with both male and female flowers, outbreeding is ensured by asynchronous maturation of male and female gametes and the evolution of various self-incompatibility systems.Outbreeding ::: Evolutionary Processes of Interest to Conservation GeneticistsOutbreeding depression occurs when very distantly related conspecific individuals are mated or when members of two different but related species hybridize.", [["flowers", "ANATOMY", 41, 48], ["gametes", "ANATOMY", 119, 126], ["Outbreeding depression", "DISEASE", 263, 285], ["gametes", "DEVELOPING_ANATOMICAL_STRUCTURE", 119, 126], ["various self-incompatibility systems", "PROBLEM", 148, 184], ["Outbreeding depression", "PROBLEM", 263, 285], ["species hybridize", "PROBLEM", 400, 417], ["species hybridize", "OBSERVATION", 400, 417]]], ["The male and female genomes are sufficiently different to produce a hybrid with genetic disorders.", [["genetic disorders", "DISEASE", 80, 97], ["genetic disorders", "PROBLEM", 80, 97]]], ["Conservation geneticists encounter outbreeding depression in inadvertently mixed captive populations.", [["outbreeding depression", "DISEASE", 35, 57], ["outbreeding depression", "PROBLEM", 35, 57]]], ["Sterility, or partial sterility in one sex, and high neonate mortality are commonly observed manifestations.Hybridization ::: Evolutionary Processes of Interest to Conservation GeneticistsOutbreeding depression occurs in nature in some hybrid zones between semispecies and species of plants and animals.", [["Sterility", "DISEASE", 0, 9], ["Outbreeding depression", "DISEASE", 188, 210], ["Sterility", "PROBLEM", 0, 9], ["high neonate mortality", "PROBLEM", 48, 70], ["Outbreeding depression", "PROBLEM", 188, 210], ["some hybrid zones", "PROBLEM", 231, 248], ["partial", "OBSERVATION_MODIFIER", 14, 21], ["sterility", "OBSERVATION", 22, 31]]], ["Hybrids are interesting because they show that the evolution of many groups of plant and animal species involves both lineage splitting and lineage anastamosis.", [["anastamosis", "DISEASE", 148, 159], ["animal species", "PROBLEM", 89, 103], ["lineage anastamosis", "TREATMENT", 140, 159], ["lineage splitting", "OBSERVATION", 118, 135], ["lineage", "OBSERVATION_MODIFIER", 140, 147], ["anastamosis", "OBSERVATION", 148, 159]]], ["Fertile interspecific hybrids permit gene flow between species (introgression).", [["hybrids", "ANATOMY", 22, 29], ["interspecific hybrids", "CELL", 8, 29], ["Fertile interspecific hybrids", "PROBLEM", 0, 29], ["gene flow between species", "PROBLEM", 37, 62], ["interspecific hybrids", "OBSERVATION", 8, 29], ["flow", "OBSERVATION_MODIFIER", 42, 46]]], ["Hybrids call into question species definitions that overemphasize reproductive isolation.", [["reproductive isolation", "TREATMENT", 66, 88]]], ["The notion that \u201cspecies\u201d are somehow \u201cpurebred\u201d and always reproductively isolated from their close relatives is not borne out by observations of some animal groups and many plants, in which low rates of hybridization between congeners often occur in nature.Hybridization ::: Evolutionary Processes of Interest to Conservation GeneticistsIn the past, it was argued that hybrid populations did not qualify for legal protection under the U.S. Endangered Species Act.", [["hybridization between congeners", "PROBLEM", 205, 236], ["hybrid populations", "PROBLEM", 371, 389]]], ["However, hybrids are very much a normal part of nature.", [["hybrids", "ANATOMY", 9, 16], ["hybrids", "CELL", 9, 16], ["hybrids", "PROBLEM", 9, 16], ["normal", "OBSERVATION", 33, 39]]], ["Rare or very rare in some groups, and more common in others, they present conservationists with a dilemma because their occurrence appears to diminish the value of a taxon.", [["very", "OBSERVATION_MODIFIER", 8, 12]]], ["Do Texas red wolves (Canis rufus) merit conservation if they are gray wolf\u2013coyote hybrids?", [["Texas red wolves", "ORGANISM", 3, 19], ["Canis rufus", "ORGANISM", 21, 32], ["gray wolf\u2013coyote hybrids", "CELL_LINE", 65, 89], ["Canis rufus", "SPECIES", 21, 32], ["red wolves", "SPECIES", 9, 19], ["Canis rufus", "SPECIES", 21, 32]]], ["Should one save the remaining Przewalski's horses if it is shown that historical mismanagement resulted in a large fraction of the surviving animals being tainted by the genes of domestic horses, a karyologically distinct species?", [["horses", "ORGANISM_SUBDIVISION", 188, 194], ["historical mismanagement", "PROBLEM", 70, 94], ["a karyologically distinct species", "PROBLEM", 196, 229], ["large", "OBSERVATION_MODIFIER", 109, 114], ["fraction", "OBSERVATION_MODIFIER", 115, 123]]], ["Whether hybrids should be afforded the same priority as nonintrogressed populations or species will remain controversial; in the previous cases, the answer was yes and geneticists contributed to pedigree management.Hybridization ::: Evolutionary Processes of Interest to Conservation GeneticistsHabitat disturbance can result in increased opportunities for hybridization between species that would not normally interbreed.", [["Habitat disturbance", "DISEASE", 295, 314], ["hybrids", "PROBLEM", 8, 15], ["pedigree management", "TREATMENT", 195, 214], ["hybridization between species", "PROBLEM", 357, 386]]], ["Fragmentation of the recently continuous Pacific Northwest old-growth forest has led to hybridization between the declining northern spotted owl (Strix occidentalis) and the barred owl (S. varia), which favors disturbed sites.Hybridization ::: Evolutionary Processes of Interest to Conservation GeneticistsHybridization is more common in plants than in animals; therefore, not surprisingly it is in plants that there are numerous examples of rare species being hybridized into extinction (genetic assimilation) by hybridization with a more common sympatric congener (Soltis and Gitzendanner, 1999).", [["sites", "ANATOMY", 220, 225], ["owl", "ORGANISM", 141, 144], ["Strix occidentalis", "ORGANISM", 146, 164], ["barred owl", "ORGANISM", 174, 184], ["S. varia", "ORGANISM", 186, 194], ["Strix occidentalis", "SPECIES", 146, 164], ["S. varia", "SPECIES", 186, 194], ["northern spotted owl", "SPECIES", 124, 144], ["Strix occidentalis", "SPECIES", 146, 164], ["barred owl", "SPECIES", 174, 184], ["S. varia", "SPECIES", 186, 194], ["Fragmentation", "PROBLEM", 0, 13], ["hybridization", "TREATMENT", 88, 101], ["disturbed sites", "PROBLEM", 210, 225], ["Conservation GeneticistsHybridization", "TREATMENT", 282, 319], ["rare species", "PROBLEM", 442, 454], ["more common", "OBSERVATION_MODIFIER", 323, 334]]], ["Other cases involve plants (Asteracea: Argyranthemum) in the Canary Islands.", [["Canary", "ANATOMY", 61, 67], ["Islands", "ANATOMY_MODIFIER", 68, 75]]], ["The Simien jackal (Canis simensis) of Ethiopia is at risk of being introgressed into extinction by hybridization with domestic dogs.", [["Simien jackal", "ORGANISM", 4, 17], ["Canis simensis", "ORGANISM", 19, 33], ["dogs", "ORGANISM", 127, 131], ["Canis simensis", "SPECIES", 19, 33], ["dogs", "SPECIES", 127, 131], ["Canis simensis", "SPECIES", 19, 33], ["domestic dogs", "TREATMENT", 118, 131]]], ["It is now recognized that restocking rivers with genetically uniform hatchery-bred salmon has contributed to the collapse of the Pacific Northwest salmon runs.", [["salmon", "ORGANISM", 83, 89], ["salmon", "SPECIES", 83, 89], ["salmon", "SPECIES", 83, 89], ["Northwest salmon", "SPECIES", 137, 153], ["the collapse", "PROBLEM", 109, 121], ["collapse", "OBSERVATION", 113, 121]]], ["Hatchery fish show reduced fitness in the wild (they are not locally adapted) and compete and hybridize harmfully with the remaining wild salmon (Lande, 1999).Gene Flow ::: Evolutionary Processes of Interest to Conservation GeneticistsGene flow is a fundamental agent of evolution based on the dispersal of genes between populations of a species.", [["salmon", "SPECIES", 138, 144], ["a species", "PROBLEM", 336, 345], ["reduced", "OBSERVATION_MODIFIER", 19, 26], ["fitness", "OBSERVATION", 27, 34]]], ["It involves the active or passive movement of individual plants, animals, gametes, or seeds.", [["gametes", "ANATOMY", 74, 81], ["seeds", "ANATOMY", 86, 91], ["active", "OBSERVATION_MODIFIER", 16, 22]]], ["Gene flow involves not just dispersal but also the successful establishment of the immigrant genotypes in the new population.", [["Gene flow", "TEST", 0, 9], ["flow", "OBSERVATION", 5, 9], ["new", "OBSERVATION_MODIFIER", 110, 113], ["population", "OBSERVATION_MODIFIER", 114, 124]]], ["Gene flow is often confusingly referred to as migration, but the latter term is best reserved to describe dispersal behaviors involving a seasonal or longer term round-trip.", [["Gene flow", "PROBLEM", 0, 9], ["flow", "OBSERVATION", 5, 9]]], ["Gene flow tends to homogenize linked populations and lack of gene flow permits interpopulation differentiation.", [["Gene flow", "TEST", 0, 9], ["homogenize linked populations", "PROBLEM", 19, 48], ["gene flow", "PROBLEM", 61, 70], ["flow", "OBSERVATION", 5, 9], ["gene flow", "OBSERVATION", 61, 70]]], ["This is typically estimated from allele frequency data and reported in terms of the number of \u201cmigrants\u201d per generation.", [["allele frequency data", "PROBLEM", 33, 54]]], ["In theory, one migrant per generation between two populations will ensure that they remain genetically homogeneous.", [["homogeneous", "OBSERVATION", 103, 114]]], ["Inbreeding depression can be ameliorated by the artificial translocation of one reproducing migrant per generation between populations.Gene Flow ::: Evolutionary Processes of Interest to Conservation GeneticistsGene flow is often gender biased and limited to certain phases of the life cycle.", [["Inbreeding depression", "DISEASE", 0, 21], ["Inbreeding depression", "PROBLEM", 0, 21], ["depression", "OBSERVATION", 11, 21]]], ["It may be accelerated under certain climatic conditions that occur at frequencies of many years or at irregular intervals many years apart.", [["may be", "UNCERTAINTY", 3, 9]]], ["Interspecific gene flow results in introgressive hybridization (discussed previously).", [["Interspecific gene flow", "TEST", 0, 23], ["introgressive hybridization", "PROBLEM", 35, 62], ["gene flow", "OBSERVATION", 14, 23], ["introgressive hybridization", "OBSERVATION", 35, 62]]], ["The translocation of individual organisms results in gene flow if they reproduce at the release site.", [["individual organisms", "PROBLEM", 21, 41], ["gene flow", "PROBLEM", 53, 62], ["gene flow", "OBSERVATION", 53, 62]]], ["In the future, genetically depauperate populations will be enhanced by translocation of individuals from more secure areas.", [["depauperate populations", "CELL", 27, 50], ["genetically depauperate populations", "PROBLEM", 15, 50]]], ["Unfortunately, such genetic enhancement carries risks associated with the introduction of pathogens that could harm the target population or completely unrelated species.", [["pathogens", "PROBLEM", 90, 99], ["completely unrelated species", "PROBLEM", 141, 169]]], ["Furthermore, the introduction of individuals from genetically well-differentiated source populations may result in outbreeding depression in the threatened population of conservation concern (discussed previously).", [["outbreeding depression", "DISEASE", 115, 137], ["outbreeding depression", "PROBLEM", 115, 137], ["outbreeding", "OBSERVATION_MODIFIER", 115, 126], ["depression", "OBSERVATION", 127, 137], ["threatened", "OBSERVATION_MODIFIER", 145, 155]]], ["Gene flow can thus erode the genetic basis of adaptation to local conditions.Gene Flow ::: Evolutionary Processes of Interest to Conservation GeneticistsIf previously continuous populations become fragmented, historical patterns of dispersal and gene flow may be disrupted with potentially serious consequences for population viability.", [["Gene flow", "PROBLEM", 0, 9], ["previously continuous populations", "PROBLEM", 156, 189], ["dispersal and gene flow", "PROBLEM", 232, 255], ["population viability", "PROBLEM", 315, 335], ["flow", "OBSERVATION", 5, 9], ["fragmented", "OBSERVATION_MODIFIER", 197, 207]]], ["For example, if young female chimpanzees can no longer emigrate from their natal social group because of habitat destruction in the surrounding countryside, their isolated natal population will experience increased inbreeding.Genetic Drift ::: Evolutionary Processes of Interest to Conservation GeneticistsGenetic drift involves the loss of alleles from a population by chance.", [["chimpanzees", "ORGANISM", 29, 40], ["alleles", "DNA", 341, 348], ["habitat destruction", "PROBLEM", 105, 124], ["the loss of alleles", "PROBLEM", 329, 348], ["destruction", "OBSERVATION", 113, 124], ["Drift", "OBSERVATION", 234, 239]]], ["Random fluctuations in allele frequencies in small populations reduce genetic variation, leading to increased homozygosity and loss of evolutionary adaptability to change.Genetic Drift ::: Evolutionary Processes of Interest to Conservation GeneticistsThe rate at which alleles are lost from a sexually reproducing population by genetic drift can be predicted.", [["Random fluctuations in allele frequencies", "PROBLEM", 0, 41], ["small populations", "PROBLEM", 45, 62], ["genetic variation", "PROBLEM", 70, 87], ["increased homozygosity", "PROBLEM", 100, 122], ["loss of evolutionary adaptability", "PROBLEM", 127, 160], ["fluctuations", "OBSERVATION_MODIFIER", 7, 19], ["small", "OBSERVATION_MODIFIER", 45, 50], ["populations", "OBSERVATION_MODIFIER", 51, 62], ["genetic variation", "OBSERVATION", 70, 87], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["homozygosity", "OBSERVATION", 110, 122], ["loss", "OBSERVATION_MODIFIER", 127, 131], ["Drift", "OBSERVATION", 179, 184]]], ["Sewall Wright (1969) developed the basic theoretical model in 1931 and showed analytically how the rate varies with population size.", [["size", "OBSERVATION_MODIFIER", 127, 131]]], ["Actually, it is not the census size (N) that is important but rather the genetic effective population size (Ne).", [["size", "OBSERVATION_MODIFIER", 31, 35], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["This parameter takes into account the fact that closely related individuals will share alleles by common descent.", [["alleles", "DNA", 87, 94]]], ["Sibs share half their genes with each other and half with each of their parents and are therefore not equivalent to two genetically unrelated individuals.", [["Sibs", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["The genetic effective number of individuals in a population is therefore almost always less than the number of individuals counted by an ecologist.", [["genetic", "OBSERVATION_MODIFIER", 4, 11], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["Ne can, under some breeding systems, be one or two orders of magnitude less than N. Consider, for example, the number of adults in a sexually reproducing population: In a monogamous species the census count of adults is useful, but in a harem species only 1 of the 10 males may be contributing to Ne.", [["Ne", "CHEMICAL", 0, 2], ["monogamous species", "OBSERVATION", 171, 189]]], ["Ne can be variously defined in terms of unequal sex ratios among breeders, fluctuations in population size over several generations, and variance in family size (Lande and Barrowclough, 1987).Genetic Drift ::: Evolutionary Processes of Interest to Conservation Geneticists", [["unequal sex ratios", "PROBLEM", 40, 58], ["fluctuations in population size", "PROBLEM", 75, 106], ["unequal", "OBSERVATION_MODIFIER", 40, 47], ["fluctuations", "OBSERVATION_MODIFIER", 75, 87], ["population", "OBSERVATION_MODIFIER", 91, 101], ["size", "OBSERVATION_MODIFIER", 102, 106], ["size", "OBSERVATION_MODIFIER", 156, 160], ["Drift", "OBSERVATION", 200, 205]]]], "PMC7232879": [["The most recent virus to appear, belonging to the family of coronaviridae, is SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)\ufeff, which causes the syndrome COVID-19 (Coronavirus Disease-2019).", [["SARS-CoV-2", "DISEASE", 78, 88], ["Acute Respiratory Syndrome Coronavirus 2)\ufeff", "DISEASE", 97, 139], ["coronaviridae", "CANCER", 60, 73], ["SARS-CoV-2", "ORGANISM", 78, 88], ["Severe Acute Respiratory", "ORGANISM", 90, 114], ["SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2", "SPECIES", 78, 137], ["The most recent virus", "PROBLEM", 0, 21], ["coronaviridae", "TREATMENT", 60, 73], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 90, 135], ["the syndrome COVID", "PROBLEM", 154, 172], ["Coronavirus Disease", "PROBLEM", 177, 196], ["virus", "OBSERVATION", 16, 21], ["Severe", "OBSERVATION_MODIFIER", 90, 96], ["Acute", "OBSERVATION_MODIFIER", 97, 102], ["Respiratory Syndrome", "OBSERVATION", 103, 123]]], ["SARS-CoV-2 mainly invades alveolar epithelial cells, resulting in acute respiratory distress syndrome that can lead to the death of infected patients.1 Unfortunately, there are no effective antiviral drugs, and developing a vaccine would likely require years.", [["alveolar epithelial cells", "ANATOMY", 26, 51], ["respiratory", "ANATOMY", 72, 83], ["SARS", "DISEASE", 0, 4], ["respiratory distress syndrome", "DISEASE", 72, 101], ["death of infected", "DISEASE", 123, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["alveolar epithelial cells", "CELL", 26, 51], ["patients", "ORGANISM", 141, 149], ["alveolar epithelial cells", "CELL_TYPE", 26, 51], ["patients", "SPECIES", 141, 149], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["alveolar epithelial cells", "PROBLEM", 26, 51], ["acute respiratory distress syndrome", "PROBLEM", 66, 101], ["the death of infected patients", "PROBLEM", 119, 149], ["effective antiviral drugs", "TREATMENT", 180, 205], ["a vaccine", "TREATMENT", 222, 231], ["alveolar epithelial cells", "OBSERVATION", 26, 51], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory distress", "OBSERVATION", 72, 92], ["infected", "OBSERVATION", 132, 140], ["no", "UNCERTAINTY", 177, 179], ["effective", "OBSERVATION_MODIFIER", 180, 189], ["antiviral drugs", "OBSERVATION", 190, 205]]]], "6f21f2e98c38c8e0490f4ac6724cd5ff30b7e6ca": [["for Medicare and Medicaid Innovation (CMMI) with alternate payment mechanisms for health care providers.", [["Medicare", "TREATMENT", 4, 12]]], ["The bar for success for those value-based payment reforms has been narrow and high.", [["those value", "TEST", 24, 35], ["narrow", "OBSERVATION_MODIFIER", 67, 73], ["high", "OBSERVATION_MODIFIER", 78, 82]]], ["For adoption by Medicare, the CMMI demonstrations must show significant improvements in either cost or quality of care -with no negative effects on either -based on evaluations with methodologies similar to therapeutic trials.", [["evaluations", "TEST", 165, 176], ["methodologies", "TREATMENT", 182, 195], ["therapeutic trials", "TREATMENT", 207, 225], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["improvements", "OBSERVATION", 72, 84]]], ["To date only four of more than 37 payment reform models have cleared that bar.4 But an additional research question might be: What do these payment models, and the increased focus on population health management that they engender, mean for the broader U.S. health system?", [["population health management", "TREATMENT", 183, 211], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["focus", "OBSERVATION_MODIFIER", 174, 179]]]], "PMC7393854": [], "PMC7159360": [], "3805ad3873783acc23134ca8b9ef9e34745e63cb": [["Bei sehr schweren COVID-19-Verl\u00e4ufen entwickelt sich eine ausgepr\u00e4gte systemische Entz\u00fcndungsreaktion, die mit einer massiven Zytokinaussch\u00fcttung einhergeht und u. a. eine disseminierte intravasale Gerinnung mit Verbrauch von pround antikoagulatorischen Gerinnungsfaktoren hervorruft [5, 6] .", [["Bei sehr schweren COVID-19-Verl\u00e4ufen entwickelt sich eine ausgepr\u00e4gte systemische Entz\u00fcndungsreaktion, die mit einer massiven Zytokinaussch\u00fcttung einhergeht und u. a. eine disseminierte intravasale Gerinnung mit Verbrauch von pround antikoagulatorischen Gerinnungsfaktoren hervorruft", "SPECIES", 0, 283], ["COVID", "TEST", 18, 23]]], ["Gef\u00fcrchtet sind bei schwer erkrankten COVID-19-Patienten thrombotische Komplikationen, die tiefe Beinvenenthrombosen, Lungenembolien, aber auch Schlaganf\u00e4lle, Myokardinfarkte und Extremit\u00e4tenarterienverschl\u00fcsse [7] .", [["Gef\u00fcrchtet sind bei schwer erkrankten COVID-19-Patienten thrombotische Komplikationen", "SPECIES", 0, 85], ["Gef\u00fcrchtet", "TEST", 0, 10], ["COVID", "TEST", 38, 43], ["Patienten thrombotische Komplikationen", "TREATMENT", 47, 85], ["Lungenembolien", "TREATMENT", 118, 132]]], ["Da ACE-2-Rezeptoren auch ausgepr\u00e4gt im Gehirn exprimiert werden, scheint auch eine direkte neuronale Infektion m\u00f6glich und k\u00f6nnte einen Teil der beobachteten Enzephalitiden erkl\u00e4ren.", [["Da ACE", "TREATMENT", 0, 6], ["Rezeptoren auch ausgepr\u00e4gt", "TREATMENT", 9, 35]]], ["Auch das bei COVID-19-Patienten h\u00e4ufig zu beobachtende Nierenversagen kann durch die systemische Entz\u00fcndung, die disseminierte intravasale Gerinnung, den Schockzustand mit Hypoxie, aber auchInfektiosit\u00e4t von COVID-19-PatientenDie \u00dcbertragung des Virus erfolgt \u00fcber Tr\u00f6pfcheninfektion aus Aerosolen der Atemwege; die Infektiosit\u00e4t ist am h\u00f6chsten zum Zeitpunkt des Auftretens von Krankheitssymptomen.", [["Auch das bei COVID-19-Patienten h\u00e4ufig zu beobachtende Nierenversagen kann durch die systemische Entz\u00fcndung, die disseminierte intravasale Gerinnung, den Schockzustand mit Hypoxie, aber auchInfektiosit\u00e4t von COVID-19-PatientenDie \u00dcbertragung des Virus erfolgt \u00fcber Tr\u00f6pfcheninfektion aus Aerosolen der Atemwege; die Infektiosit\u00e4t ist am h\u00f6chsten zum Zeitpunkt des Auftretens von Krankheitssymptomen", "SPECIES", 0, 398], ["COVID", "TEST", 13, 18], ["Die \u00dcbertragung des Virus", "TREATMENT", 226, 251]]], ["Die Virusausscheidung [9] und damit die Infektiosit\u00e4t beginnt aber schon etwa 2-3 Tage vor dem Auftreten erster Symptome [10] .", [["Infektiosit\u00e4t", "TEST", 40, 53], ["etwa", "TEST", 73, 77]]], ["In epidemiologischen Studien konnte gezeigt werden, dass Infektionen durch Indexpatienten 5 Tage nach Symptombeginn selten sind [12] .Klinische Pr\u00e4sentation und VerlaufDie allermeisten Patienten entwickeln klinische Symptome einer SARS-CoV-2-Infektion sp\u00e4testens 12 Tage nach Inokulation des Erregers, meist bereits nach 5 Tagen [13] .", [["Klinische Pr\u00e4sentation und VerlaufDie allermeisten Patienten entwickeln klinische Symptome einer SARS-CoV-2-Infektion sp\u00e4testens 12 Tage nach Inokulation des Erregers, meist bereits nach 5 Tagen", "SPECIES", 134, 328], ["CoV", "TEST", 236, 239], ["Infektion sp\u00e4testens", "TREATMENT", 242, 262]]], ["Bei schwer Erkrankten treten auch zerebrovaskul\u00e4re Manifestationen und in bis zu 8 % der Patienten auch Enzephalitiden auf [17, 18] .", [["Bei schwer Erkrankten treten auch zerebrovaskul\u00e4re Manifestationen und in bis zu 8 % der Patienten auch Enzephalitiden auf", "SPECIES", 0, 122]]], ["Ven\u00f6se oder auch arterielle thrombembolische Komplikationen erleiden 10-25 % der mit COVID-19 hospitalisierten Patienten; bei den intensivmedizinisch behandelten Patienten sind diese noch h\u00e4ufiger [19, 20] .Klinische Pr\u00e4sentation und VerlaufEine intensivmedizinische Behandlung ist bei ca.", [["Ven\u00f6se oder auch arterielle thrombembolische Komplikationen erleiden 10-25 % der mit COVID-19 hospitalisierten Patienten; bei den intensivmedizinisch behandelten Patienten sind diese noch h\u00e4ufiger", "SPECIES", 0, 196], ["Ven\u00f6se oder auch arterielle thrombembolische", "TREATMENT", 0, 44], ["Komplikationen erleiden", "TREATMENT", 45, 68], ["Klinische Pr\u00e4sentation", "TREATMENT", 207, 229]]], ["Eine Leberbeteiligung mit erh\u00f6hten Leberwerten wurde in einer anderen Studie in 19 % der F\u00e4lle beschrieben.Screening auf die M\u00f6glichkeit einer SARS-CoV-2-InfektionIn der Pandemie stellt sich bei jedem Patienten, der sich in einem Notfallzentrum des Krankenhauses vorstellt, die Frage, ob eine SARS-CoV-2-Infektion vorliegt und diese die beobachteten Krankheitserscheinungen erkl\u00e4ren kann [21] .", [["Screening", "TEST", 107, 116], ["SARS", "TEST", 143, 147], ["CoV", "TEST", 148, 151], ["Infektion", "PROBLEM", 154, 163], ["ob eine SARS", "TEST", 285, 297], ["CoV", "TEST", 298, 301], ["Infektion", "PROBLEM", 304, 313]]], ["Es ist wichtig, infektionsgef\u00e4hrdende COVID-19-Patienten sofort zu identifizieren.", [["Es ist wichtig, infektionsgef\u00e4hrdende COVID-19-Patienten sofort zu identifizieren", "SPECIES", 0, 81], ["COVID", "TEST", 38, 43]]], ["Das bedeutet, dass die Patienten bereits vor Betreten des eigentlichen Krankenhausbereichs auf Symptome hin befragt werden m\u00fcssen, die auf eine Infektion hinweisen sowie nach einem Aufenthalt in einem Gebiet mit hohem Infektionsrisiko.", [["Das bedeutet, dass die Patienten bereits vor Betreten des eigentlichen Krankenhausbereichs auf Symptome hin befragt werden m\u00fcssen, die auf eine Infektion hinweisen sowie nach einem Aufenthalt in einem Gebiet mit hohem Infektionsrisiko", "SPECIES", 0, 234], ["Betreten des", "TREATMENT", 45, 57]]], ["Hierzu hat das Robert Koch-Institut (RKI) eine Orientierungshilfe f\u00fcr \u00c4rzt*innen entworfen, die an die Bedingungen der jeweiligen H\u00e4user angepasst werden muss [22] .", [["Hierzu hat das Robert Koch-Institut (RKI) eine Orientierungshilfe f\u00fcr \u00c4rzt*innen entworfen", "SPECIES", 0, 90]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["1 das Vorgehen in der M\u00fcnchen Klinik dargestellt.Screening auf die M\u00f6glichkeit einer SARS-CoV-2-InfektionAuf diesem Triagebogen werden prim\u00e4r schwerste Infektionen anhand des Q-SOFA-Scores identifiziert und die weiteren relevanten Informationen inTherapie der hypox\u00e4mischen respiratorischen InsuffizienzBei Vorliegen eines L-Typs stehen zur Therapie der oxygenatorischen respiratorischen Insuffizienz die Sauerstoffapplikation mittels Nasenbrille, Venturi-Maske (mit oder ohne Reservoir) sowie die High-flow-Sauerstofftherapie (HFOT) zur Verf\u00fcgung.", [["Auf diesem Triagebogen werden prim\u00e4r schwerste Infektionen anhand des Q-SOFA-Scores identifiziert und die weiteren relevanten Informationen inTherapie der hypox\u00e4mischen respiratorischen InsuffizienzBei Vorliegen eines L-Typs stehen zur Therapie der oxygenatorischen respiratorischen Insuffizienz die Sauerstoffapplikation mittels Nasenbrille, Venturi-Maske (mit oder ohne Reservoir) sowie die High-flow-Sauerstofftherapie (HFOT) zur Verf\u00fcgung", "SPECIES", 105, 547], ["Screening", "TEST", 49, 58], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["Infektion", "PROBLEM", 96, 105], ["Triagebogen", "TEST", 116, 127], ["respiratorischen", "TEST", 274, 290], ["InsuffizienzBei", "TEST", 291, 306], ["Vorliegen", "TEST", 307, 316], ["Typs stehen zur Therapie", "TREATMENT", 325, 349], ["respiratorischen Insuffizienz", "TREATMENT", 371, 400], ["Sauerstoffapplikation mittels Nasenbrille", "TREATMENT", 405, 446], ["Venturi-Maske (mit oder ohne Reservoir", "TREATMENT", 448, 486]]], ["Bei deutlicher Progredienz der respiratorischen Insuffizienz unter dieser Therapie, sollte der Einsatz einer CPAP-Therapie (\"continuous positive airway pressure\"), einer nichtinvasi-ven Beatmung (NIV) oder der invasiven Beatmung gepr\u00fcft werden.", [["airway", "ANATOMY", 145, 151], ["airway", "MULTI-TISSUE_STRUCTURE", 145, 151], ["Bei deutlicher Progredienz der respiratorischen Insuffizienz unter dieser Therapie, sollte der Einsatz einer CPAP-Therapie", "SPECIES", 0, 122], ["CPAP", "TREATMENT", 109, 113], ["Therapie", "TREATMENT", 114, 122], ["continuous positive airway pressure\"", "TREATMENT", 125, 161], ["einer nichtinvasi-ven Beatmung", "TREATMENT", 164, 194]]], ["Als Zielwerte der Therapie wird ein SpO2 \u226590 % bzw. ein paO2 >55 mm Hg empfohlen [27] .", [["Hg", "CHEMICAL", 68, 70], ["SpO2", "TEST", 36, 40], ["ein paO2", "TEST", 52, 60]]], ["W\u00e4hrend die Sauerstoffzufuhr mittels Nasenbrille und Venturi-Maske Therapieoptionen f\u00fcr die Normalstationen sind, sollten HFOT und NIV nur unter strengem Monitoring und unter Intubationsbereitschaft auf der Intensivstation angewandt werden.High-flow-Sauerstofftherapie (HFOT)Bei der HFOT wird mit Sauerstoff angereicherte Luft (FiO2 bis 100 %) mit einem hohen Fluss (bis 70 l/min) durch eine Nasenkan\u00fcle verabreicht.", [["FiO2 bis", "CHEMICAL", 328, 336], ["W\u00e4hrend die Sauerstoffzufuhr mittels Nasenbrille und Venturi-Maske Therapieoptionen f\u00fcr die Normalstationen sind, sollten HFOT und NIV nur unter strengem Monitoring und unter Intubationsbereitschaft auf der Intensivstation angewandt werden", "SPECIES", 0, 239], ["Bei der HFOT wird mit Sauerstoff angereicherte Luft (FiO2 bis 100 %) mit einem hohen Fluss (bis 70 l/min) durch eine Nasenkan\u00fcle verabreicht", "SPECIES", 275, 415], ["High-flow-Sauerstofftherapie (HFOT)", "TREATMENT", 240, 275], ["Luft (FiO2 bis", "TREATMENT", 322, 336], ["mit einem hohen Fluss (bis", "TREATMENT", 344, 370], ["durch eine Nasenkan\u00fcle verabreicht", "TREATMENT", 381, 415]]], ["Dadurch kommt es neben der Oxygenierung zu einer CO2-Auswaschung und der Erzeugung eines geringf\u00fcgigen PEEP.", [["Dadurch kommt es neben der Oxygenierung zu einer CO2-Auswaschung und der Erzeugung eines geringf\u00fcgigen", "SPECIES", 0, 102], ["PEEP", "TREATMENT", 103, 107]]], ["Bei mildem oder moderatem ARDS (paO2/FiO2 100-300 mm Hg) kann ein Therapieversuch mit HFOT durchgef\u00fchrt werden [27, 30] .", [["ARDS", "DISEASE", 26, 30], ["Hg", "CHEMICAL", 53, 55], ["ARDS", "PROBLEM", 26, 30], ["paO2", "TEST", 32, 36], ["FiO2", "TEST", 37, 41], ["ARDS", "OBSERVATION", 26, 30]]], ["Bei der HFOT sollten die Patienten einen Mund-Nasen-Schutz \u00fcber der Nasenkan\u00fcle tragen, um die Aerosolbildung zu reduzieren [31] .", [["Bei der HFOT sollten die Patienten einen Mund-Nasen-Schutz \u00fcber der Nasenkan\u00fcle tragen, um die Aerosolbildung zu reduzieren", "SPECIES", 0, 123]]], ["In unserem Patientenkollektiv mussten ca.", [["mussten ca", "OBSERVATION", 30, 40]]], ["50 % der mit NIV therapierten Patienten im Verlauf invasiv beatmet werden, u. a. auch aufgrund unzureichender Toleranz der Beatmungsmaske \u00fcber einen l\u00e4ngeren Zeitraum.Aerosolbildung bei atemunterst\u00fctzenden VerfahrenSowohl bei der Low-flow und High-flow-Sauerstoffapplikation als auch bei der NIV kann es zu einer erh\u00f6hten Aerosolbildung mit potenzieller Viruskontamination kommen.", [["Aerosolbildung bei atemunterst\u00fctzenden VerfahrenSowohl bei der Low-flow und High-flow-Sauerstoffapplikation als auch bei der NIV kann es zu einer erh\u00f6hten Aerosolbildung mit potenzieller Viruskontamination kommen", "SPECIES", 167, 379], ["der mit NIV therapierten", "TREATMENT", 5, 29], ["Aerosolbildung", "TEST", 167, 181], ["Sauerstoffapplikation als auch bei der NIV", "TREATMENT", 253, 295]]], ["Dabei kommt es jedoch zu keiner erh\u00f6hten Belastung bei einem Abstand von mehr als einem Meter [33] .", [["Dabei kommt es jedoch zu keiner erh\u00f6hten Belastung bei einem Abstand von mehr als einem Meter [33", "SPECIES", 0, 97]]], ["Unter Verwendung der pers\u00f6nlichen Schutzausr\u00fcstung (Augenschutz, Handschuhe, Kittel und mindestens FFP 2-Maske) k\u00f6nnen diese Therapieformen ohne erh\u00f6htes Infektionsrisiko angewandt werden.Invasive BeatmungBei [35] .", [["FFP", "TREATMENT", 99, 102]]], ["Im Gegensatz dazu ist der Nutzen einer Bauchlagerung wacher Patienten noch nicht ausreichend gut belegt, aber durchaus ein interessanter Therapieansatz [36] .", [["Im Gegensatz dazu ist der Nutzen einer", "TREATMENT", 0, 38]]], ["Zeigt sich unter lungenprotektiver Beatmung eine therapierefrakt\u00e4re Hypoxamie (paO2/FiO2 ) <80 bzw. unter 60 mm Hg, stellt der Einsatz einer venoven\u00f6sen extrakorporale Membranoxygenierung (ECMO) eine Therapieoption dar [27] .", [["Hg", "CHEMICAL", 112, 114], ["Zeigt sich", "TREATMENT", 0, 10], ["Hypoxamie", "TEST", 68, 77], ["paO2", "TEST", 79, 83], ["FiO2", "TEST", 84, 88], ["stellt der Einsatz einer venoven\u00f6sen", "TREATMENT", 116, 152]]], ["Allerdings ist die Prognose in dieser Patientengruppe sehr schlecht [37] .Thrombembolische KomplikationenThrombembolische Ereignisse sind h\u00e4ufige Komplikationen bei COVID-19-Patienten [38, 39] , die auch unter einer Thromboseprophylaxe auftreten k\u00f6nnen.", [["Thrombembolische KomplikationenThrombembolische Ereignisse sind h\u00e4ufige Komplikationen bei COVID-19-Patienten", "SPECIES", 74, 183], ["Thrombembolische", "TEST", 74, 90], ["COVID", "TEST", 165, 170]]], ["B. bei raschem Anstieg der D-Dimere, in Abh\u00e4ngigkeit des individuellen Blutungsrisikos, eine intensivierte Antikoagulation begonnen werden [27] .PneumothoraxUnter den nichtinfekti\u00f6sen Lungenkomplikationen bei COVID-19-Patienten findet man vereinzelt Berichte zu Pneumothoraces.", [["man", "SPECIES", 235, 238], ["B. bei raschem Anstieg der D-Dimere", "SPECIES", 0, 35], ["PneumothoraxUnter den nichtinfekti\u00f6sen Lungenkomplikationen bei COVID-19-Patienten findet man vereinzelt Berichte zu Pneumothoraces", "SPECIES", 145, 276], ["bei COVID", "TEST", 205, 214], ["Pneumothoraces", "PROBLEM", 262, 276], ["zu Pneumothoraces", "OBSERVATION", 259, 276]]], ["Der Gesamtanteil an Pneumothoraces liegt jedoch im unteren einstelligen Prozentbereich, und auch hier\u00fcber gibt es wenig systematische Publikationen.PneumothoraxIn einer chinesischen Publikation wurden bei 2 % der Patienten ein Pneumothorax bei manifester, schwerer CO-VID-19-Infektion festgestellt [40] .", [["Pneumothorax bei", "DISEASE", 227, 243], ["PneumothoraxIn einer chinesischen Publikation wurden bei 2 % der Patienten ein Pneumothorax bei manifester, schwerer CO-VID-19-Infektion festgestellt", "SPECIES", 148, 297], ["Der Gesamtanteil", "TREATMENT", 0, 16], ["PneumothoraxIn", "PROBLEM", 148, 162], ["CO", "TEST", 265, 267], ["VID", "TEST", 268, 271], ["Pneumothoraces", "OBSERVATION", 20, 34], ["Pneumothorax", "OBSERVATION", 227, 239]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["2).Sekund\u00e4rinfektionenDie Gefahr bakterieller Superinfektionen scheint bei COVID-19-Patienten weitaus seltener zu sein als beispielsweise bei Influenza, und eine prophylaktische antibiotische Therapie, auch bei hospitalisierten Patienten oder intensivpflichtigen COVID-19-Patienten, ist generell nicht indiziert [41] .Sekund\u00e4rinfektionenDennoch m\u00fcssen diese Patienten regelm\u00e4\u00dfig und engmaschig auf pulmonale Superinfektionen oder nosokomiale Infektionen \u00fcberwacht werden.", [["pulmonale", "DISEASE", 398, 407], ["Sekund\u00e4rinfektionenDie Gefahr bakterieller Superinfektionen scheint bei COVID-19-Patienten weitaus seltener zu sein als beispielsweise bei Influenza, und eine prophylaktische antibiotische Therapie, auch bei hospitalisierten Patienten oder intensivpflichtigen COVID-19-Patienten, ist generell nicht indiziert", "SPECIES", 3, 311], ["Sekund\u00e4rinfektionen", "TEST", 3, 22], ["COVID", "TEST", 75, 80], ["Influenza", "PROBLEM", 142, 151], ["COVID", "TEST", 263, 268]]], ["Die Hauptkomplikation von COVID-19-Patienten mit schwerem Verlauf, die etwa 10 % des Gesamtkollektivs der SARS-Abb.", [["Die Hauptkomplikation von COVID-19-Patienten mit schwerem Verlauf, die etwa 10 % des Gesamtkollektivs der SARS-Abb", "SPECIES", 0, 114]]], ["3Medikament\u00f6se TherapieDas Bestreben, eine m\u00f6glichst effiziente Therapie zu entwickeln, war aufgrund der hohen kontagi\u00f6sen Potenz und der rasch zunehmenden Erkrankungsf\u00e4lle von Anfang ansehrgro\u00dfund f\u00fchrte zu einerVielzahl klinisch-pharmakologischer Studien sowie empirischer Therapieversuche.Medikament\u00f6se TherapieLopinavir/Ritonavir oder auch Chloroquin waren bei den ersten Medikamenten, denen eine antivirale Wirkung zugeschrieben worden ist.", [["der hohen kontagi\u00f6sen Potenz und der rasch zunehmenden Erkrankungsf\u00e4lle von Anfang ansehrgro\u00dfund f\u00fchrte zu einer", "SPECIES", 101, 213], ["Vielzahl", "TEST", 213, 221], ["Medikament\u00f6se TherapieLopinavir", "TREATMENT", 292, 323], ["Ritonavir", "TREATMENT", 324, 333], ["Chloroquin waren bei den ersten Medikamenten", "TREATMENT", 344, 388]]], ["Jedoch erwiesen sich beide Substanzen sehr bald als unwirksam und teilweise sogar unvorteil-haft aufgrund des Nebenwirkungsprofils und werden auch seitens der Weltgesundheitsorganisation (WHO) negativ bewertet [44] .Medikament\u00f6se TherapieEinen vielversprechenden und interessanten Therapieansatz boten sehr bald auch antiinflammatorische Interventionsversuche.", [["Jedoch erwiesen sich beide Substanzen sehr bald als unwirksam und teilweise sogar unvorteil-haft aufgrund des Nebenwirkungsprofils und werden auch seitens der Weltgesundheitsorganisation (WHO) negativ bewertet", "SPECIES", 0, 209], ["Medikament\u00f6se TherapieEinen vielversprechenden", "TREATMENT", 216, 262]]], ["Interleukin 6 zu sein [45] .", [["Interleukin 6", "GENE_OR_GENE_PRODUCT", 0, 13], ["Interleukin 6", "PROTEIN", 0, 13]]], ["Leider sind aber die bisherigen Studienergebnisse zur Wirksamkeit von IL-6-Antik\u00f6rpern sehr ern\u00fcchternd und zeigen keine Vorteile gegen\u00fcber Placebo (Pressemitteilung des Herstellers Ende Juli 2020, Daten bisher nicht publiziert).Medikament\u00f6se TherapieLediglich Kortikosteroide scheinen in der Phase der Hyperinflammation, also i. d.", [["Leider sind aber die bisherigen Studienergebnisse zur Wirksamkeit von IL-6-Antik\u00f6rpern sehr ern\u00fcchternd und zeigen keine Vorteile gegen\u00fcber Placebo (Pressemitteilung des Herstellers Ende Juli 2020, Daten bisher nicht publiziert", "SPECIES", 0, 227], ["Antik\u00f6rpern sehr ern\u00fcchternd", "TREATMENT", 75, 103], ["Placebo (Pressemitteilung des", "TREATMENT", 140, 169], ["Medikament\u00f6se TherapieLediglich Kortikosteroide scheinen", "TREATMENT", 229, 285]]], ["Krankheitswoche einen nachweisbaren Nutzen zu zeigen.", [["Krankheitswoche einen nachweisbaren Nutzen zu zeigen", "SPECIES", 0, 52]]], ["Insbesondere scheint Dexamethason protektiv zu sein bez\u00fcglich der Ausbildung einer kryptogen-organisierenden Pneumonie oder einer Lungenfibrose [46, 47] .Medikament\u00f6se TherapieUnter den direkt antiviral wirkenden Medikamenten kann derzeit einzig Remdesivir eine in gro\u00dfen multizentrischen Studien nachgewiesene Verk\u00fcrzung der Krankheitsdauer bewirken.", [["Insbesondere scheint Dexamethason protektiv zu sein bez\u00fcglich der Ausbildung einer kryptogen-organisierenden Pneumonie oder einer Lungenfibrose", "SPECIES", 0, 143], ["Medikament\u00f6se TherapieUnter", "TREATMENT", 154, 181], ["antiviral wirkenden", "TREATMENT", 193, 212], ["kann derzeit einzig Remdesivir eine", "TREATMENT", 226, 261]]], ["Voraussetzung f\u00fcr einen Benefit bei Einsatz von Remdesivir ist allerdings, dass es m\u00f6glichst fr\u00fch im Krankheitsverlauf gegeben wird.", [["Voraussetzung f\u00fcr einen Benefit bei Einsatz von Remdesivir ist allerdings, dass es m\u00f6glichst fr\u00fch im Krankheitsverlauf gegeben wird", "SPECIES", 0, 131], ["Voraussetzung", "TREATMENT", 0, 13]]], ["Bei bereits schwer erkrankten CO-VID-19-Patienten mit z.", [["Bei bereits schwer erkrankten CO-VID-19-Patienten mit z.", "SPECIES", 0, 56], ["CO", "TEST", 30, 32], ["VID", "TEST", 33, 36]]], ["B. invasiver Beatmung und fortgeschrittenem Organversagen vor Remdesivir-Gabe zeigt sich dagegen keine positive Wirkung [48] [49] [50] [51] .", [["B. invasiver Beatmung und fortgeschrittenem Organversagen vor Remdesivir-Gabe zeigt sich dagegen keine", "SPECIES", 0, 102], ["Beatmung", "TEST", 13, 21], ["fortgeschrittenem", "TEST", 26, 43], ["Organversagen", "TEST", 44, 57], ["vor", "TEST", 58, 61], ["Remdesivir", "TEST", 62, 72]]]]}